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Summary 
 
This thesis focuses on the analysis of protein modifications and protein isoforms in 
biopharmaceuticals. It evaluates the potential of HPLC-UV, HPLC-ESI-MS, CE-UV and CE- 
ESI-MS methods, when optimized and used together with specific enzymatic treatments, for 
characterizing protein modifications like deamidation, modifications leading to a shift in the 
charge pattern, and on PEGylation. 
In a first study, the effect of various forced degradation conditions on asparagine 
deamidation in peptides and proteins was investigated. Capillary electrophoresis and 
chromatography were applied to examine this kind of peptide and protein degradation in 
intact and digested samples. It is demonstrated that both analytical methods provide very 
good resolution of deamidated species and allow to distinguish between asparagine, 
aspartate and isoaspartate in intact samples. Although the introduced electrophoretic 
conditions did not yield the detection of succinimides (whereas they were clearly detected by 
chromatography), CZE was a preferred choice over chromatography. Using the CZE 
method, the analysis time was reduced more than three times and the present Asn, Asp, 
isoAsp variants were separated in close proximity to each other always in the same way 
(migration order depends on pH value of separation buffer). This fact allowed determination 
of present deamidation by visual comparison of the UV electropherograms of unstressed 
and stressed intact samples. Introducing the specific cleavage of aspartates by Asp-N 
enzyme, the presence of deamidation could be verified using electrophoresis (or 
chromatography) without employment of MS detection. The electrophoretic (and 
chromatographic) profiles of unstressed and stressed digested samples were compared. 
The presence of some new peak(s) in stressed digested sample was commonly a sign of 
deamidation. The explanation for this observation is the increased presence of aspartates in 
stressed (deamidated) samples. It was shown that the application of Asp-N digestion is 
particularly useful for the investigation of forced degradation in peptides. When applying this 
approach to larger polypeptides and proteins, the results become more complicated to 
interpret. One of the reasons, why the visual detection of deamidation by the comparison of 
the data was nearly impossible, was the low level of deamidation in molecules with longer 
amino acid chain. These molecules are better protected from deamidation and the attempts 
to produce some deamidated sample were often unsuccessful. To avoid the long incubation 
times (often needed to induce deamidation in proteins) and frequently observed sample 
degradation, L-Asparaginase was applied to accelerate the deamidation rate of asparagine. 
Although the utilization of this method led to faster deamidation in Peptide 1, no acceleration 
of the deamidation rate could be observed in proteins under the conditions described. 
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In a second study, charge variants (i.e. isoforms with different net-charge) of two 
monoclonal antibodies (IgGs) were examined by capillary zone electrophoresis. By means 
this method, various isoforms with different net-charge could be separated and detected 
when using bare fused silica capillaries without any additional permanent capillary coating, 
but using ε-aminocaproic acid (EACA) as additive to the running buffer. An enzymatic 
cleavage was applied to reduce the complexity of these proteins. Papain digestion followed 
by electrophoretic analysis led to an improved demonstration of single charge variants. The 
described strategy also allowed the better localization of changes that occurred in the 
structure of stressed samples. The developed CZE method with EACA as additive to the 
background electrolyte was employed for further enzymatic studies using pepsin or lysine 
hydrolysis and a coupled papain-PNGase digestion. 
Finally, in the third study, the application of diverse electrophoretic and chromatographic 
methods for a study of a PEGylated and glycosylated protein is demonstrated. Considering 
the possibility of the detection of PEGylated peptides and the quantification of PEG by 
capillary electrophoresis, this analytical tool was favoured over chromatography. Capillary 
electrophoresis showed its potential for the investigation of the degree of PEGylation and for 
the localization of PEGylation sites (followed by calculation of PEG occupancy - PEGocc). 
For this purpose the findings from previous studies were utilized and the advantages of the 
introduced methods were taken to achieve an optimal separation. 
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1 Aim 
 
In this work we would like to demonstrate the efficiency and performance of capillary 
electrophoresis when used for the characterization of posttranslational modifications in 
proteins. This powerful technique allows the separation of a wide variety of analytes in only 
one type of capillary, whereas with HPLC often various column types have to be chosen to 
achieve optimal separation. Applying CZE for the investigation of biopharmaceutical drugs, 
high throughput (short analysis times) can be expected, often with higher resolving capability 
compared to other analytical methods. CZE as the preferred method will be combined with 
various other analytical techniques within this work. 
With proteins used as biopharmaceuticals, deamidation (i.e. the change of asparagine to 
aspartate and isoaspartate) has to be controlled as deamidation might have a serious impact 
on the drugs’ functionality. Thus, deamidation in peptides and proteins is subject of our 
investigation. In the first part of the study, optimum conditions for forced degradation were 
examined to attain a reproducible production of stressed material. Shortly after that, the 
mapping of the deamidated species was performed. For investigating the degraded species 
the commonly used CZE-UV and HPLC-MS methods were employed together with a novel 
procedure, i.e. the specific cleavage with the enzyme Asp-N for distinguishing between 
asparagine, aspartate and isoaspartate residues. The possibility to generate faster and more 
specific formation of aspartate was studied. It is known that L-Asparaginase is able to 
hydrolyse the asparagine single amino acid to aspartate. Therefore the function of the 
catalytic effect in peptides and proteins was examined. The aim of this study was to evaluate 
the potential of these combined methods, i.e. CZE-UV and HPLC-ESI-MS together with Asp- 
N treatment for monitoring deamidation events on routine basis. 
The aim of the second study was to demonstrate how well capillary zone electrophoresis 
(CZE) could replace capillary isoelectric focusing (CIEF) methods in examining charge 
variants and charge alterations in monoclonal antibodies. This procedure is aimed at the 
investigation of intact monoclonal antibodies as well as to the polypeptide chains obtained 
by enzymatic hydrolysis with papain or other proteolytic enzymes. 
Finally, the aim of the third study was demonstrating the potential and the usefulness of 
capillary zone electrophoresis for characterizing the modifications of proteins by 
polyethylenglycol poly/oligomers. This characterization covered the determination of the 
PEGylation degree (quantity of all PEG moieties attached), the localization of the PEG 
attachment sites and the determination of the PEG occupancy. CZE was evaluated as tool 
for monitoring protein heterogeneity caused by PEGylation. 
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2 Introduction 
 
2.1 Protein based biologics 
 
Development and production of pharmaceutical products belongs to the strongest 
growing areas in industry and business worldwide. With the rapidly aging population, the 
medical requirements steadily increased in recent decades [1]. To face the challenges of 
complex oncology or of auto-inflammatory diseases, to address just two examples, the 
products supplied to market have dramatically changed. Over the last decade, 
biopharmaceutical companies tended to focus on the discovery and development of protein- 
based drugs [2, 3]. Especially in oncology, monoclonal antibodies (mAbs) have proved to be 
an important tool for fighting threatening diseases [4, 5]. The top ten pharmaceutical 
products by sales worldwide in 2014 are presented in Scheme 1 which shows that five of 
these ten pharmaceuticals are protein-based drugs, two of them ranking in the top two 
positions. 
 
 
Scheme 1: Overview over the global pharmaceutical market – top ten best-selling 
products worldwide in 2014 [6]. 
 
Without doubt, researchers will succeed also in the future in finding new ways of treating 
not only widely spread but also rare diseases, and many medical and pharmaceutical 
products will emerge aimed at improving human life quality. For consumers’ protection both, 
best quality and highest safety of these products have to be assured [7]. 
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Protein therapeutics are obtained in complex production processes, mostly involving cell 
cultures of microorganisms. Unlike chemical synthesis, reaction pathways are highly 
interconnected potentially resulting in a large number of side-products and modifications that 
might impact product quality [8]. Purification, storage and administration as a part of the 
protein drug lifecycle should also be taken into account. Finally, the aspects of aggregation, 
fragmentation and degradation have to be considered as they can negatively impact the 
drug’s safety profile [9]. 
Proteins in cells can undergo various modifications, as for instance co- and post- 
translational modifications like glycosylation, phosphorylation and methylation, coupling of 
cysteine-thiols by disulphide bridges etc. [1]. In addition, there might occur chemical 
degradation or modification by hydrolysis, isomerization, racemization, deamidation, 
oxidation etc. [10], as well as physical degradation and aggregation, denaturation, 
precipitation etc. [11, 12]. For biopharmaceuticals (biologica) it is very important to be able to 
control and demonstrate the product integrity, lot-to-lot manufacturing consistency and long- 
term product stability (under recommended storage conditions) to ensure the biological 
function of the product. 
Commonly, particularly if the protein is glycosylated, the product shows a certain 
heterogeneity arising from slight variations in the glycan species attached to the protein 
(micro-heterogeneity) or from other modifications like deamidation, glycation, C-terminal Lys 
cleavage, N-terminal glutamine cyclization, etc. [13, 14, 15]. This heterogeneity pattern is 
influenced primarily by the manufacturing process but also by the storage conditions. In any 
instance, these variants have to be controlled, since alterations, for example in some glycan 
epitopes and in surface-charge properties (e.g. deamidation, incorrect disulfide bond 
formation, partial denaturation etc.) can lead to an unwanted immune response [16, 17]. The 
availability of a wide set of specific and sensitive test procedures for controlling product 
integrity, purity and stability, as well as type and concentration of impurities is thus essential. 
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2.1.1 Structural features relevant in biopharmaceuticals 
 
Modification (degradation) of asparagine to aspartate or isoaspartate residues in proteins 
(deamidation) can impact in vitro stability and in vivo biological functions. The deamidation 
reaction kinetics is found to depend on the polypeptide sequence next to the deamidation 
sites. It probably differs for synthetic peptides and intact proteins, where the higher order 
structure plays an important role. It is an interesting issue, how deamidation processes can 
be influenced and how a better stability against deamidation can be achieved. (This question 
will be addressed in chapter 3.1 of this Thesis.) 
Deamidation, phosphorylation, sulfation, acetylation etc., as well as the presence of 
charged sugars like sialic acids, lead to a set of protein isoforms exhibiting differences in 
their net charge (charge variants). The charge variant profile (charge heterogeneity) is an 
important issue when characterizing therapeutic proteins like monoclonal antibodies. (This 
topic will be addressed in 3.2.) 
Biomolecules typically studied in the context of therapeutic use are composed of amino 
acids, nucleic acids, glycans or complex combinations of these groups of substances. They 
cover different ranges of molecular weight and often differ in their production. They might 
range from lower molecular mass (from peptides with approximately 5 to 10 kDa), over 
proteins (IgGs with approx. 150 kDa) up to large macromolecules (IgMs with about 300 kDa 
and others over 500 kDa). Often, the therapeutic potential of biomolecules and their 
biotechnological production efficiency can be enhanced by coupling these proteins to partner 
compounds building conjugates. Examples cover different types of conjugates, from 
radionuclide chelators, to protein conjugates with cytotoxic drugs, and e.g. polyethylenglycol 
(PEG) modified protein drugs [2]. Protein modification with PEG, referred to as PEGylation, 
is a procedure of growing interest and several PEGylated protein conjugates are 
commercially available. Attachment of PEG molecules to a protein is a covalent modification 
that increases the half-life of proteins in vivo, improves efficacy of the drugs, and reduces 
immunogenicity [18, 19, 20]. PEGylation, however, leads to enhanced protein heterogeneity 
which is difficult to study and to control in detail. Detailed structural characterization of such 
complex molecules as PEGylated proteins is a demanding task. Determining the linkage 
sites of PEG to a polypeptide requires sensitive and accurate analytical methods [19]. (This 
issue is part of the investigations reported in chapter 3.3). 
Typically, biological drugs are delivered by transgenic organisms; they are widely 
expressed in bacterial, fungal and mammalian cell cultures. Bacterial expression systems 
are very popular for protein expression because of the low costs and the simplicity of 
cultivating bacteria [21]. However, these prokaryotes lack enzymes typical for humans, and 
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this fact can cause incorrect disulfide bond formation, very significant changes in post- 
translational modifications (PTMs) like unmatching or totally absent glycosylation. Therefore, 
many molecules obtained from bacterial expression systems are in their detailed structure 
not identical to those gained from mammalian cells. Although the therapeutic action of 
proteins is widely determined by the amino acid sequence, post-translational modifications 
as well play a crucial role for protein function, availability and stability. Even small differences 
in the structure of proteins can lead to protein aggregation, reduced solubility or to 
differences in the pharmacokinetic and pharmacodynamic properties. In some instances, 
even the entire loss of function (e.g. caused by missing glycosylation in the case of 
erythropoietin) might occur, or a change in the strength of action (e.g. observed with 
aberrant fucosylation in the case of monoclonal antibodies (mAbs) and their antibody 
dependent cell-mediated cytotoxicity (ADCC) activation effect [22]). Hence, molecules that 
need this type of modification for their desired function need to be expressed in mammalian 
or insect cells [23, 24]. 
Using mammalian cells for protein expression, however, is no guarantee for achieving the 
desired product. Often, major differences were detected when using two different cell lines, 
but also production of proteins by different lots of one cell line might lead to a certain 
variation in the glycopattern, for instance regarding decoration and amount of sialic acids 
[25]. 
When considering the growing market of “biosimilars”, it is important to keep in mind that 
the properties of pharmaceuticals are dependent on the used clone in the cell culture and on 
the overall manufacturing process including the protein extraction and purification scheme. A 
certain structural variation of the resulting products has thus to be expected as 
manufacturing methods and processes cannot be duplicated in all instances [26]. 
Quality control (QC) and quality assurance (QA) must focus on all these structural 
features and properties in order to prove and ascertain the quality of drugs, beginning from 
pre-clinical research up to the clinical application to patients. 
 
2.2 Analytical tools for characterizing biopharmaceuticals 
 
For the extensive physicochemical and biological characterization of protein drugs the 
use of state-of-the-art analytical methods is necessary. There are several techniques 
considered as well suited and essential for structural and physicochemical characterization 
of biologics [27]. Amongst the numerous methods available in the field of bioanalysis, 
capillary electrophoresis (CE), high-performance liquid chromatography (HPLC), as well as 
mass spectrometry (MS) have attained the most sincere attention in the context of 
characterization of protein and nucleic acid based biologics [28, 29, 30]. 
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2.2.1 Capillary electrophoresis 
 
Capillary electrophoresis (CE) is a powerful analytical technique that can be used in 
several modes of operation. Numerous application areas (DNA, carbohydrates, peptides and 
proteins, metabolites, enantiomers, inorganic anions, biologics, biotechnological, clinical and 
forensic samples) use CE in routine analysis for qualitative and quantitative characterization 
of products [31]. This technology is a widely applied separation technique during the last two 
decades. The separation unit simply consists of a fused silica capillary with an inner 
diameter below 100 µm (mostly 50 µm) containing <1 ppm metal oxide (quartz contained 60 
ppm). Such materials were developed in the late 1970s [32]. An external coating of 
polyimide, which gives the capillary full flexibility and stability, protects this fragile capillary. 
The high separation efficiency and selectivity of CE in combination with small sample 
(and solvent) consumption are some of the reasons, why this technique is widely used as 
analytical tool. The used capillaries should be chemically and physically resistant. With bare 
silica capillaries, adsorption of analytes onto the inner wall of the capillary might be a 
problem, particularly with (basic) proteins [33, 34]. Covering/modifying the surface by 
permanent or dynamic coatings can solve this problem. Coatings have also a major effect on 
the electroosmotic flow (EOF), a non-selective bulk-flow in the capillary towards the cathode 
if the capillary surface is net-negatively charged (creating a negative zeta-potential). With 
bare silica a cathodic EOF is established at pH values above 2.5 to 3, resulting from the 
dissociation of the silanol groups at the silica surface exhibiting pKa values in the range of 
4.5 to 5.5. 
Since 1989, fully automated capillary electrophoresis instruments became available [35]. 
To cope with the tiny peak volumes injected (nanoliters), the small internal capillary 
diameters (typically 50 µm) and the short light-pathways, highly sensitive detectors are 
required. Often, the detection is carried out directly on-capillary after removing the polyimide 
external coating (mostly by burning or scraping). Expansion of the light-path-length can be 
done by using bubble-cell capillaries or Z-shaped flow-through detection cells [35]. Up to the 
present, UV/VIS detectors are the most widely adopted detectors in the majority of the 
commercial systems, though potentially much more sensitive fluorescence detectors (FLD) 
with laser excitation (LIF) or excitations by light-emission diodes (LedIF) are available and 
increasingly used. The same holds for the universal contactless conductivity detectors. CZE 
can also be on-line coupled electrospray ionization (ESI) mass spectrometry (MS), a 
combination which allows one to profit from the entire potential of modern MS 
instrumentation and methodology for the purpose of structure elucidation. 
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! 
! 
Ultraviolet-visible (UV/VIS) detectors can be operated either at one wavelength using only 
filters for the specified wavelength window. Alternatively, multi-wavelengths detectors based 
on a photodiode array (PDA) can be implemented; they allow the simultaneous 
measurement of light absorption at various single wavelengths in the range of 190-600 nm. 
Their sensitivity is usually lower than single-wavelength instruments. For attaining high 
sensitivity in CZE, often the application of laser-induced fluorescence (LIF) is required. As 
with this method, the wavelength of the laser has to match with the excitation wavelength for 
the analytes, derivatization of the analytes is often necessary for attaining good 
fluorescence. 
 
Basic principles: 
 
In the most simple and most often used cases, capillary zone electrophoresis (CZE) takes 
place as electric potential driven migration (electrophoresis) in free homogeneous solution, 
i.e. without interactions between surfaces, or micellar or polymeric pseudo-stationary phases 
or sieving gels. Often, selectivity is easily and successfully tuned by use of secondary 
equilibria involving e.g. protonation/deprotonation or complexation equilibria. 
Electrophoretic separation is based on the differential movement of charged species in an 
electric field. Ions are separated according to the ratio of their charge, q, to their 
hydrodynamic radius, r, as the electrophoretic mobility of an ion, µe, is dependent on q/r in 
the following way: 
µ  = ! !∙!∙!∙!  (2.1) 
 
where η is the viscosity of the BGE solution. 
 
The electrophoretic migration velocity, ve, of an ion results from the mobility of the ion and 
the electric field strength (E) applied [32, 35]: 
 
𝑣𝑣! =  µ! ∙ 𝐸𝐸 (2.2) 
where E is dependent on the applied voltage, V, and the length of the capillary, L. 
 
𝐸𝐸 = ! ! (2.3) 
When dealing with non-permanent ions, the effective net-charge number, zeff, resulting 
from protonation/deprotonation or complexation equilibria have to be considered as it 
determines the effective mobility, µ!"", of the ion under the given pH conditions. 
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µ!!!  =  !!!""    (2.4) ! !∙!∙!∙!  
with 
 
𝑧𝑧!"" = ! 
   (2.5); for acidic analytes (one dissociation step) and 
 
 ! !!!"!"#!!" 
𝑧𝑧!"" = !  (2.6); for basic analytes (one protonation step)   ! !!!"!"!!"#  
In presence of a non-selective bulk flow, as e.g. an electroosmotic flow (EOF), the 
migration velocity and the finally attained selectivity and resolution is affected by this flow as 
well. 
One can define an “apparent” mobility, µapp, the mobility that is directly determined from 
the measured migration time according to the formula 
 ! ! 
  !!"" ! (2.7) 
 
where l indicates the distance from capillary inlet to detector. The apparent mobility, µapp, 
is the vector sum of the effective mobility, µeff, (depending on the features of the analyte) and 
the mobility inferred by the EOF, µEOF. 
µ!""  = µ!"" + µ!"# (2.8) 
If electrophoretic mobility of the ion and the direction of the EOF are towards the same 
direction (co-migration), the apparent ion migration becomes faster (shorter migration times). 
In case of counter-migration, apparent ion migration becomes slower (longer migration 
times) and the selectivity is enhanced in many cases. The strength of the EOF is thus an 
important parameter to be adjusted for a good CZE separation. 
The EOF originates at the capillary wall, under certain conditions, when a buffer solution 
is placed inside the capillary after applying a voltage. With bare silica, the silanol groups 
(SiOH) are (at least partially) ionized to negatively charged silanate groups (SiO-) if the pH 
value of the background electrolyte is higher than 2.5. Positively charged ions of the BGE 
are lining up opposite to the silanate ions creating an electric double layer. The loosely 
bound water-surrounded cations from the outer layer migrate to the cathode (most often is 
this the direction to the detector) dragging the uncharged molecules of the solvent (water) in 
this direction creating so the EOF. The velocity of the EOF (vEOF) is given by the following 
equation: 
𝑡𝑡 = 
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!"# 
! 
!  
! 
! 
𝑣𝑣 = ! !∙!∙! 𝜁𝜁 ∙ 𝐸𝐸 (2.9) 
 
where ε is the dielectric constant of the solution, η is the solution viscosity, and ζ is the 
potential established at the capillary wall. 
 
Selectivity and resolution 
 
The separation selectivity in electrophoresis is usually expressed in terms of the 
selectivity coefficient between pairs of analytes, j and i, and this selectivity coefficient is 
defined by the ratio of the effective mobilities: 
 
 
𝑟𝑟!,! = !""    !  !"" !  (2.10) 
 
Since the effective electrophoretic mobility 𝜇𝜇!""   is given by the actual mobility 𝜇𝜇!"#   times ! ! 
the degree of dissociation 𝛼𝛼! (or protonation), the selectivity coefficient can be written as: 
 
𝑟𝑟!,! =  !!"# !"# ! ! ! !!  (2.11) 
 
In CE systems with EOF, the selectivity coefficient of interest it the “apparent” selectivity, 
rjiapp, which is defined as the ratio of the apparent mobilities: 
 
𝑟𝑟!"" = !""    !   (2.12) !,! !"" !  
This equation allows one to estimate how strong an EOF enhances or decreases the 
selectivity of a CE system. 
Based on the previous definition of the selectivity coefficient, the resolution 𝑅𝑅!,! between 
two compounds j and i is obtained by the following equation. 
 
𝑅𝑅!,! = ! (𝑟𝑟!,! − 1) (2.13) 
 
where Ni is the so-called number of theoretical plates providing a measure for the 
efficiency of the system. It should be noticed that the resolution is proportional to (rj,iapp – 1). 
Most often, electrophoretic separations are based on differences in the pKa values of 
analytes, which can be tuned by the composition of the running buffer (i.e. background 
electrolyte, BGE). Differences in pKa values are the major sources for a successful 
separation in CZE. Systems with 100 000 theoretical plates (under typical conditions a CE 
separation invokes 50 000 – 500 000 theoretical plates [36, 37]) enable to achieve the 
separation of two compounds with very subtle differences in the pKa values which might be 
𝑁𝑁! 
! 
! 
! 
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even less than 0.01 units. Thus, even compounds with equal actual mobilities can be 
resolved under BGE conditions that allow one to use small differences in the pKa values. 
(This is often associated with low effective charge numbers of the analytes leading to long 
migration times and considerable peak broadening.) 
 
Capillary electrophoresis instrumentation 
 
A schematic drawing of a CE instrument is given in Scheme 2. The instrumental set-up 
basically consists of the capillary filled with BGE, two buffer vials filled with BGE as well, 
several injection vials filled with the sample solutions, a high-voltage source with voltages up 
to 30 kV, a sample/capillary temperature control, a detector and a data acquisition device 
(computer). 
 
Scheme 2: Capillary electrophoresis system. 
 
Modes of capillary electrophoresis 
 
Capillary electrophoresis comprises a family of techniques, which differ in separation 
principle/mechanism. The most frequently used modes of CE are: capillary zone 
electrophoresis (CZE, introduced above), capillary gel electrophoresis (CGE), micellar 
electrokinetic capillary chromatography (MEKC) – both take place in capillary zone 
electrophoretic modus, capillary isoelectric focusing (cIEF), capillary isotachophoresis (CITP) 
and capillary electro-chromatography (CEC), which is a chromatography (for neutral 
analytes) using EOF for the transport of solutes along the capillary towards the detector or a 
combination of chromatography and CZE (for ions). 
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Capillary gel electrophoresis 
 
Capillary gel electrophoresis (CGE) is a capillary electrophoresis method that uses 
sieving gels and charged surfactants like SDS for denaturation and uniform net-charging of 
the proteins. In this respect it is the method analogous to SDS/PAGE carried out in capillary 
format. A constant amount of SDS per unit protein weight (i.e., 1.4 g SDS/g of protein - with 
a few exceptions) is bound to the denatured proteins mainly by interactions between 
hydrophobic structures [38] resulting in a detergent-protein complex. Attached SDS masks 
the intrinsic charge of protein and leads to constant negative charge per unit mass as well as 
to a similar denatured shape of each complex. Without the sieving gel, SDS-protein 
complexes would hardly be resolvable by electrophoresis. 
CGE-SDS has been applied in protein analysis for more than two decades. By using 
replaceable and water-soluble linear polyacrylamide as the sieving matrix in the capillary, 
reproducible and robust analyses of proteins are attained since early 1990s [39]. CGE 
provides faster and more efficient separations than traditional SDS-PAGE without the need 
of gel fixation and visualization by staining but with on-column detection connected to data 
acquisition device [40]. 
 
Capillary isoelectric focusing 
 
Isoelectric focusing (IEF) is a separation method that can be applied to amphoteric (at 
least zwitterionic) analytes. When dealing with a mixture of amphoteric compounds, upon 
application of an electric field, these “ampholytes” line-up in a capillary according to their pI 
values forming a pH gradient. The anolyte (often phosphoric acid) terminates at the anodic 
side, the catholyte (often NaOH or NH4OH) at the cathodic side. As illustrated in Scheme 3, 
when inserting amphoteric or polyacidic/basic analytes like peptides and proteins into this 
IEF system and applying voltage, these compounds will migrate to positions in the pH 
gradient at which their net-charge will be zero (isoelectric point, pI). At this position, their 
migration stops because of zero charge [41]. The analytes are thus separated according to 
differences in their isoelectric points [42]. The system is autofocussing and generates very 
narrow peaks. With intact proteins, the reduced solubility at the pI might become a problem. 
Surfactants used for improved solubilisation must not infer any charge to the analytes. Non- 
ionic surfactants or permanently zwitterionic ones (like CHAPS) are suited for this purpose. 
IEF is a highly effective high-resolution technique allowing to resolve proteins with pI 
differences lower than 0.005 pH units [41]. IEF can be carried out in casted gels (e.g. 
polyacrylamide based) to which ampholyte solutions are added, or in polyacrylamide based 
gels with immobilized weakly acidic and weakly basic moieties which form an immobilized 
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pH gradient (IPG strips), or in a capillary format (cIEF) where ampholyte solutions are 
positioned in the capillary between the anolyte and the catholyte zones. 
The latter mentioned form of IEF provides automation, repeatable detection and 
quantification of various peptides and proteins. When carrying out a cIEF separation the 
capillary is initially filled with the carrier ampholyte solution and the analytes/proteins. Carrier 
ampholytes are mixtures of small molecules containing multiple amino- and carboxylate 
groups, they develop the pH gradient after application of an electric field. For attaining good 
focusing, it is decisive that the ampholyte species are well distributed in the desired pH 
range [41]. An ideal carrier ampholyte mixture includes good buffering capacity at the pI (|pI 
– pKa| <1), high conductivity at the pI of the studied molecule, cover molecular weights 
between 500-1000 Da and is soluble in common protein precipitants [43, 44, 45]. 
Free solution isoelectric focusing in a capillary (cIEF) can be performed on standard 
equipment for capillary electrophoresis, e.g. Beckman Coulter PA800, Agilent 7100 or the 
“Protein Simple iCE280” instrument can be used. Detection is commonly done by an on- 
column detector like in normal CZE or, often, also with a whole column UV absorption 
detector. Such a whole column imaging detection (WCID) avoids disturbances of focused 
protein zones [46] as it does not need any mobilization of the focused zones towards the 
detector site. Usually, the detectors are programmed to monitor at 280 nm as at this 
wavelength the absorption of the ampholytes, which form the pH gradient, is usually low. At 
254 nm, the interference with aromatic structures in the ampholytes might be significant. 
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Scheme 3: Isoelectric focusing. 
 
2.2.2 High-performance liquid chromatography of proteins 
 
High-performance liquid chromatography (HPLC) is an analytical tool that is widely 
applied for investigating in a quantitative way structural features of proteins and protein- 
based pharmaceuticals. The migration velocity (and thus the retention time) of a compound 
is determined by its intrinsic affinity for both the mobile phase and the stationary phase. The 
mobile phase is a liquid flowing through a column packed with solid particles – the stationary 
phase. The column is a tube of various lengths (usually 30-250 mm) and diameters 
(generally 2.1-4.6 mm) made from stainless steel or quartz filled with adsorbents (stationary 
phase) with particle sizes of 3 to 5 µm (HPLC) (and up to 50 µm in classical LC), various 
shapes (e.g. spherically or irregularly particles, monolithic porous media in shape of a 
cylinder or down to the shape of membranes) and the chemical nature of their material and 
surfaces (e.g. silica with all the various surface modifications, alumina, polymers neat or with 
attached ligands, etc.). Operating pressures are between 50-350 bars [47, 48, 49, 50]. 
Characterization of biopharmaceutical products is predominantly provided by HPLC in 
combination with UV-detection. Because of its high resolution, the reversed-phase HPLC 
technique (RP-HPLC) is well adapted for the analysis of protein samples [51]. The RP 
chromatographic mode uses a polar (i.e. most often aqueous organic) mobile phase and a 
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stationary phase that is less polar than the mobile phase. The stationary phase is based on 
chemically modified silica, using various functional groups to achieve a high selectivity and 
efficiency (an example of commonly used stationary phase ligands listed from non-polar to 
the most polar: alkyl, phenyl, fluoro, cyano and silica) [52]. 
The separation of analytes into single peaks by RP method is based on slight differences 
in the hydrophobicity of analytes. The use of organic modifier (most often acetonitrile and 
methanol) and, in the case of peptides, also of an ion-pairing agent (usually trifluoroacetic 
acid) is mandatory to attain optimal separation conditions [53]. The choice of organic 
modifier plays an important role because it affects the selectivity of the separation [54]. 
Organic modifiers can also affect the conformation of the protein, and this might impact 
protein quantification [55]. 
Another type of HPLC widely used in protein separation is size exclusion chromatography 
(SEC). In contrast to RP-HPLC, SEC separations can be carried out under non-denaturing 
solution conditions and, thus, have no or only minimal impact on higher order structures of 
proteins [56]. Until now, a variety of materials exhibiting size-exclusion effects was 
developed. Dextrans cross-linked with epichlorohydrine are known under the trade-name 
Sephadex. These gels are weakly acidic and tend to adsorb basic analytes, a problem that 
can be avoided by addition of salt to the eluent. Thanks its inertness, non-swelling behaviour 
and superior mechanical strength, porous silica became predominant as a column packing 
material. The utility of porous silica for the analysis of proteins is limited because of the 
strong ionic interaction due to the acidic surface silanols. Thus, diol-modified surfaces seem 
to be the best choice to mitigate these interactions and attaining non-adsorbing SEC 
surfaces for proteins. It is also worth to mention other polymeric resins, such as 
polyacrylamide-based gels or agarose [57]. 
Regarding detectors, similarly to CE, by far the most widely adopted detectors in 
commercial HPLC systems are UV/VIS diode array detectors (DAD) and fluorescence 
detectors (FLD). In modern commercial instruments, there are many other detectors 
available, which can be coupled to LC. Examples are (i) conductivity detectors, based on the 
fact that ionic components conduct electricity, measure the electric resistance which is 
indirectly proportional to the ions concentration [58]; (ii) multi-angle light scattering detectors 
[59]; (iii) evaporative light scattering detectors [58], (iv) refractive index detector (RID) which 
is suitable for detecting all analyte components in a sample. An important detection method 
which can be combined with HPLC, particularly RP-HPLC and SEC, is mass spectrometry 
(MS). It can easily be on-line coupled to HPLC when using an electrospray ionization (ESI) 
device. 
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Protein therapeutics must be “well-characterized” to assure their safety and efficacy. The 
demand for developing accurate, effective and reproducible methods is driven by the need 
to support the manufacturing process and product formulation. The development of 
appropriate analytical methods involves the considering of method benefits, method 
robustness and reproducibility, available laboratory equipment, needed operation personal, 
as well as its costs. In addition to HPLC, electrophoretic methods are rapidly becoming the 
tool of choice in pharmaceutical analysis. Within the last decades, CE manufacturers have 
invested much effort in improving the weak points in CE in order to develop a technique 
competitive to HPLC. Therefore, problems like insufficient reproducibility (due to reliance on 
the EOF), and low concentration sensitivity in optical detection (due to the short light pass) 
are being solved. In case of the unwanted presence of an EOF, the use of capillary coatings 
(dynamic or permanent) will be beneficial [60]. The use of more sensitive detection methods 
like laser-induced fluorescence (LIF) and electrochemical detection (ElD) as well as nano- 
ESI-MS can help to solve the sensitivity problem often associated with UV detection etc. 
[61]. (A rather practical problem is that, currently and compared to HPLC, only a few 
manufacturers of CE instruments are on the market, a situation which limits competition. 
The particular advantages of using capillary electrophoresis over HPLC deserve attention 
and should be described briefly. It is well known that CE separations are highly efficient (very 
narrow peaks), can be carried out within short analysis time, and time consuming sample 
pre-treatment is often not required, at least when using UV detection [60]. 
Based on the small diameter of the capillary, CE separations need only low sample 
volumes (some nL) and low solvent amounts. (This fact is very environmental-friendly and 
represents also a non-negligible financial advantage) [36]. A major advantage of CE is that 
the molecule charge, and thus migration velocity and selectivity, can easily be 
influenced/optimized by small variations in pH. This is more easily done in CZE than in 
HPLC. To keep a method reproducible and robust, the adjusting of the pH values of the 
running buffers have to be done very precisely [62]. It is worth to mention that there is an 
area in which CE has proved to be an excellent method, even better than all other 
separation techniques: separation of enantiomers. 
Some advantages and constraints of HPLC (RP, SEC, IEX) and CE (CZE, CGE-SDS, 
cIEF) techniques commonly used for biomolecule analyses and utilised within the studies of 
this Thesis are listed in Table 1: 
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Table 1: Benefits and limitations of HPLC and CE analytical techniques in the context of 
protein analysis. 
  Assessment of identity and purity of intact proteins  
Technique Benefits Limitations 
 
RP-HPLC/UV various column types available 
 
fractions can be collected for MS 
 
CZE/UV orthogonal to HPLC limited ability to collect fractions 
one multipurpose fused silica 
capillary (also coated) 
small amounts of sample sufficient 
 
SEC High-resolution separations of 
aggregates and impurities based 
on their size 
various column types 
fractions can be collected for 
further analysis 
CGE-SDS one multipurpose fused silica 
capillary (eventually coated) 
 
good resolution of high molecular 
weight aggregates and low 
molecular weight impurities 
limited resolution of high molecular 
weight aggregates and low 
molecular weight impurities 
 
 
long analysis times compared to 
CGE-SDS 
limited ability to collect fractions 
necessity of high pressure 
instruments (stable at 60 psi), 
frequent capillary blockages, usage 
of sticky gels demands proper 
cleaning of instruments 
 
fast, reproducible and quantitative expensive commercially available 
  buffers  
 
Peptide mapping 
 
Technique Benefits Limitations 
 
RP-HPLC/UV protein fingerprint can be monitored 
thorough QA/QC 
no mass information (fractions can 
be collected for further MS 
analysis) 
 
reliable, robust methods long gradients, time consuming 
CZE/UV one multipurpose fused silica 
capillary (eventually coated) limited ability to collect fractions 
 
RP-HPLC/MS peptide mass information requires experts for use and data 
analysis 
 
verification of sequence coverage, 
site identification of post- 
translational modifications 
 
CZE/MS orthogonal to HPLC Possible reproducibility issues with separations 
does not provide the same 
  sensitivity as LC/MS  
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Charge isoform analysis 
 
Technique Benefits Limitations 
 
IEX separation of protein charge 
variants using various anion and 
cation resins 
ability to fractionate and collect 
separated isoforms for further 
analysis 
cIEF high-resolution separation of 
protein isoforms 
one multipurpose fused silica 
capillary (eventually coated) 
long gradients, high buffer 
consumption, time consuming 
 
not directly MS compatible 
 
higher resolution separations than 
IEX 
not MS compatible, no possibility to 
collect fractions 
 
faster  separation than IEX expensive equipment 
UV  light applied over whole column no LIF detection 
whole-column 
cIEF 
no migration step to the detection 
window necessary 
not MS compatible, no possibility to 
collect fractions 
 
faster separation than cIEF expensive equipment 
 
 
2.2.3 Mass Spectrometry in hyphenation to separation methods 
 
Mass spectrometry (MS) is a highly effective analytical technique (its origin can be dated 
to the end of 19th or the beginning of the 20th century [63]) that plays an increasingly 
significant role in the study of biomolecules [64]. The ability to measure molecular masses 
with high sensitivity can be exploited in many fields of protein analytics; it is a favoured 
technique for protein characterization and quality control, routinely used for protein 
identification as well as for a detection and characterization of posttranslational modifications 
(PTMs) [64, 65]. Two major types of soft ionization MS methods should be briefly introduced: 
Matrix-assisted laser desorption ionization (MALDI) and Electrospray ionization (ESI). In 
MALDI, a mixture of analyte sample (usually less than one microliter) and a MALDI-matrix 
solution (also about 0.5 to 1 µL) are deposited onto a metal plate for co-crystallization. After 
drying, the sample/matrix spot becomes irradiated by a sequence of nanosecond laser 
pulses. By this method, predominantly ions of the type [M+H+]+ (attachment of a proton), or 
[M+Na+]+ and [M+K+]+ (attachment of an alkali cation) are generated. 
The electrospray method has been developed for analysing samples in solution. In ESI, a 
strong electrical field is applied to create fine charged droplets leading to more efficient 
ionization. During solvent evaporation by a flow of gas (typically nitrogen) and heat charged 
droplets are repeatedly reduced in size resulting in production of gas-phase ions. The in this 
way produced desolvated ions are immediately accelerated into the mass spectrometer by 
the applied electric fields [66]. Using this technique, larger molecules like peptides and 
proteins become multiply charged ions during the desolvation process leading to a charge 
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state distribution (detection in m/z ranges of 500 to 3000). For effective ionization in ESI, the 
analytes have to be to a large extent free of salts and detergents. 
By ESI, typically ions of the type [M+nH+]n+ (attachment of a several protons leading to a 
charge-state distribution) are generated, or [M+kNa+]k+ and [M+kK+]  k+  (attachment  of  a  
several cations). ESI can generate also  negatively  charged  ions  generated  by  the  
subtraction of a proton. The ion types are then mostly [M-nH+]n-, again giving a charge-state 
distribution with several values for n. In the  presence  of alkali ions, the  following  ion  types  
can be generated as well: [M+kNa-nH+](n-k)-. ESI-MS can be  utilised  for  studying  thermally 
labile molecules if their polarity allows the attachment of a charge (positive ion mode) or the 
detraction of charge (negative ion mode). The technique is described in more detail below in   
part HPLC-ESI-MS. 
Mass spectrometers are rather expensive instruments, particularly used in areas, where 
alternative analytical techniques cannot provide the level of performance required. All of 
these instruments measure the mass-to-charge ratio of ions generated from molecules. MS 
instruments differ by the working principles of the mass analyser employed, i.e. how they 
achieve mass separation. The most common instruments use time-of-flight (TOF) analyzers, 
quadrupole (Q) analyzers, ion trap (IT) analyzers, and (in more advanced instruments) 
orbitrap or ion-cyclotron-resonance- (ICR) analyzers. 
In hybrid instruments aimed for tandem mass spectrometry (MS/MS), combinations of 
these MS separation principles can be used. Examples are ESI-Qq-RTOF, ESI-QqQ, ESI-IT- 
ICR instruments. In this set up, a quadrupole (q) or an IT analyser is used as collision cell for 
the fragmentation of selected ions. The analyser following the collision cell is used for mass 
analysis of the generated fragments [67]. The MS/MS technique is commonly applied in 
structural analysis of biomolecules, for instance peptide sequencing and analysis of 
glycosylation or other PTMs. 
For peptide sequencing, the peptides become fragmented e.g. by vibrational excitation in 
the course of collision-induced dissociation (CID) (sometimes also called collision-activated 
dissociation (CAD)) or by generating impaired electrons e.g. by electron-transfer dissociation 
(ETD)-based fragmentation [68]. Here, the energy released in the exothermic capture of a 
thermal electron is used for fragmentation [69]. Peptide sequencing using CID-fragmentation 
occurs in the collision cell by collision with an inert gas. (The gas can be present constantly 
or introduced for a short moment especially for this purpose.) In case of CID [70] several 
peptide bonds along the backbone can be cleaved resulting in the formation of b ions 
(containing the N-terminus plus one more additional residues) and y ions (containing the C- 
terminus plus one more additional residues) as shown in Scheme 4. 
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Scheme 4: Nomenclature for ions generated in the fragmentation of peptide molecules by 
tandem mass spectrometry. 
 
Since CID may result sometimes in undesired cleavages of labile bound PTMs, the 
development of alternative fragmentation techniques was necessary. Applying the ETD 
technique, labile modifications (like acetylation, glycosylation, phosphorylation etc.) can be 
preserved providing the more comprehensive information on the site-specificity of 
modification. 
High-resolution (HRMS) instruments allow one to attain high mass accuracy as well, 
which is now typically between 3 to 5 ppm (with R values about 40,000 to 60,000) and sub 
1 ppm (with R values about several 100,000). Often external calibration or lock masses [71, 
72] are needed for assuring such high accuracy. The given numbers refer to the analyses of 
peptides and small molecules; for intact proteins a mass accuracy 10-20 ppm is a more 
realistic number [73]. 
With ESI ionization, large molecules like protein drugs typically acquire multiple charging 
(charge state distribution). For the molecular weight determination of such molecule the 
process called deconvolution [64] is commonly used (an algorithm-based process that 
groups the signals of various intensities into a single peak at the molecular weight of the 
analyte). 
 
HPLC-ESI-MS 
 
In HPLC-ESI-MS experiments, the sample components of interest are eluted from a 
HPLC- column, followed by ionization and transfer into mass spectrometer for analysis [64]. 
Reversed-phase HPLC (using C18 columns) (used for hydrophobicity based separations) 
directly coupled to a mass spectrometer (MS) became a very widely used technique in the 
context of protein identification. There, this set up is used for the monitoring of the peptides 
generated from the protein by enzymatic digestions. For this purpose a mobile phase 
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gradient with increasing content of organic solvent is routinely employed. The separated 
peptides are not only characterized according to their molecular masses but also (at least) 
partially sequenced by CID- or ETD-based fragmentation analysis. Protein identification and 
identity tests are commonly performed in this way [71]. 
 
CE-ESI-MS 
 
Since the end of the 80s, capillary electrophoresis coupled to MS has become an 
extremely powerful tool for the analysis of protein drugs. CE-MS exhibits interesting 
possibilities for the characterization of intact proteins, because particularly high separation 
efficiency can be achieved [74]. Also, relatively mild conditions as low temperature and low 
concentrations of salts or organic solvents contribute to the creation of high-performance 
separation systems for protein study, because conformational changes of proteins can be 
minimised [75]. 
In contrast to HPLC-MS, coupling of CE with MS is less straightforward. With CE-MS the 
effluent flow from the capillary is often not sufficient to generate an effective electrospray, 
particularly when using nano-ESI devices in combination with nano-HPLC-columns or HPLC 
chips. Therefore, various interfaces for various types of ionization sources (e.g. ESI, MALDI 
and ICP ionization for protein and peptide CE-MS analysis) have been designed [60, 76]. 
Coupling of CE to MS is most commonly carried out by ESI using either sheath liquid, 
sheathless, or liquid junction interfaces [77]. 
The components of the CE running buffers are an important aspect in CE-ESI-MS 
analyses. Preferably volatile, low concentrated buffers should be used to achieve a sensitive 
MS response. However, such buffers might not provide optimal conditions for CE 
separations. Efficient separations can be obtained by use of volatile buffers in the BGE, 
comprising acetate, formate anions and ammonium cation [77]. However, as discussed by 
Haselberg et al. in [76], ammonia, frequently used for the pH adjustment of the BGE, might 
lead to some extent to ionization suppression which could adversely affect sensitivity. 
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3 Results 
 
3.1 Study on the deamidation and aspartate isomerization of peptide and protein 
therapeutics using CZE-UV and HPLC ESI-MS 
 
One of the most common modifications in protein drugs is the deamidation of asparagine. 
The transformation of this molecule to aspartate can be described as a spontaneous, non- 
enzymatic reaction and although only minor structural changes can be observed, this 
process might have a serious impact on the drug functionality. Such medicament alteration 
may cause severe health problems to the patients and therefore this molecule alteration has 
to be controlled properly. 
This study presents various conditions that can be employed to produce some stressed 
material (where the asparagine is a subject of the transformation to aspartate). The impact of 
miscellaneous factors on the deamidation rate of a small model peptide (VYPNGA) is shown 
in detail and the results are compared with published data of other researchers. The findings 
from the peptide study were applied for further work with another small peptide (GSNSG) 
and more structurally complex molecules (Glu1-Fibrinopeptide, Hirudin, Lysozyme, 
Aprotinin, Interferon, Hemoglobin, BSA, Avastin and Erbitux). The ability to employ CZE-UV 
system for the determination and quantification of the deamidation products (aspartate and 
isoaspartate) is studied. The analysis conditions used by Boni et al. [78] and Lai et al. [79] 
were applied and adapted to achieve the most effective separation. Furthermore, the 
compliance with the requirements of mass spectrometry was considered. 
Under the natural (non-enzymatic) deamidation circumstances (or application of relatively 
mild stress conditions; as harsh conditions may lead to the protein degradation) long times 
are often necessary to produce deamidated samples. Considering the catalytic function of L- 
Asparaginases, which are able to hydrolyse asparagine to aspartate, the enzyme was used 
in the study of the acceleration of the deamidation rate in peptide (VYPNGA) and various 
proteins. 
The asparagine deamidation sites were investigated by common methods (HPLC-MS, 
CZE-MS). A novel procedure applied for the examination of deamidated molecules is also 
described: A utilization of an Asp-N enzyme for the pre-localization of newly formed 
aspartates by an enzymatic cleavage followed by CZE analysis with UV detection. 
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3.1.1 Introduction 
 
Structural aspects of deamidation, mechanism and factors involved 
 
In the last decades, biological applications within the pharmaceutical industry are one of 
the most developing technological areas. The monoclonal antibodies and antibody-domain 
based molecules represent the majority of protein therapeutics. The specificity of these 
molecules is determined by amino acid sequences in the complementarity determining 
regions of variable Fv domain. If asparagine or aspartate participates in antigen recognition, 
their modifications can lead to loss of functionality. These alterations can be recognized at 
the beginning of protein designing, which leads often to elimination of this product from the 
list of potential candidates. Some protein therapeutics can be protected by implementing of 
formulation strategies that are able to improve the stability of proteins to deamidation and 
isomerization. Sometimes in the drug development process such candidates are re- 
engineered and the problematical hot spots are removed. Despite of these protective actions 
the risk of degradation increases with the storage period and the therapeutic proteins can 
undergo deamidation. One of the most frequent routes of peptide and protein degradation is 
deamidation of asparagine and glutamine [80, 81]. This amino acid alteration may result in 
structural and functional changes, which depending on its position in the amino acid 
sequence of the affected protein may cause decreased bioactivity or unwanted immune 
response [82, 83]. Glutamine undergoes deamidation leading to glutamic acid formation with 
much slower deamidation rate than asparagine [84]. The degradation mechanism of 
asparagine proceeds via different pathways at acidic and alkaline pHs. Capasso et al. [85] 
reported that the deamidation pathway in the pH range 5-10 carries on exclusively via 
succinimide as shown in Scheme 5. The illustrated reaction is a visualization of asparagine 
joined to other amino acids on both sites in some peptide or protein. 
 
 
Scheme 5: Asparagine deamidation reaction. 
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Nucleophilic attack of the adjacent backbone nitrogen on the side chain carbonyl carbon 
of asparagine (Asn) leads to formation of a 5-membered cyclic succinimide intermediate and 
the release of ammonia [86]. This intermediate is spontaneously opened by the attack of 
water on either the α- or β-carbonyl group, resulting either in the formation of aspartate 
residue (Asp) or an isomerized isoaspartate (isoAsp) [80, 81]. It was observed that the 
mentioned hydrolytic cleavage of the succinimide intermediate provides a 
isoaspartate:aspartate product ratio of about 3:1 [80, 87, 88] in peptides (pH range 5-10). 
Deamidation of peptides or proteins results in a mass increase of 1 Da (see Scheme 5, NH2 
- 16 Da is replaced by OH – 17 Da [80, 89]). 
 
At pH ≥7 glutamine (Gln) deamidation follows the same reaction path as observed by 
asparagine through formation of a cyclic imide intermediate [81]. The slower rate of 
glutamine deamidation is explained by ring structure of cyclic imide intermediate. The six- 
membered ring cyclic imide is less stable than the five-membered ring of succinimide 
intermediate [84] and the direct hydrolysis of glutamine to glutamic acid (Glu) is favoured. 
The deamidation rate of asparagine and glutamine is dependent on buffer type, pH, 
temperature, ionic strength, primary sequence and structural aspects [80, 90]. Phosphate 
buffers were found more appropriate to catalyse deamidation [84, 90]. It has been observed 
that ammonium bicarbonate has also an increased catalytic effect compared to Tris-HCl [91]. 
At neutral to alkaline pH the rate of asparagine deamidation is affected by the amino acid 
sequence of the peptide. The more basic pH accelerates the deamidation rate by increasing 
hydroxide ion concentration [90, 92]. In contrast, acidic buffers do not lead to the typical 
aspartate and isoaspartate formation since almost exclusively aspartate is formed [87]. 
Deamidation rate increases with temperature, but too high temperatures may cause 
decomposition of the deamidation buffer [87, 93, 94]. In the case of Tris-HCl the elevated 
temperature leads to the formation of formaldehyde, which could form a covalent adduct with 
tyrosine [94]. Deamidation buffer decomposition could also result in the alteration of pH 
value, formation of small particles and the elevated risk of protein precipitation. The 
importance of ionic strength effects on deamidation has not been elucidated completely to 
date, but was observed in couple of studies. The higher the concentration of deamidation 
buffer, the faster is the deamidation reaction [95, 96]. Primary sequence plays a crucial role 
in deamidation. Cumulative evidence from a number of peptides and proteins indicates that 
these molecules contain deamidation-prone sites also called “hot spots” with N1-X motifs. 
The neighbour amino acid X is relatively small and hydrophilic (X=G, S, H2). Glycine was 
 
 
1 N – asparagine 
2 G – glycine, S – serine, H - histidine 
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found as the most destabilizing flanking amino acid, because this small molecule leaves the 
peptide group exposed and so able to be attacked by nucleophile [80, 87]. The asparagine 
destabilization is also expected in the proximate presence of serine, but this process is not 
described as fast as in the presence of glycine [80, 87, 97]. Also histidine, alanine, aspartic 
acid and arginine were found as semi-destabilizing (peptides including this amino acids 
deamidate with rate in the intermediate range) [87]. In contrast to these, amino acids with a 
large, bulky side chains (V, Y, L, P3 [81]) cause steric hindrance preventing or reducing 
deamidation of asparagine [87, 97]. Some experiments [98, 99] have shown that secondary 
structure has influence on deamidation. Asparagines hidden in the middle of alpha-helix or 
beta-turn are better sheltered from deamidation than the ones closer to the carboxyl end 
sequence [98]. M. Xie and Schowen [99] explained the protection of asparagine by 
conformation effects (e.g. different properties of alpha and beta in this regard). 
Tertiary and quaternary structure elements of proteins are also inhibiting deamidation 
rates [98]. Kossiakov [100] investigated the structural features that affect the deamidation 
process of asparagine in trypsin. Modelling suggested that certain sets of peptide torsion 
angles are incompatible with deamidation. All deamidated groups in trypsin were 
conformationally similar; asparagines were followed by serine residues. The non-deamidated 
asparagine is distinguished from the deamidated asparagines by having a different 
hydrogen-bonding structure. This interaction hinders the formation of the productive 
deamidation geometry. 
The aspartates present in peptides and proteins (not derived from asparagines by 
deamidation) are also unstable amino acids as they may undergo isomerization and 
enantiomerization [78, 101, 102]. This degradation mechanism is similar to the conversion 
mechanism of asparagine to aspartate and involves the nucleophilic attack of the β-carbonyl 
carbon by α-nitrogen next amino acid leading to the formation of an aminosuccinimide. The 
effect of various C-flanking amino acids on isomerization of Asp residue has been studied in 
peptides, proteins and monoclonal antibodies. As observed by Asn also here the C-terminal 
glycine and serine facilitate succinimide formation and aspartate isomerization [103, 104, 
105]. 
 
Separation and identification of deamidated forms 
 
To detect deamidation of asparagine in protein drugs and to separate the newly formed 
deamidated structures from parent molecules is still a challenging job in protein analysis. 
Since the additional negative charge and increase in molecular mass are close associated 
 
3 V – valine, Y – tyrosine, L – leucine, P - proline 
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with aspartate formation, electrophoretic (isoelectric focusing (IEF), capillary zone 
electrophoresis (CZE)) as well as chromatographic methods (reversed-phase 
chromatography (RP-HPLC), ion exclusion chromatography (IEX), hydrophobic and affinity 
chromatography) are the suitable analytical tool for the separation of deamidated forms [10, 
106 and 107]. 
HPLC is a common analytical technique, which is to date state-of-the-art technology for 
separation of peptides. Changes in hydrophobicity caused by replacement of an amide by a 
carboxylic acid can be exploited with RP-HPLC [10, 108]. Long analysis times are needed in 
order to achieve a good separation profile of not deamidated peptide from its deamidated 
isoforms (L-Asp, D-Asp, isoAsp and succinimide), since very shallow gradients are applied 
[109, 110, 111]. Because the alterations can be better detected in peptide pattern than in 
whole protein, the enzymatic treatment of proteins is used to produce peptide fragments. 
Afterwards the asparagine deamidation is monitored by peptide mapping. It was observed, 
that four different isoforms of hexadecapeptide elute in this order: isoAsp, Asn, Asp and 
succinimide using H2O/TFA and acetonitrile/TFA as eluents [89]. Despite such methods, 
separation of asparagine peptide from isoaspartate peptide remains challenging due to the 
similar selectivity (e.g. asparagine and isoaspartate have the same hydropathy index [112]). 
Fortunately, isomerization induces structural changes, which might have some influence on 
retention time of these isomers and lead to separated peaks [89]. 
 
Capillary electrophoresis is able to provide superior resolution of peptides and proteins 
due to its charge-based separation mechanism [33]. In comparison with RP-HPLC, this 
method offers fast separation without any long equilibration steps, stable capillary to capillary 
reproducibility (after suppression of EOF) and is also very environmental-friendly because 
only small amounts of background electrolytes are required [113]. Capillary electrophoretic 
separation mechanism differs from HPLC. Capillary zone electrophoresis separation 
mechanism is based on charge-to-mass ratio [114], or better charge-to-hydrodynamic 
radius, whereas RP-HPLC separation of analytes uses the distribution between stationary 
and mobile phase, where polarity of the analytes is responsible for the separation of 
compounds [115]. Upon deamidation the amide in the side chain of the amino acid converts 
into carboxylic acid, which leads to the formation of an additional negative charge and 
possibility to separate asparagine-containing peptide from aspartate. By contrast to RP- 
HPLC, the CE is capable to separate closely related species if they possess even small 
differences in charge [79]. Asp and isoAsp peptides differ slightly in the pKa values of their 
carboxylic groups, which causes small charge differences. Separation buffers with pH near 
the pKa of these carboxylic acids (pH 3.0) should result in resolution in this order: Asn, Asp, 
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isoAsp [79]. The separation systems that fulfil these requirements are acetic acid and 
phosphate run buffers and fused silica capillaries [79, 78, 107]. 
Mass spectrometric identification of deamidated small peptides is straightforward while 
direct quantitation of aspartate and isoaspartate stays challenging, due to the missing mass 
difference between aspartate and isoaspartate. The level of isomerization can be determined 
after methylation, using protein isoaspartate methyltransferase, followed by hydrolysis of 
methyl ester, which leads to a mass shift of 2 Da [116]. The isoaspartyl methyl esters are 
labile molecules, which spontaneously cyclize within couple of minutes to form succinimides 
followed by hydrolysis to Asp or isoAsp. To reach the stable molecule the isoAsp methyl 
esters are coupled with nucleophilic hydrazines or hydroxylamines resulting in peptide 
hydrazides [117, 118]. 
Another elegant approach in aspartate/isoaspartate detection is an utilization of site- 
specific enzymatic cleavage. Enzyme, which possesses the ability to fulfil this task, is called 
endoproteinase Asp-N [119]. Asp-N is a metallo (Zn) protease, which hydrolyses peptide 
bonds on the N-terminal side of aspartate while isoaspartate residues remain undigested 
[120]. Many researchers have studied the specificity of this enzyme. It has been reported 
that Asp-N cleaves also on the N-terminal side of cysteic acid residues, if they are not 
alkylated [120, 121]. It appears that this metalloprotease has some preferences for small 
hydrophilic residues [122]. Published data about Asp-N digestion of erythrocyte carbonic 
anhydrase and erythrocyte D-aspartyl/L-isoaspartyl methyltransferase demonstrate cleavage 
specificity for N-terminal side of glutamyl residue [123]. This enzyme property could be also 
used for detection of glutamine deamidation to glutamic acid in peptides and proteins. It 
seems that Asp-N prefers some acidic residues more, than other independently of flanking 
sequences [123]. Finding of the optimal digestion conditions would contribute to the higher 
enzyme specificity. Enzyme digestions conditions were therefore a part of the study and are 
later discussed. 
The application of Asp-N enzymatic digest on samples of interest combined with CZE-UV 
technique might be an interesting approach for a pre-localization of deamidated sites. The 
strategy, facts and expectations are introduced below. 
If one asparagine is present in peptide or protein, which undergoes 
deamidation/deamidation, isomerization to aspartate and isoaspartate and the Asp-N digest 
is applied, following situation can be described by Scheme 6. 
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Scheme 6: Deamidation of asparagine and its Asp-N cleavage. 
 
X-N-Y in Scheme 6 represents the peptide P (I.) with one deamidation site (N). 
Asparagine undergoes deamidation/deamidation, isomerization after incubation and forms 
newly more acidic X-D-Y/X-Diso-Y variants (III.). If Asp-N is applied, the enzyme will be able 
to cleave only X-D-Y motifs at the N-terminus of aspartate (II., IV.). 
 
Scheme 7: Visualization of electrophoretic separation of deamidated peptide and its Asp- 
N cleavage products. 
 
For better illustration of the deamidation process of peptide P followed by Asp-N digestion 
as depicted in Scheme 6, a respective schematic CZE profile is shown in Scheme 7. The 
demonstration of peptide separation using an acidic run buffer system, where all ions carry 
positive charge [79], is explained in four following simplified examples. After incubation of P 
(upper left panel, I.) a decreased signal of P is observed. At the same time new signals PD, 
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PD, iso appear (upper right panel, III.). This process might continue during the entire 
incubation period until the asparagine is completely deamidated. 
Asp-N digestion induces no changes in the separation profile, if no aspartates are present 
in the peptide (lower left panel, II.). In contrast, the aspartate in PD (upper right panel, III.) is 
a subject of enzymatic digestion and its signal will disappear with concurrently creation of 
two new signals P1, P2 (lower right panel, IV.). At the same time PD, iso signal will stay 
unaltered, since the Asp-N enzyme is able to hydrolyse only non-isomerized aspartate [119]. 
It must be taken into account, that the new appeared signals P1 and P2 are not the 
quantitative mirror of the PD peak. The intensities of the observed peaks do not reflect the 
quantitative amount of the respective peptides using a wavelength of 214 nm. This detection 
technique is used for monitoring of peptide bonds. Therefore for a semi-quantitative 
comparison the length of the observed peptides (number of amino acids, responding peptide 
bonds) should be concerned [124]. 
 
Enzymatic deamidation by L-Asparaginase 
 
L-asparaginases are widely used in the treatment of cancer, especially acute 
lymphoblastic leukemia. This enzyme is capable to perform the hydrolysis of L-asparagine to 
L-aspartate and ammonia. Using this ability, there is an eventual possibility to induce the 
deamidation in peptides and proteins without long deamidation procedure. Avoiding the long 
incubation process would decrease the risk of possible test sample decomposition, targeted 
deamidation would offer faster results and minimize side effects caused by long incubation. 
Until now there is no known example of successful experiment, where the asparaginase 
was used as a tool to deamidate asparagine within a peptide or protein. All published works 
discuss about free asparagine conversion to aspartate [125, 126]. Expected enzyme activity 
is shown in Scheme 8. 
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Scheme 8: Hypothetical function of L-Asp. 
 
Michalska and Jaskolski [127] described the catalytic mechanism of asparaginases as 
follows: “In the first step, the enzyme's nucleophile, activated via a strong O-H...B hydrogen 
bond to an adjacent basic residue, attacks the C atom of the amide substrate, leading 
through a tetrahedral transition state to an acyl-enzyme intermediate product. The negative 
charge that develops on the O atom of the amide group in the transition state is stabilized by 
interactions with adjacent hydrogen bond donors. The constellation of those donors (which 
typically are main-chain N-H groups) is known as the "oxyanion hole". The second step of 
the reaction is similar, but now the attack on the ester C atom is launched by an activated 
water nucleophile”. 
 
Strategy for the investigation of deamidation 
 
The overall strategy is described in depth in section “Separation and identification of 
deamidated forms” (page 31-33). Briefly the test sample is exposed to various conditions to 
induce deamidation, non-deamidated and deamidated samples are analysed (intact and 
digested by Asp-N) by CZE and HPLC. Upon deamidation, the Asp-N digestion pattern may 
be different as shown in Figure 3 and Figure 4. This results from multiple presences of 
cleavable sites in larger peptides and proteins. The careful selection of test samples (see 
Table 2) should result in better understanding of deamidation behaviour therefore a broad 
spectrum of samples (e.g. molecules with short/long amino acid chains; molecules with 
typical N-G, N-S deamidation motifs; molecules with one, two or more possible deamidation 
sites etc.) was assessed regarding relevance and applicability in the study’s context. 
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Table 2: Studied samples introduced in detail. 
 
Sample Amino acid sequence 
Peptide 1 (P1) VYPN4GA 4 
Peptide 2 (P2) GSN3SG 
Glu1-Fibrinopeptide (F) EGVN4DN6EEGFFSAR [128] 
Hirudin (H) VVYTDCTESGQN
12LCLCEGSN20VCGQGN26KCILGSDGE 
KN37QCVTGEGTPKPQSHN52DGDFEEIPEEYLQ [129] 
 
Literature [80] describes the VYPNGA peptide as an unstable peptide with a deamidation 
half-life of one day in 150 mM Tris-HCl (pH 7.4 at 37 °C). According to the same literature 
source, the deamidation rate of GSNSG peptide is significant slower with the deamidation 
half-time of 15 days using the same degradation conditions. These two peptides will be 
studied in detail and the acquired knowledge will be applied for further examinations. 
 
3.1.2 Materials and Methods 
 
Materials 
 
Test samples used in this study were purchased from various manufacturers: Peptide 1 
(VYPNGA), Peptide 2 (GSNSG) from Bachem; Aprotinin, bovine serum albumin (BSA), 
Glu1-Fibrinopeptide, Hirudin, Hemoglobin, Lysozyme and Myoglobin from Sigma; Avastin 
from Roche; Erbitux from Merck; Interferon from Fluka and Protein P from customer. 
Acetic acid, ammonium bicarbonate, disodium hydrogen phosphate, dithiothreitol (DTT), 
ethylenediaminetetraacetic acid (EDTA), hydroxypropyl methylcellulose (HPMC), 
iodoacetamide (IAA), 1 M Tris-HCl, pH 8.05 and zinc acetate were purchased from Sigma. 
Acetonitrile (ACN), ammonium hydroxide, hydrochloric acid (HCl), sodium hydroxide 
(NaOH), trifluoroacetic acid (TFA), tris(hydroxymethyl)aminomethane (Tris) were purchased 
from Fluka. Conditioning solution, SDS-MW gel buffer were purchased from AB Sciex, 
RapiGest from Waters. Enzymes Asp-N and Lys-C were obtained from Roche, L- 
Asparaginase from Emelca Bioscience. 
Fused silica capillary was obtained from CM scientific, 3 kDa filters from Millipore, air 
displacement pipettes, thermomixer and centrifuge from Eppendorf. 
Methods 
 
Forced deamidation. Stressed samples were prepared in 50 mM ammonium bicarbonate 
pH 8.0, (except degradation study of Hirudin, following the instructions in [130]: 170 mM 
disodium hydrogen phosphate, pH 8.0). If not otherwise specified, all test samples were 
 
 
4 Summary of standard amino acids and their abbreviations are presented in Table 41. 
5 for all Tris-HCl solutions of pH 8.0 
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incubated at 40 °C. Concentrations of dissolved samples: Peptide 1 and Peptide 2: 1 
mg/mL, Glu1-Fibrinopeptide 2 mg/mL, Hirudin 5 mg/mL. 
 
Asp-N digestion. Asp-N enzyme was added to the peptide at a ratio 1:100, the 
peptide/enzyme mixture was then diluted to a final concentration of 0.8-2 mg/mL with milli-Q 
water and incubated at 37 °C (25 °C in case of Peptide 1) for 14-18 h. 
 
Asp-N digestion of Hirudin. Prior to Asp-N digestion, Hirudin sample was incubated after 
addition of 0.1 % final concentration RapiGest and 50 mM final concentration DTT at 37 °C 
for 1 h. Alkylation was achieved using 85 mM final concentration IAA. Current buffer was 
changed to digestion buffer containing 50 mM Tris-HCl, pH 8.0, 2 mM zinc acetate using 3 
kDa filters and centrifugation. The Asp-N was added to the sample at a ratio 1:100 (w/w) and 
the protein/enzyme mixture was diluted to a final concentration of 1.5 mg/mL with the 
digestion buffer and incubated at 37 °C for 18 h. 
 
Lys-C digestion of Hirudin. Prior to Lys-C digestion, the Hirudin sample was incubated 
after addition of 50 mM final concentration DTT (37 °C for 1 h). Alkylation was achieved 
using 80 mM final concentration IAA. Current buffer was changed to digestion buffer 
containing 50 mM Tris-HCl/2mM EDTA, pH 8.0 using 3 kDa filter and centrifugation. Lys-C 
enzyme was added to the peptide at a ratio 1:20 (w/w), the protein/enzyme mixture was then 
diluted to a final concentration of 1.5 mg/mL with the digestion buffer and incubated at 37 °C 
for 18 h. 
 
L-Asparaginase digestion. One unit of L-asparaginase was added to each 20 µg of 
peptide/protein in 50 mM Tris-HCl pH 8.66. After gentle homogenization the sample/enzyme 
mixture was incubated at 40, 50 and 60 °C. 
 
Electrophoretic conditions. CZE was carried out on the PA800 Beckman Coulter (AB 
Sciex) instrument with temperature controlled autosampler using fused silica capillary (50 cm 
of length, 50 µm id) with normal polarity (unless otherwise stated). The cathode was at the 
detector end of the capillary for the analyses with pH of 2.5. The capillary was flushed (by 
HCl, NaOH and milli-Q water) from appropriate buffer reservoirs using pressure (50 psi) prior 
to each run. The dynamic coating was applied (conditioning solution, 20 psi) and the 
capillary was filled with running buffer (3 % AcA, pH 2.5, unless otherwise stated7) using 
pressure (50 psi). The sample was injected using pressure (0.5 psi) for 10-20 s, the constant 
voltage of 30 kV was applied and the operation temperature of 25 °C was kept. 
 
6 prepared from Tris powder, pH adjusted by 1 M HCl. 
7 acetate running buffers with pH above 2.5 were adjusted by 10 % NH3.OH. 
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Electropherograms were UV-monitored at 214 nm and the data were processed with 32 
Karat. 
Mass spectrometry analyses were carried out in positive mode on Agilent G1600 AX and 
Bruker microTOF-Q instruments using sheath Liquid: IPA/H2O 60:40 + 1 % formic acid.8 
Chromatographic conditions. Reversed phase chromatography was carried out using an 
Agilent 1200 binary pump system with temperature controlled autosampler and vacuum 
degasser coupled to Thermo Quadrupole Ion Trap MS LTQ XL (linear ion trap mass). The 
analytes were introduced onto X-Bridge BEH300 C18 3.5 µm, 2.1 x 150 mm column from 
Waters and the flow rate was maintained at 0.2 mL/min. The column was equilibrated with 
mobile phase A (0.1 % TFA in H2O). Mobile phase A and mobile phase B (0.1 % TFA in 
ACN) were used to establish the 120 min gradient as shown in Table 3. 
The UV chromatograms were obtained by monitoring absorbance at 214 nm and the data 
were processed with Chromeleon software (Dionex). Peptides were then analysed on the 
LTQ XL equipped with HESI-probe Version 1 at an electrospray potential of 4.5 kV and 
capillary temperature of 275 °C, sheath gas pressure 25 psi and auxiliary gas flow 10 arb 
units. The LTQ XL was set to perform data acquisition in the positive ion mode (m/z full scan 
range 200-2000). The most intense ion was selected for Zoom Scan and then for MS/MS by 
using a data dependent scheme and dynamic exclusion. The data were acquired with 
Thermo Scientific™ Xcalibur Software. Data analysis was performed using Thermo 
Scientific™ PepFinder™. 
 
Table 3: Gradient. 
 
time [min] mobile phase B [%] 
0 0 
5 0 
85 50 
86 90 
96 90 
97 0 
120 0 
 
 
 
 
 
 
 
 
 
 
8 CZE MS results provided K. Jooss, University Aalen. 
39  
3.1.3 Results and Discussion 
 
3.1.3.1 Forced degradation of Peptide 1 - VYPNGA 
 
As introduced in detail in chapter 3.1.1 (Separation and identification of deamidated 
forms, Strategy for the investigation of deamidation), chromatography and electrophoresis 
will be applied for the examination of intact and Asp-N digested unstressed and stressed 
samples. In this study forced deamidation of Peptide 1 was induced using a degradation 
buffer consisting of 50 mM ammonium bicarbonate, pH 8.0 and elevated temperature 
(40°C). 
In theory, the partial deamidation of Peptide 1 asparagine leads to the formation of three 
possible peptide variants: P1 (Asn), P1D (Asp) and P1D, iso (isoAsp) as illustrated in Scheme 
99. Masses and pI values of Peptide 1 deamidation variants were calculated using the 
Expasy software [131] and are summarized in Table 4. 
 
 
 
Scheme 9: Expected signals after heating stress of Peptide 1 (no enzyme digest) with 
possible peptide modifications: P1: no deamidation, P1D: N4 position deamidated, P1D, iso: 
N4 position deamidated and isomerized. 
 
Table 4: Calculated [131] monoisotopic masses and pI values for undigested Peptide 1: 
not-deamidated and N4 deamidated. 
 
Peak name / Sequence Mass [Da] pI 
P1: VYPN4GA 619.30 5.49 
P1D:VYPDGA 620.66 3.80 
 
In a first step, LC coupled to MS was used to study the unstressed and forced 
deamidated Peptide 1. The present signals were identified and investigated for the presence 
of deamidation of asparagine. After peak detection further experiments were performed 
using capillary zone electrophoresis and UV detection. 
As described in chapter 3.1.1, HPLC in the reversed-phase mode is well suited for the 
investigation of asparagine deamidation due to subtle differences in hydrophobicity and 
structure between Asn, Asp and isoAsp [10, 108]. According to Yang and Zubarev [89] four 
different variants of asparagine containing peptide/protein can be expected after partial 
deamidation. The separation order of these variants will be following: isoAsp, Asn, Asp and 
 
9 The presence of succinimides is not demonstrated, because this unstable intermediate product is 
according to literature quickly hydrolysed to the aspartyl or the isoaspartyl residue. 
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succinimide when using H2O/TFA and acetonitrile/TFA as eluents. Nilsson et al. [132] 
introduced another elution order of these peptide/protein forms: Asn, isoAsp, Asp and 
succinimide in presence of low pH buffers (pH 2). They observed a co-elution of Asn and 
isoAsp as well as separated aspartate in the more hydrophobic region than Asn signal. 
 
Figure 1: RP-HPLC: Zoomed UV-chromatogram (214 nm wavelength) overlay from 18- 
32 min for Peptide 1. From bottom to top: unstressed (black), 24 h 40 °C (blue). 
Experimental conditions: X-Bridge BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN 
with 0.1 % TFA, flow rate 0.2 mL/min, column temperature 50 °C. 
 
Figure 1 shows an overlay of two HPLC/UV chromatograms taken before and after the 
forced degradation of Peptide 1. Additionally, mass spectrometry data were used for peak 
identification (see Figure 41, Figure 42 in chapter 7) and the results are listed in Table 5. The 
peak names represent the Peptide 1 variants/fragments. In addition to P1, a small amount of 
P1D, succinimide dimer and VYPN fragment were detected in unstressed sample (black 
trace). The not defined peak between P1 and P1 dimer could represent an intermediate 
dimer. 
Four deamidated variants (with elution order: P1D, iso, P1D, succinimide and succinimide 
dimer), P1 and P1 dimer were observed in the chromatogram of stressed Peptide 1 (blue 
trace). The same elution order was reported by Nilsson et al. [132] under similar 
chromatographic conditions. Comparing the findings in Figure 1 with the ones reported by 
Nilsson et al., we were able to separate Asn, Asp and isoAsp peptide variants of Peptide 1 
when using the above described separation conditions. Results illustrated in Figure 1 and 
discussed above differ significantly from HPLC results published by Lai et al. [79]. Lai 
described the presence of only three Peptide 1 variants (P1, P1D and P1D, iso in their 
chromatograms. The missing succinimide could be due to several reasons, including the fact 
that their forced degradation conditions differed from the conditions used in this study (they 
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degraded the peptide in 50 mM ammonium bicarbonate, pH 12). Also Lai’s separation 
conditions were not the same; a flow rate was 1.2 mL/min, whilst Figure 1 represents the 
separation using the shallow gradients with a lower flow rate of 0.2 mL/min. Steep gradient 
could lead to co-elution of some signals. Unfortunately Lai had not discussed the absence of 
succinimide. 
 
Table 5: Comparison of theoretical m/z values [131] with observed masses in 
unstressed/stressed Peptide 1 (HPLC UV/MS).10 
 
Peak name RT [min] Theoretical m/z Measured m/z 
VYPN 21.4 492.24 492.38 
P1 24.5 620.30 620.38 
P1 dimer § 25.5 1221.58 1221.72 
P1D, iso § 24.9 621.28 621.34 
P1D 26.5 621.28 621.31 
P1succinimide § 26.9 603.30 603.42 
P1succinimide, dimer § 29.0 1187.58 1187.69 
z = 1 for all signals; § found in stressed sample only. 
 
It is obvious that small amount of P1D (black trace, 26.5 min) has been already detected 
in unstressed test sample. The presence of such peptide modification might be caused by 
e.g. long storage in freezer or sample manipulation. Compared to the unstressed sample a 
much higher P1D signal was observed in the stressed sample (26.5 min). The signal with the 
elution time of 24.9 min was assigned to P1D, iso. The molecular masses found for this signal 
do not differ from P1D and the peak assignment will be discussed in section Asp-N digestion 
(Figure 3). The following new signal (blue trace, 26.9 min), which was eluted in the 
subsequent neighbourhood of P1D, represents succinimide. Succinimide converted from 
asparagine leads to a mass decrease of 17 Da due to the release of ammonia (see Scheme 
5). Based on their masses also the presence of P1 dimer (25.5 min) and its succinimide 
(29.0 min) was confirmed. Some small hydrophilic fragments (black and blue trace, 21 min) 
in front of the P1 signal were assigned to amino acid sequence VYPN and are most likely a 
result of the unsuccessful attachment of G and A amino acids during production. 
 
As discussed above, the presence of the deamidated species was verified by the 
described HPLC method. In order to prevent long analysis times and to achieve the best 
possible separation of the deamidated products CZE was chosen for further investigations. 
The application of appropriate electrophoretic conditions allows the separation of closely 
related species such as Asp and isoAsp (as described in detail in chapter 3.1.1, Separation 
 
10 LTQ XL typical accuracy +/- 0.5 m/z. 
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and identification of deamidated forms) in a short period of time. As published by Lai et al. 
[79] the resolution of Asp and isoAsp will be achieved by using a separation buffer with a pH 
close to the pKa values of Asp and isoAsp peptide carboxylic acids. We optimised Lai’s 
analytical method (instead of using phosphate buffer, pH 3.0 the separation was performed 
with 3 % acetic acid, pH 2.5) to study the deamidated forms of Peptide 1. Using the acetate 
running buffer system of pH 2.5 we expect the following migration order of peptides: P1: 
P1D: P1D, iso ([79], Scheme 7). 
 
 
Figure 2: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay from 0-     
10 min for Peptide 1 (1 mg/mL). From  bottom  trace to top trace: unstressed (black), 2 h    
40 °C (dark blue), 4 h 40 °C (green), 6 h 40 °C (pink), 24 h 40 °C (light-blue). Experimental 
conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm fused silica capillary, dynamic coating 
with capillary conditioning solution,  separation  temperature:  25  °C,  separation  voltage: 
30 kV, injection 0.5 psi 10 s. 
 
A series of CZE measurements was performed to monitor the deamidation of Peptide 1 
during the incubation period of 24 hours (shown in Figure 2). The peaks were identified on 
the basis of the known migration order in this separation system and of the expected 
isoAsp:Asp ratio 1:3 [80]. The signal decrease of P1 (5.5 min) is clearly visible during the 
whole incubation procedure. The amount of deamidated products increased with time 
judging from  the peak areas of two new signals in electropherograms (P1D 6.5 min and 
P1D, iso 7 min). 
When applying CZE, a faster separation of asparagine peptide and both main 
deamidation variants (P1D and P1D, iso) was achieved compared to HPLC. The pH value of 
the background electrolyte (2.5) used in this analysis resulted in an unwanted peak 
broadening. Increasing the pH to 3.0, (as reported by Lai [79]), led to an impaired peak 
resolution. The separation of only three signals was achieved using acetate buffer. The 
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additional signals (succinimide, dimers) present in Figure 1 were not observed, even with 
further modifications of the running buffer. 
Following the strategy introduced in chapter 3.1.1 (Separation and identification of 
deamidated forms), the site-specific enzymatic cleavage of unstressed and stressed material 
was performed. The application of Asp-N enzymatic digest on samples of interest should 
lead to the presence of new peptides, if there is some aspartate present in stressed sample 
(Scheme 6, Scheme 7). As performed with intact Peptide 1 samples (Figure 1 and Figure 2), 
the chromatographic signals were identified according to their masses after Asp-N digestion. 
Further experiments with Asp-N digested samples were performed using CZE with UV 
detection after identification by LC-MS. 
The Asp-N enzyme cleavage of partially deamidated Peptide 1 yields peptides as 
illustrated in Scheme 10. 
 
 
Scheme 10: Expected signals after heating stress and complete Asp-N digestion of 
Peptide 1. P1: no deamidation, P1D, iso: N4 position deamidated and isomerized, P2, P3 
cleavage products of Asp-N digested deamidated Peptide 1. Presented Asp-N cleavage 
products were expressed with respect on partial peptide deamidation or deamidation, 
isomerization. 
 
Asp-N enzyme creates new peptides only in the presence of aspartate. Therefore it is 
anticipated that the chromatographic profile of unstressed digested Peptide 1 will not differ 
from the profile of samples, which have not been digested (black trace, Figure 1). Because 
the presence of aspartate (P1D) was confirmed in the stressed sample (blue trace, Figure 1) 
P1D signal should be cleaved by Asp-N enzyme. In addition to the presence of P1D, iso, two 
new peaks (P2 and P3) should be detected in the HPLC chromatogram with the properties 
stated in Table 6. 
 
Table 6: Calculated [131] monoisotopic masses and pI values for in-silico Asp-N digested 
deamidated Peptide 1. 
 
Peak name / Sequence Mass [Da] pI 
P2: VYP 377.20 5.49 
P3: DGA 261.11 3.80 
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Figure 3: RP-HPLC: Full scale (0-32 min) and zoomed UV-chromatogram (214 nm 
wavelength) overlay for Peptide 1 digested by Asp-N. From bottom trace to top trace: 
unstressed, Asp-N (black), 24 h 40 °C, Asp-N (blue). Experimental conditions: X-Bridge 
BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 
mL/min, column temperature 50 °C. 
 
The chromatograms obtained after Asp-N digestion of Peptide 1 (unstressed and 
stressed) are shown in Figure 3. In addition to P1 peptide (24.4 min), VYPN fragment    
(21.6 min), succinimide dimer (29.1 min) and traces of P2 and P3 signals were detected in 
the mass spectrum of unstressed Asp-N digested sample. The presence of VYPN fragment 
was already discussed above. The observation of P2 and P3 peptides can be explained by 
the presence of low P1D signal in unstressed sample (Figure 1). 
In comparison with results obtained for stressed non-digested Peptide 1 (Figure 1) a 
significant decrease of the P1D signal (blue trace, 26.5 min) and two additional peaks were 
detected (blue trace, 2.5 and 25.5 min) in chromatogram of stressed Asp-N digested sample. 
The molecular weights of these two signals were determined by mass spectrometry and the 
peaks were assigned to P2 and P3 peptide fragments. This demonstrates clearly that Asp-N 
enzyme cuts selectively at the N-terminal side of aspartate. In addition to the new created 
peptides, P1 (blue trace, 24.4 min) and P1D, iso signals (blue trace, 24.9 min) were identified 
in the chromatogram. The MS data evaluation is shown in Table 7. 
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Table 7: Comparison of theoretical m/z values [131] with observed masses in 
unstressed/stressed Asp-N digested Peptide 1 (HPLC UV/MS).11 
 
Peak name tR [min] Theoretical m/z Measured m/z 
P3 2.5 378.20 378.34 
VYPN 21.6 492.24 492.32 
P1 24.4 620.30 620.42 
P1D, iso § 24.9 621.28 621.41 
P2 25.5 262.10 262.18 
P1D § 26.5 621.28 621.38 
P1succinimide § 26.9 603.30 603.42 
P1succinimide, dimer 29.1 1187.58 1187.71 
z = 1 for all signals; § found in stressed sample only 
 
It became apparent after the chromatographic study of Asp-N digested samples, that the 
present deamidation can be clearly detected using UV detection. This can be achieved by 
visual comparison of chromatograms of the unstressed and stressed digested samples. A 
major benefit of this method is the detection of deamidation without using mass 
spectrometry. 
The previous CZE experiments with intact Peptide 1 samples demonstrated the ability of 
this method to visualize the deamidated variants within a short period of time. The 
electrophoretic analysis of Asp-N digested samples will complete the whole investigation 
strategy. As illustrated in Scheme 7, there should not be any further signals present in 
unstressed digested Peptide 1, except of P1. The situation for stressed digested Peptide 1 
should offer a greater variety of signals; presence of P1, P1D, iso and P2 or P3 (or both) 
peaks is expected in the electropherogram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 LTQ XL typical accuracy +/- 0.5 m/z 
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Figure 4: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for Peptide 
1 digested by Asp-N(0.8 mg/mL). From bottom trace to top trace: unstressed, Asp-N (black), 
24 h 40 °C, Asp-N (blue). Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm 
fused silica capillary, dynamic coating with capillary conditioning solution, separation 
temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
As apparent from electropherograms of unstressed and stressed Peptide 1 (Figure 4), P1 
(both 7.5 min) was not subjected to enzymatic hydrolysis. The same situation was observed 
for P1D, iso (blue trace, 9.5 min). As expected the P1D (blue trace, 8.5 min) was enzymatically 
cleaved and one new signal – P212 was found in electropherogram (blue trace, 6.5 min). The 
low P1D signal found after Asp-N digestion corresponds with the situation in Figure 3. The 
not labelled peak (7.5 min) is presumed to be a VYPN signal found in MS spectrum (Figure 1 
and Figure 3). 
 
Factors involved in deamidation process 
 
As specified in more detail in chapter 3.1.1, the deamidation process is affected by many 
factors. The deamidation rate depends, i.a., on primary sequence. Asparagine can be 
degraded easily to aspartate and isoaspartate form, if the side chain of the C-flanking amino 
acid is relatively small and hydrophilic [80, 87]. It was expected that asparagine in Peptide 1 
undergoes rapid deamidation reaction due to N-G motif. The fast aspartate and isoaspartate 
formation was observed in the degradation study monitored by CZE (Figure 2). But there are 
further factors having an influence on deamidation rate of peptides and proteins that would 
be worthwhile to study (e.g. buffer type and buffer concentration, pH, temperature). Many of 
them were miscellaneously combined and used for the deamidation studies of Peptide 1. 
 
 
12 The peak assignment was done after the electrophoretic run using the wavelength of 280 nm 
(fragment VYP consist of aromatic amino acid). 
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How the three of them influenced the asparagine degradation is presented in Table 8 and 
the results are discussed below. 
 
Table 8: Observed degradation of Peptide 1 within 24 hours in 50 mM ammonium 
bicarbonate, pH 8.0 at 40 °C, within 3 days in 20 mM ammonium bicarbonate, pH 8.0 at 
40 °C and within 24 hours in 50 mM Tris-HCl, pH 8.0 at 40 °C. 
 
50 mM ABC pH 8.0, 40 °C 
Incubation period Acorr % P1 Acorr % P1D Acorr % P1D, iso P1D, iso / P1D 
2 h 95.2 1.2 3.6 3.0 
4 h 79.1 4.6 16.3 3.5 
6 h 69.3 6.6 24.2 3.6 
24 h 13.3 18.3 68.4 3.7 
20 mM ABC pH 8.0, 40 °C 
Incubation period Acorr % P1 Acorr % P1D Acorr % P1D, iso P1D, iso / P1D 
1 d 64.9 6.8 28.3 4.2 
2 d 39.2 12.1 48.7 4.0 
3 d 10.5 18.6 70.9 3.8 
50 mM Tris-HCl pH 8.0, 40 °C 
Incubation period Acorr % P1 Acorr % P1D Acorr % P1D, iso P1D, iso / P1D 
2 h 93.8 1.5 4.7 3.1 
4 h 83.7 4.1 12.2 3.0 
6 h 70.0 7.7 22.3 2.9 
24 h 14.2 24.2 61.6 2.5 
Results are reported as means of duplicate determinations. 
 
The acceleration effect of all three buffers on deamidation of Peptide 1 was tested. As 
apparent from P1D, iso / P1D (isoAsp/Asp) results, the succinimide hydrolysis to isoaspartate 
varied not only between studies, but also during the incubation period. Patel and Borchardt 
[133] studied the effect of pH and buffer concentration on the ratio of isoAsp/Asp in 
hexapeptides at 37 °C and observed that this ratio varied in the range of 3.2 to 4.2 in the 
basic pH (6.0-12.0) depending on deamidation buffer. When comparing different molarities 
of ammonium bicarbonate deamidation buffer the same degree of deamidated variants was 
achieved after an incubation time of 24 hours in 50 mM ammonium bicarbonate, whereas an 
incubation time of 3 days is needed when using 20 mM bicarbonate. The results of the 
degradation study in 50 mM Tris-HCl are comparable with 50 mM ammonium bicarbonate. 
Tris-HCl conditions seem to affect the succinimide hydrolysis resulting in the production of 
more aspartate, than it has been observed by ammonium bicarbonate. The highest 
deamidation rate was observed for 50 mM ammonium bicarbonate, pH 8.0 – within 24 hours 
almost  70  %  of  asparagine  was  deamidated.  Because  it  was  reported  that  elevated 
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temperatures could lead to the formation of formaldehyde using Tris-HCl [94], the 50 mM 
ammonium bicarbonate will be the preferred choice for further degradation studies. 
 
3.1.3.2 Forced degradation of Peptide 2 - GSNSG 
 
Using the same degradation conditions as described in chapter 3.1.3.1, the slower 
deamidation rate was expected due to the present N-S motif [15, 87] in contrast to the 
Peptide 1. Partial deamidation of N3 asparagine leads to presence of three peptide variants: 
P2 (Asn), P2D (Asp) and P2D, iso (isoAsp) as illustrated in Scheme 1113. 
 
 
Scheme 11: Expected signals after heating stress of Peptide 2 (no enzyme digest) with 
possible peptide modifications: P2: no deamidation, P2D: N3 position deamidated, P1D, iso: 
N3 position deamidated and isomerized. 
 
It has been shown on Peptide 1 sample that capillary electrophoresis combined with Asp- 
N digestion is a very effective method in detection of asparagine deamidation. Similarly as 
described above, firstly, the measurements of intact (unstressed and stressed) samples 
were planned. If some indication of deamidation is found, the electrophoretic examination of 
Asp-N digested samples will follow. 
To induce asparagine deamidation in Peptide 2, the peptide was subjected to elevated 
temperature (40 °C) and degradation buffer (50 mM ammonium bicarbonate, pH 8.0). For 
the estimation of the deamidation rate the incubated peptide was analysed by CZE in 
intervals of approximately 2 days. As shown in Figure 5 about 30 % of Peptide 2 was 
degraded in almost one week. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 The presence of succinimides is not demonstrated, because this unstable intermediate product is 
according to literature quickly hydrolysed to the aspartyl or the isoaspartyl residue. 
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Figure 5: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for Peptide 
2 (1 mg/mL). From bottom trace to top trace: unstressed (black), 6 d 40 °C (blue). 
Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm fused silica capillary, 
dynamic coating with capillary conditioning solution, separation temperature: 25 °C, 
separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
In addition to the main signal P2 (6.0 min) being found in unstressed and stressed 
samples, there were two further signals: P2D? (blue trace, 6.7 min) and P2D, iso? (blue  trace, 
7.7 min) detected in electropherogram of stressed sample in Figure 5. In comparison to the 
CZE deamidation profile of Peptide 1 in Figure 2 these three signals are not separated in 
typical distances. Especially the P2D, iso? deviates from the expected separation profile and 
does not migrate in the close proximity of P2D?. Besides generating different electrophoretic 
profile of degradation products a P2D, iso?:P2D? (isoAsp:Asp) peak area percentage ratio was 
approximately 5:1 after 3 weeks of incubation (see Table 9). The described situation is 
nevertheless possible, because the stress conditions differ from nature conditions. Despite 
of this fact, aforementioned result is surprising when compared to the isoAsp:Asp ratio 3:1 
findings from studies of other peptides [80, 87, 88] or to Peptide 1 results (stated in Table 8). 
 
Table 9: Observed degradation of Peptide 2 within 21 days in 50 mM ammonium 
bicarbonate, pH 8.0 at 40 °C. 
 
50 mM ABC pH 8.0, 40 °C 
Incubation period Acorr % P2 Acorr % P2D? Acorr % P2D, iso? P2D, iso? / P2D? 
2 d 90.5 3.0 6.2 2.1 
8 d 70.1 5.2 21.5 4.1 
15 d 52.1 7.7 36.2 4.7 
21 d 46.5 7.8 41.6 5.3 
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As performed with Peptide 1 (Figure 4), the unstressed and stressed Peptide 2 was 
digested with Asp-N enzyme and analysed by CZE. It is expected that the enzyme will cause 
the hydrolysis of P2D? if P2D? represents the aspartate form of Peptide 2. 
 
 
Figure 6: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for Peptide 
2 digested by Asp-N (1 mg/mL). From bottom trace to top trace: unstressed, Asp-N (black), 
6 d 40 °C, Asp-N (blue). Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm 
fused silica capillary, dynamic coating with capillary conditioning solution, separation 
temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
Two electropherograms of Asp-N digested samples (Figure 6) are practically identical to 
the data introduced in Figure 5. Based on these results it can be presumed, that the peaks 
labelled as degradation products (7.5 and 9.0 min) do not represent any form of deamidated 
asparagine. The CZE signals demonstrate with a relatively high probability some fragments 
formed by hydrolysis of N- or C-terminal amino acid. Further HPLC-MS investigation of intact 
and Asp-N digested samples proved neither presence of deamidated variants nor aspartate 
cleavage products in MS spectrum (data not shown). The knowledge derived from these 
experiments might be helpful to recognize deamidation in further research. Besides 
appearing new signals, the particular attention must be given also to the peak distances and 
isoAsp:Asp ratio. 
 
3.1.3.3 Forced degradation of Glu1-Fibrinopeptide 
 
The application of CZE and Asp-N digestion for the investigation of deamidation will be 
demonstrated on more complex molecule than Peptide 1 or Peptide 2. 
To induce deamidation, the Glu1-Fibrinopeptide was exposed to a degradation buffer 
consisting of 50 mM ammonium bicarbonate, pH 8.0 and an elevated temperature (40°C). 
The peptide degradation was monitored by CZE-UV of intact samples. Mass spectrometry 
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(CZE-MS, HPLC-MS) was introduced to identify the degradation products and to determine 
the number of deamidated asparagines. Afterwards, the CZE-UV (CZE-MS) analysis of Asp- 
N digested samples completed the investigation. 
As apparent from the primary structure of Glu1-Fibrinopeptide (referred to as a signal 
variant F in Scheme 12), there are two potential deamidation sites (asparagines) located on 
the N- and C-terminal side of aspartate. Under certain circumstances the D5 aspartate can 
be converted into isoaspartate and/or the N4, N6 asparagine(s) can undergo 
deamidation/isomerization as demonstrated by possible scenarios in Scheme 12. 
 
 
Scheme 12: Possible signals variants after forced degradation of Glu1-Fibrinopeptid: no 
deamidation, D5 position isomerized, N4 position deamidated/isomerized, N6 position 
deamidated/isomerized and its combinations. 
 
The variability of the degradation products increases with each deamidated asparagine. If 
both of the asparagines will be partially deamidated/isomerized and D5 partially isomerized 
there is the possibility to observe 18 different forms of this peptide. Including the presence of 
succinimide, the amount of possible peptide variants will continue to grow. 
52  
 
 
Scheme 13: Visualization of electrophoretic separation of unstressed and stressed Glu1- 
Fibrinopeptide. In addition to the main signal (F), further signals can be observed after forced 
degradation leading to a partial N4 deamidation/isomerization and partial D5 isomerization. 
 
Exemplary, an electropherogram (Scheme 13), where N4 asparagine is partially 
deamidated/isomerized and D5 aspartate is partially isomerized14, would appear as 
described subsequently. Because of the partial degradation, the peak representing Glu1- 
Fibrinopeptide (F) can still be detected in the electropherogram. This F signal will be lower 
than the one in unstressed sample, because it is reduced by the amount of all degradation 
products. F1D and F1D, iso as two expected N4 deamidation products will be visible as two 
peaks under optimal electrophoretic conditions in the electropherogram. Is the isomerization 
of D5 faster than deamidation of N4, Fiso variant will be participating on reduction of the F 
signal. Should the isomerization of D5 occur simultaneously with N4 asparagine 
deamidation, the Fiso1D and Fiso1D, iso peaks will be also found between degradation products. 
Using the acidic buffer (pH 2.5) and normal polarity, at least three peaks (in the 
separation order Asn, Asp and isoAsp) are expected in electropherograms of stressed 
samples. Should the N4 and N6 deamidated variants be present (labelled as F1D and F2D in 
Scheme 12), it is quite likely that these signals will co-migrate. As listed in Table 10, the F1D 
and F2D deamidated forms have the same physicochemical properties and will possess the 
same charge. It is anticipated that the variant F1D2D will be separated later than F1D or F2D 
due its lower pI value. 
 
 
 
 
 
 
 
 
 
14 The presence of succinimides is not demonstrated, because this unstable intermediate product is 
according to literature quickly hydrolysed to the aspartyl or the isoaspartyl residue. 
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Table 10: Calculated [131] monoisotopic masses and pI values for undigested Glu1- 
Fibrinopeptide: non-deamidated and N4, N6 deamidated. 
 
Peak name / Sequence Mass [Da] pI 
F: EGVN4DN6EEGFFSAR 1570.59 4.00 
F1D: EGVDDNEEGFFSAR 1571.58 3.83 
F2D: EGVNDDEEGFFSAR 1571.58 3.83 
F1D2D: EGVDDDEEGFFSAR 1572.56 3.71 
 
 
 
 
Figure 7: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for Glu1- 
Fibrinopeptide (2 mg/mL). From bottom trace to top trace: unstressed (black), 1 d 40 °C 
(blue), 4 d 40 °C (green), 7 d 40 °C (pink). Experimental conditions: BGE: 3 % AcA pH 2.5, 
40/50 cm 50 µm fused silica capillary, dynamic coating with capillary conditioning solution, 
separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
As illustrated by electropherograms in Figure 7, the forced degradation of Glu1- 
Fibrinopeptide resulted in the presence of a couple of new peaks. As the F signal decreases 
the signals representing the deamidation and degradation products are concurrently 
increasing during the whole incubation. Derived from previous experiences (the CZE study 
of stressed Peptide 1), some of these signals could represent the deamidated variants. The 
molecular weights of present peaks were determined by mass spectrometry and the main 
three signals were assigned to F (5.7 min), F1D, F2D (6.2 min) and F1D, iso, F2D, iso (6.7 min). 
Also, the presence of F1D2D was detected (observable as peak shoulder at F1D. Using this 
method it cannot be distinguished between F1D and F2D signals, as well as between F1D, iso 
and F2D, iso, therefore the present peaks were assigned to both variants. The corresponding 
MS data are summarised in Table 11. 
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Table 11: Comparison of theoretical m/z values [131] with observed masses in 
unstressed/stressed Glu1-Fibrinopeptide (CZE-ESI-MS).15 
 
Peak name tm [min] Theoretical m/z Measured m/z 
F 5.7 786.29 786.31 
F1D, (F2D) § 6.2 786.79 786.79 
F1D2D § 6.2 787.28 787.30 
F1D, iso, (F2D, iso) § 6.7 786.79 786.76 
z = 2 for all signals; § found in stressed sample only. 
 
The peptide degradation was monitored within a period of one week. As shown in Table 
12, the incubation of Glu1-Fibrinopeptide led to degradation of about 50 % of F signal after  
7 days. In addition to the above-described Glu1-Fibrinopeptide variants there were also 
some signals present in the more acidic area. These degradation products were mostly 
fragments formed by hydrolysis of N- or C-terminal amino acids and participated on F 
degradation from almost 10 % after 7 days (data not shown). The ratio of isoAsp/Asp16     
(FD, iso/FD) increased from 2.9:1 after one day to 3.2:1 after one week and it could be 
presumed, that this ascending trend in the succinimide hydrolysis to isoAsp would continue 
with further incubation. 
 
Table 12: Observed degradation of Glu1-Fibrinopeptide within 7 days in 50 mM 
ammonium bicarbonate, pH 8.0 at 40 °C. 16 
 
50 mM ABC pH 8.0, 40 °C 
Incubation 
period Acorr % F Acorr % FD
16
 Acorr % FD, iso FD, iso/FD 
1 d 89.4 2.5 7.3 2.9 
4 d 73.4 5.8 17.6 3.0 
7 d 51.8 9.7 30.7 3.2 
Results are reported as means of triplicate determinations. 
 
As demonstrated in Table 11, the presence of two deamidated asparagines was 
confirmed using CZE-ESI-MS. Additionally, chromatographic investigations of intact samples 
were performed in order to verify the results (data not shown). A molecular mass 
representing the F1D2D variant (m/z = 787.112+) was found in mass spectrum after 
chromatographic separation. MS/MS was applied for further confirmation of multiple 
deamidation (for ion chromatogram see Figure 43 in chapter 7). The b4-ion was observed 
 
 
 
15 Micro-TOF typical accuracy +/- 100 ppm. 
 
16 FD demonstrates the F1D or F2D variant (or both if they co-migrate), FD, iso represents F1D, iso or 
F2D, iso (or both). 
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after low-energy CID fragmentation with m = 401.3 Da, whereby the N4 deamidation has 
been proved. The y9-ion at m = 1057.4 Da confirms the N6 deamidation site. 
Because the separation of the multiple deamidated products was not achieved using 
current electrophoretic conditions, the electrophoretic method was optimized. Gennaro and 
Solano reported [134], that the multiple N→D17 substitutions could be separated using a    
20 mM acetic acid, pH 4.5 as a running buffer. Exemplary, three synthetic peptides with 
nearly equal amino acid chains (NN, ND, DD) were examined and the separation resulted in 
superior resolution of charged peptide variants. To achieve the optimal separation conditions 
for multiple deamidated species of Glu1-Fibrinopeptide, the following aspects were 
considered: 
(1) Using of higher pH than pI value of peptide variants will affect the ion charges; they 
became a negative and therefore the reverse polarity will be applied for separation. 
(2) Dynamic coating will control the peptide adsorption onto capillary wall. 
 
Based on previous experience and applying the above-mentioned conditions to double 
deamidated Glu1-Fibrinopeptide, the order of separation can be predicted: 
F1DF2D:F1D(F2D):F18. In addition to these peaks, the presence of isomerized variants is also 
expected in electropherogram. 
 
Figure 8: CZE: Full scale UV-electropherogram (214 nm wavelength) of Glu1- 
Fibrinopeptide stressed for 7 d at 40 °C. Experimental conditions: BGE: 20 mM AcA pH 4.5, 
40/50 cm 50 µm fused silica capillary, dynamic coating with capillary conditioning solution, 
separation temperature: 25 °C, separation voltage: -30 kV, injection 0.5 psi 10 s. 
 
 
 
17 one letter abbreviation system: N for asparagine and D for aspartate 
18 Using the one letter abbreviations then DD:DN(ND):N represent the F1DF2D:F1D(F2D):F Glu1- 
Fibrinopeptide variants. 
56  
A significant improvement of former  peak  resolution  (Figure  7)  was  achieved  using 
20 mM acetic acid as BGE for the separation of stressed Glu1-Fibrinopeptide. As evident 
from the electropherogram in Figure 8, it is not only possible to separate DD:D:N signals 
[134], but also their isomerized products. Using the above-described conditions, the Glu1- 
Fibrinopeptide - F is separated with the longest migration time (13.5 min). As introduced in 
Table 10, F has the highest pI value and is the weakest anion of all present peptide variants. 
Based on the MS results (summed in Table 13), the peaks with migration time between 8 
and 13 minutes were assigned to the various Glu1-Fibrinopeptide variants. The separation 
order was following: F1D, iso 2D, iso, F1D2D, F2D, iso, F2D, F1D, iso, F1D. The deamidated peptide 
variants have lower pI values (Table 10), a more negative charge and are separated with 
shorter migration times than F. The F1D and F2D signals (DN, ND variants) cannot be 
determined from the UV profile. The peak assignment was established as described below. 
The peak with the migration time of 11.7 min was labelled as F1D and the other deamidated 
form as F2D (10.0 min). The explanation for the peak resolution of two peptides with same 
amino acid sequences is seen in different physical properties (hydrodynamic radii) of DN 
and ND variants. The signal with migration time of 11.3 min was assigned to the F1D, iso.. Iso 
determination was based on the known migration order of isoAsp and Asp forms and 
approximately 3:1 isoAsp:Asp ratio. The same principle was applied to the F2D, iso variant. 
The possibility to separate the F1D and F1D, iso (F2D and F2D, iso) from each other is 
explained by slight differences in pKa’s of aspartate and isoaspartate. The DD form 
represented by F1D2D peak (8.8 min) migrated with the lowest migration time in relation to 
the DN or ND variant. As stated in Table 10, this molecule has the lowest pI value, therefore 
a strongest negative charge and moves fastest towards the anode. The peak F1D, iso 2D, iso 
(8.5 min) was considered to be an isomerized form of F1D2D. 
Contrary to the improved peak resolution demonstrated in Figure 8, these electrophoretic 
conditions led to an unstable current during the MS runs. This fact mainly disturbed the peak 
identification via ESI-MS19. Higher concentration of running buffer (50 mM) offered the same 
electrophoretic profile and significantly more stable current during the MS run. Despite of this 
improvement, the identification of peptides with a migration time lower than 8.3 min was not 
achieved. 
 
 
 
 
 
 
 
 
 
19 CZE MS results provided K. Jooss, University Aalen. 
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Table 13: Comparison of theoretical m/z values [131] with observed masses in stressed 
and stressed Asp-N digested Glu1-Fibrinopeptide (CZE-ESI-MS).20 
 
Peak name mt [min] Theoretical m/z Measured m/z 
F1D, iso 2D, iso 8.5 787.28 787.32 
F1D2D 8.8 787.28 787.38 
F2D, iso 9.7 786.79 786.83 
F2D 10.0 786.79 786.79 
F1D, iso 11.3 786.79 786.85 
F1D 11.7 786.79 786.79 
F 13.5 786.29 786.30 
z = 2 for all signals. 
 
Further electrophoretic experiments with Asp-N digested samples should help to improve 
the introduced peak assignment. It is expected that all Glu1-Fibrinopeptide variants will be 
cut into smaller peptides; except one: Fiso1D, iso 2D, iso. Despite of the short amino acid chain of 
Glu1-Fibrinopeptide, many peptide variants may be present in electropherogram after 
analysis. It must be taken into account that the studied stressed molecule will not be very 
likely fully degraded. The partially isomerized aspartate and partially deamidated/isomerized 
asparagine will increase the number of present signals after Asp-N digestion. An example 
will be introduced in detail below the Scheme 14. This scheme describes the specific Asp-N 
cleavage of Glu1-Fibrinopeptide with partially isomerized D5 aspartate and/or 
deamidated/isomerized N4 and N6 asparagines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 microTOF-Q typical accuracy +/- 100 ppm. 
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Scheme 14: Possible signal variants after Asp-N digest of forced degraded Glu1- 
Fibrinopeptide: no deamidation, D5 position isomerized, N4 position deamidated/isomerized, 
N6 position deamidated/isomerized and its combinations. Presented Asp-N cleavage 
products were expressed with respect on partial/fully peptide isomerization, deamidation or 
deamidation, isomerization. 
 
For example, if N4 partially deamidates/isomerizes and D5 partially isomerizes, 6 variants 
of Glu1-Fibrinopeptide could be observable – F, Fiso, F1D, Fiso1D, F1D, iso, Fiso1D, iso. Because 
of the Asp-N enzyme specificity, the Fiso and Fiso1D, iso variants do not undergo enzymatic 
cleavage. The other Glu1-Fibrinopeptide variants will be enzymatically hydrolysed to P1, P2, 
P3, P6, P8 and P11 peptides. pI values and masses of all peptide fragments are listed in 
Table 14. 
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Table 14: Calculated [131] monoisotopic masses and pI values for in-silico Asp-N 
digested Glu1-Fibrinopeptide: not-deamidated, N4, N6 deamidated/isomerized. 
 
Peak name / Sequence Mass [Da] pI 
P1: EGV 303.32 4.00 
P2: EGVN 417.42 4.00 
P3: EGVDiso 418.40 3.67 
P4: EGVNDiso 532.51 3.67 
P5: EGVDisoDiso 533.49 3.49 
P6: D – not visible 133.10 3.80 
P7: DNEEGFFSAR 1171.19 4.14 
P8: DEEGFFSAR 1057.08 4.14 
P9: DDisoEEGFFSAR 1172.17 3.92 
P10: DDisoNEEGFFSAR 1286.28 3.92 
P11: DDisoDisoEEGFFSAR 1287.26 3.77 
 
Asp-N enzyme should cleave the unstressed Glu1-Fibrinopeptide at the N-terminal side 
of D5 aspartate leading to the generation of two new peptides (P2 and P7). The same 
electrophoretic conditions as for the examination of stressed sample in Figure 8 will be 
applied. Due to different physicochemical properties, P2 and P7 should appear as two 
separated peaks in electropherogram, P7 as a weaker anion with longer migration time than 
P2. Presence of F1D, iso 2D, iso, F1D2D, F2D, iso, F2D, F1D, iso and F1D peaks, demonstrated in 
stressed sample (Figure 8), is no longer anticipated in electropherogram after Asp-N 
digestion. In addition to the presence of P2 and P7, some other peptide variants illustrated in 
Scheme 14 are expected. 
60  
 
 
Figure 9: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for Glu1- 
Fibrinopeptide unstressed and stressed for 7 d at 40 °C, Asp-N digestion (1.0 mg/mL). From 
bottom trace to top trace: unstressed, Asp-N (black), 7 d 40 °C, Asp-N (blue). Experimental 
conditions: BGE: 20 mM AcA pH 4.54, 40/50 cm 50 µm fused silica capillary, dynamic 
coating with capillary conditioning solution, separation temperature: 25 °C, separation 
voltage: -30 kV, injection 0.5 psi 10 s. 
 
An electrophoretic separation of Asp-N digested unstressed and stressed sample is 
illustrated in Figure 9. MS was used to identify the present electrophoretic signals and the 
mass spectrometric data obtained for the two Asp-N digests are listed in Table 15. Data 
concerning the Asp-N digest of unstressed sample show the presence of both expected 
digestion products P2 (11.3 min) and P7 (14.8 min). The peptide at a migration time of 
8.5 min (previously determined as F1D, iso 2D, iso) remained undigested. Because Asp-N 
enzyme does not hydrolyse the isoaspartates the former peak description was stated more 
precisely to Fiso1D, iso 2D, iso. Some peaks (F1D2D, F2D, iso, F2D, F1D, iso and F1D) that were 
present in non-digested sample (Figure 8) disappeared after Asp-N digestion and a series of 
new peptides became detectable. Peptide P9 (9.5 min) could be assigned to a digestion 
product of deamidated Glu1-Fibrinopeptide. The rest of the peptides detected at a migration 
time between 5.0 to 7.5 min could not be identified using MS (this was most likely caused by 
the current problems in this time interval). The new occurred signals were considered as P3, 
P4, P5 or P11 (5.0-7.5 min) peptides on the basis of their low pI values. Based on the 
remaining peptide F signal (13.5 min), it should be emphasized that some changes occurred 
in enzyme action compared to the unstressed sample. It was presumed that the cleavage 
sites of stressed peptide are not easily accessible for enzyme as it was seen for unstressed 
sample. Although the amount of the undigested F peptide was minimal, this observation 
should be, in the future, kept in mind. 
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Table 15: Comparison of theoretical m/z values [131] with observed masses in stressed 
and stressed Asp-N digested Glu1-Fibrinopeptide (CZE-ESI-MS).21 
 
Peak name mt [min] Theoretical m/z Measured m/z 
Fiso1D, iso 2D, iso 8.5 787.28 787.32 
P9 * 9.5 587.08 586.74 
P2 11.4 418.421+ 418.181+ 
F * 13.5 786.29 786.30 
P7 15.0 586.60 586.23 
z = 2 for all signals (unless otherwise stated); * found in stressed sample only. 
 
In order to gain a better idea of disappearing and new present signals after Asp-N 
digestion the electropherograms of stressed undigested and stressed digested samples 
were compared in Figure 10. 
 
 
Figure 10: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for intact 
(2 mg/mL) and Asp-N digested (1 mg/mL) stressed Glu1-Fibrinopeptide. From bottom trace 
to top trace: 7 d 40 °C (black), 7 d 40 °C, Asp-N (blue). Experimental conditions: BGE: 
20 mM AcA pH 4.5, 40/50 cm 50 µm fused silica capillary, dynamic coating with capillary 
conditioning solution, separation temperature: 25 °C, separation voltage: -30 kV, injection 
0.5 psi 10 s. 
 
The data illustrated in Figure 10 were already discussed in detail above (Figure 8 and 
Figure 9). By the visual comparison of these two experiments it is easier to detect all 
deamidated variants. 
Because there were a couple of nonspecific cleaved peptides present in Glu1- 
Fibrinopeptide, some attempts were made to optimize the digestion procedure. The producer 
recommendation [135] of using Tris buffer and pH about 8.0 was followed. The cleavage of 
 
21 microTOF-Q typical accuracy +/- 100 ppm. 
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cysteine residues can be protected by alkylation and this step was carried out after sample 
denaturation and reduction before digestion buffer exchange. To minimize the cleavage at 
the N-terminus of glutamate the concentration of enzyme and incubation time should be 
optimized. It was observed, that the aspartyl specific cleavage is the 2000-fold faster than 
the glutamyl side activity of Asp-N [136]. The prevention of additional cleavage can be 
achieved by reducing the enzyme concentration (enzyme/substrate ratio of 1:1000, (w/w) 
and incubation time of 2-6 h. The fact is that the specificity and nonspecificity of the 
endoproteinase Asp-N is tested on two different peptides by the producer (glucagon and 
melittin), which do not include any glutamate in their amino acid sequences [135]. The 
enzyme concentrations used for the digestion procedure are relatively high (1:10 and 1:20). 
The incubation of Glu1-Fibrinopeptide has been done at 1:200 (enzyme/substrate ratio) and 
the incubation was performed at 37 °C for 3 h. Despite of the short digestion time the 
cleavage at the N-terminal side of glutamyl was observed. 
 
3.1.3.4 Forced degradation of Hirudin 
 
After the study of deamidation in short peptides the investigation strategy was further 
implemented on larger molecule – Hirudin. This complex polypeptide consists of 65 amino 
acids with three disulphide bonds between the thiol groups of six cysteine residues (C6-C14, 
C16-C28, C22-C39). Five asparagines are equally distributed among the whole molecule 
with one most probably deamidation site: N52 [130]. As observed in previous deamidation 
studies, the isomerization of aspartates has to be also considered. 
To induce deamidation, Hirudin was exposed to  a  degradation  buffer  consisting  of  
170 mM disodium hydrogen phosphate, pH 8.0 and elevated temperature (40°C). The 
polypeptide degradation was monitored by CZE-UV of intact samples. Mass spectrometry 
(CZE-MS) was introduced to identify the degradation products. Afterwards, the CZE-UV 
(CZE-MS) analysis of Asp-N digested samples completed the investigation. 
Scheme 15 illustrates the all expected signals as a result of partial deamidation of N52 
asparagine. Masses and pI values of Hirudin with N52 deamidation/isomerization are listed 
in Table 16. 
 
 
Scheme 15: Expected signals after forced degradation (Asn deamidation) of undigested 
Hirudin. H: no deamidation, HD: N52 position deamidated, HD, iso: N52 position deamidated 
and isomerized. 
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Table 16: Calculated [131] monoisotopic masses and pI values of not-deamidated and 
N52 deamidated Hirudin. 
 
Peak name / Sequence Mass [Da] pI 
H:   VVYT DCTESGQNLCLCEGSNVCGQGNKCILGS 
DGEKNQCVTGEGTPKPQSHN52DG    DFEEIPEEYLQ 6969.53 4.04 
HD: VVYT DCTESGQNLCLCEGSNVCGQGNKCILGS 
DGEKNQCVTGEGTPKPQSHD52DG DFEEIPEEYLQ 6970.51 3.97 
 
Using acetate of pH 2.5 as a BGE and normal polarity, the following migration order of 
Hirudin variants is expected: H, HD, HD, iso. As apparent from listed H and HD pI values (Table 
16) the difference between these two variants is marginal. Due to the long amino acid chain, 
in addition to deamidated products, also a presence of various peptide fragments can be 
expected after forced degradation. 
 
Figure  11:  CZE:  UV-electropherogram   (214  nm   wavelength)  overlay  for  Hirudin    
(5 mg/mL). From bottom trace to top trace: unstressed (black), 2 d 40 °C (blue), 4 d 40 °C 
(green), 12 d 40 °C (pink). Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm 
fused silica capillary, dynamic coating with capillary conditioning solution, separation 
temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
As demonstrated by electropherograms in Figure 11, the forced degradation of Hirudin 
resulted in the presence of some new peaks. As the H* signal decreases the signals 
representing the deamidation and degradation products are concurrently increasing during 
the whole incubation. About 66 % of Hirudin was degraded in almost two weeks. MS was 
used to identify the present electrophoretic signals of unstressed and stressed sample. The 
mass spectrometric data obtained for unstressed and 12 days stressed samples are listed in 
Table 17. As apparent from results the observed molecular weights differ from the 
theoretical. Applying the typical instrument accuracy of 100 ppm, a maximal mass difference 
of 0.7 Da can be expected for protonated [M + 1H]+ Hirudin sample (this would be then 
0.14 Da for the charge state of 5+). Despite of low accuracy, the mass found for the  signal at 
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6.7 min represents very likely the alkylated H* form. A significant decrease of H* signal was 
observed with some concurrently increasing signals in the acidic region during the whole 
incubation period. The non-alkylated form (H) was not directly identified. However, the UV 
signal with the migration time of 7.7 min was regarded as non-alkylated Hirudin. A couple of 
peaks (HD?, HD,D?, HD, iso?) detected between 6.9 to 7.4 min (blue, green and pink trace) are 
supposed to be a demonstration of deamidation of one or more asparagines. Other peaks 
represent very likely peptide fragments. 
The presence of H is explained by incomplete alkylation of free thiols by IAA due to 
excess amount of DTT. When IAA was added to the reaction, the remaining DTT in the 
sample competed with the cysteinyl thiols to react with alkylating agent. Based on previous 
experiments (data not shown), the use of concentrations of DTT lower than 50 mM led to an 
insufficient reduction of disulfide bonds. 
The peptide denaturation and reduction was achieved using mild conditions to avoid 
further sample degradation. This decision was taken because even a short heating period 
over 50 °C led to the peptide degradation (new signals were present in electropherogram, 
data not shown). Therefore the sample was reduced using incubation temperature of 37 °C 
(sample was incubated for 1 h instead of the more usual 10-15 min at 60 °C). 
 
Table 17: Comparison of theoretical m/z values [131] with observed masses in 
unstressed Hirudin (CZE-ESI- MS).22 
 
Peak name Rt [min] Theoretical m/z Measured m/z 
H* 6.7 1463.515+ / 1219.756+ 1462.985+ / 1219.366+ 
H 7.7 1743.384+ / 1394.915+ 1741.684+ / 1393.555+ 
H*§ 6.7 1463.515+ / 1219.756+ 1463.195+ / 1219.626+ 
* alkylated; § found in stressed sample only. 
 
Further electrophoretic experiments with Asp-N digested samples should help to improve 
the introduced peak assignment. It is anticipated that unstressed Hirudin will be cleaved into 
five smaller peptides (P1-P5) as illustrated in Scheme 16. In addition to the aforementioned 
cleavage products the presence of further peptides (P6-P8) is expected after digestion of 
partially deamidated Hirudin. 
 
 
 
 
 
 
 
 
 
22 microTOF-Q typical accuracy +/- 100 ppm. 
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Scheme 16: Possible signals variants after Asp-N digest of forced deamidation of Hirudin. 
P1-P5: no deamidation, P6-P7: N52 position deamidated, P8: N52 position 
deamidated/isomerized. Presented Asp-N cleavage products were expressed with respect 
on no/partial/fully peptide deamidation or deamidation, isomerization. 
 
It was assumed, that the Asp-N enzyme would not cleave the unstressed and stressed 
Hirudin variants as shown in Scheme 16. As reported by Šlechtová et al. [137], the missed 
cleavage sites in protein digestions using trypsin are frequently observed, if the cleavage 
sites are close to each other. Therefore it is presumed that also the sequence motifs with 
successive aspartates (or aspartates in the close proximity to each other) can represent a 
source of miscleavages. Skipping a cleavable residue D53 would lead to the formation of a 
new peptide P9 (P3+P4). Miscleavage of a D55 residue would create other peptide variant 
P10 (P4+P5). The situation can be even more complicated if N52 asparagine is deamidated. 
Three aspartates are now located close to each other: D52, D53 and D55 and therefore the 
presence of further miscleavage products is quite likely. In case of the specific enzyme 
cleavage, the deamidation can be proven by signal decrease of P5 and finding the P6 
peptide. Signal for P7 will not be visible in UV spectrum. Using the visual comparison of both 
electropherograms to detect deamidation becomes almost impossible. Therefore the MS 
data will be required to identify the digestion products. 
Corresponding masses and pI values of peptides produced by specific Asp-N cleavage 
are listed in Table 18, Table 19. 
 
Table 18: Calculated [131] monoisotopic masses and pI values for in-silico Asp-N 
digested not-deamidated Hirudin. 
 
Peak name / Sequence Mass [Da] pI 
P1 1-4: VVYT 480.56 5.49 
P2 5-32: DCTESGQNLCLCEGSNVCGQGNKCILGS 2833.15 4.14 
P3 33-52: DGEKNQCVTGEGTPKPQSHN 2126.24 5.45 
P4 53-54: DG 190.16 3.80 
P5 55-65: DFEEIPEEYLQ 1411.49 3.45 
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Table 19: Calculated [131] monoisotopic masses and pI values for in-silico Asp-N 
digested N52 deamidated/isomerized Hirudin. 
 
Sequence Mass [Da] pI 
P6: DGEKNQCVTGEGTPKPQSH 2012.14 5.45 
P7: D – not visible 133.10 3.80 
P8: DGEKNQCVTGEGTPKPQSHDiso 2127.23 4.75 
 
 
 
Figure 12: CZE: UV-electropherogram (214 nm wavelength) overlay for Hirudin, Asp-N 
digestion (1.5 mg/mL). From bottom trace to top trace: unstressed, Asp-N (black), 12 d 40 
°C, Asp-N (blue). Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm fused 
silica capillary, dynamic coating with capillary conditioning solution, separation temperature: 
25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
An electropherogram overlay of unstressed and stressed Asp-N digested Hirudin samples 
is shown in Figure 12. The peak identification based on the knowledge of pI peptide values 
was not possible. MS evaluation23 of present signals has brought interesting findings and is 
summarised in Table 20. There were only two signals found in their expected form: P1     
(6.1 min), and P5 (12.8 min). The other peptides were present as miscleavage products or 
as products of unspecific enzyme cleavage. As apparent from the amino acid sequences of 
newly present products, cutting the molecule at the N-terminal side of glutamyl residue 
created many peptides. One important observation from these experiments is that none of 
the identified peptides was cleaved at peptide bond N-terminal to asparagine. The focus was 
primarily placed on finding the P6 peptide or its fragment. The presence of the P6f1 (E43- 
H51) peptide fragment – EGTPKPQSH (blue trace, 4.7 min) demonstrates the deamidation 
of N52. Finding the e.g. P8 signal or EGTPKPQSHDiso peptide fragment would confirm the 
 
 
23 CZE MS results provided K. Jooss, University Aalen. 
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deamidation statement based on the presence of P6f1. Unfortunately these measurements 
did not yield relevant results and no other signals verifying deamidation were found. 
 
Table 20: Matching theoretical m/z values [131] with observed masses and corresponding 
sequences in unstressed and stressed Asp-N digested Hirudin (CZE-ESI-MS).24 
 
Peak 
name 
tm 
[min] 
Calculated 
m/z 
Measured 
m/z Sequence 
P3f1 4.7 1095.151+ 1094.491+ EGTPKPQSHN 
P6f1 4.7 491.022+ 490.742+ EGTPKPQSH 
P1+P2+ 
P3* 
 
4.9 
 
1436.584+ 
 
1436.234+ 
VVYTDCTESGQNLCLCEGSNVC 
GQGNKCILGSDGEKNQCVTGEG 
TPKPQSHN 
H* 
 
6.0 
 
1463.515+ 
 
1463.115+ 
VVYTDCTESGQNLCLCEGSNVC 
GQGNKCILGSDGEKNQCVTGEG 
TPKPQSHNDGDFEEIPEEYLQ 
P1 6.1 481.561+ 481.271+ VVYT 
P2f1* 7.0 897.372+ 897.412+ EGSNVCGQGNKCILGSN 
P4+P5f1 9.5 452.521+ 453.151+ DGDF 
P5f2 10.0 1149.221+ 1149.531+ EEIPEEYLQ 
P5f3 10.1 409.151+ 409.121+ DFE 
P5 12.8 1411.481+ 1411.581+ DFEEIPEEYLQ 
P2f2* 13.6 1456.421+ 1456.501+ DCTESGQNLCLC 
P4+P5 13.8 1583.631+ 1583.601+ DGDFEEIPEEYLQ 
*alkylated; 1+ z = 1, 2+ z = 2 etc. 
 
As previously described in chapter 3.1.3.3, the Asp-N digestion Glu1-Fibrinopeptide led to 
the presence of unspecific digested peptides. For Hirudin the enzyme/substrate ratio was 
also 1:200, but the incubation duration of three hours (as used for Glu1-Fibrinopeptide) was 
too short (undigested protein was still present). Because the Asp-N is a zinc metallo 
protease, the digestion of Hirudin was accomplished in the presence of zinc with various 
incubation times. Zinc ion should improve the catalytic ability of enzyme by directly 
participation in the catalytic mechanism (interacts with the substrate molecules) [138]. 
Presence of the undigested Hirudin was minimal after 18 hours and therefore this incubation 
period was adopted. 
The interpretation of the data was challenging after Hirudin Asp-N digestion (too many 
cleavages at glutamates, miscleavages, co-migrations in CZE). Therefore the polypeptide 
digestion by some other enzyme was considered. Lys-C was chosen as an appropriate 
cleavage agent creating four peptides (P1-P4) as illustrated in Scheme 17. On account of 
the deamidation of N52, the presence of further P4 forms (P4D and P4D, iso) was expected. 
The newly formed peptides produced by Lys-C digestion were separated by capillary 
 
24 microTOF-Q typical accuracy +/- 100 ppm. 
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electrophoresis using UV detection and the signals were identified by MS. The molecular 
masses and pI values of the digestion products are listed in Table 21. 
 
Scheme 17: Possible signals variants after forced degradation and Lys-C digest of 
Hirudin: no deamidation: P1-P4 signals, N52 position deamidated/isomerized: P4D, P4D, iso. 
 
Table 21: Calculated [131] monoisotopic masses and pI values for in-silico Lys-C 
digested not-deamidated and N52 deamidated Hirudin. 
 
Sequence Mass [Da] pI 
P1: VVYTDCTESGQNLCLCEGSNVCGQGNK 2820.18 4.14 
P2: CILGSDGEK 920.43 4.37 
P3: NQCVTGEGTPK 1132.52 5.99 
P4: PQSHNDGDFEEIPEEYLQ 2145.91 3.77 
P4D: PQSHDDGDFEEIPEEYLQ 2146.90 3.66 
 
Considering the presence of three P4 variants, using the acetate buffer of pH 2.5 as BGE 
and normal polarity, this migration order is expected in electropherogram: P4, P4D and   
P4D, iso. 
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Figure 13: CZE: UV-electropherogram (214 nm wavelength) overlay for Hirudin digested 
by Lys-C  (1.5 mg/mL). From  bottom  trace to top trace: unstressed, Lys-C  (black), 12 d   
40 °C, Lys-C (blue). Experimental conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm fused 
silica capillary, dynamic coating with capillary conditioning solution, separation temperature: 
25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
An overlay of two CZE electropherograms of Lys-C digested unstressed and stressed 
sample is shown in Figure 13. The MS data evaluation25 (summarised in Table 22) led to the 
identification of P2 (5.6 min), P3 (5.8 min) and P4 (7.8 min) peptides. Evidence of P1 mass 
was found (6.2 min) but could not be confirmed within the MS accuracy 100 ppm. Also two 
signals separated between 8.0 and 8.4 minutes were identified. These peaks represent the 
deamidated forms of P4 peptide. An accurate assignment of P4D and P4D, iso signals was 
done based on the known migration order of Asp and isoAsp peptide variants. 
As apparent from the electropherogram of stressed Hirudin, only partial enzymatic 
hydrolysis of this sample was achieved, because  there  was  still  the  H  signal  present 
(8.5 min). The other signal with longer migration time (9.3 min) was assigned to H derivate. 
The present peptide could not be identified from MS spectra. The assumption that this signal 
represents some H derivate was verified by a spiking experiment. The stressed sample was 
spiked to the digested one and the signal representing the H derivate increased significantly. 
 
 
 
 
 
 
 
 
 
 
 
25 CZE MS results provided K. Jooss, University Aalen. 
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Table 22: Comparison of theoretical m/z values [131] with observed masses in Lys-C 
digested Hirudin (CZE-ESI-MS).26 
 
Peak name tm [min] Calculated m/z Measured m/z 
P1* 6.2 1017.063+ 1017.743+ 
P2* 5.6 978.431+ 978.411+ 
P3* 5.8 1133.521+ 1133.491+ 
P4 7.8 1074.602+ 1074.442+ 
P4D § 8.0 1075.092+ 1074.932+ 
P4D, iso § 8.4 1075.091+ 1074.911+ 
1+ z = 1, 2+ z = 2 etc.; * alkylated; § found in stressed sample only. 
 
3.1.3.5 Deamidation of proteins 
 
Deamidation of protein P 
 
The idea of employing of the Asp-N enzyme for determination of deamidation of 
asparagine in proteins came couple years ago during the extensive study of therapeutic 
protein P within work on unspecified customer project in Solvias. PD Dr. Maria Schwarz as a 
leading scientist has performed this investigations with her group and at the end of this work 
the CZE method could be established for qualitative analysis of this protein including the 
determination of the deamidation factor of the sample. 
Use of CZE to study deamidated intact protein P was disabled by the tendency of protein 
to form aggregates. The separation profile was diffuse and the deamidated variants co- 
migrated with various aggregation forms. Therefore the enzyme digest (e.g. Lys-C, Glu-C 
and trypsin) was necessary to cleave the protein into peptides which enabled the individually 
peptide identification and localization of deamidation site(s). 
Enzyme cleavage by Asp-N introduces aspartate specificity in the digest enzymes and 
allows fast peak identification by visual comparison of separation patterns of unstressed and 
stressed sample. If some signal of unstressed sample decrease after digest and some new 
signals are present in stressed sample, presence of deamidation can be predicted. 
Deamidated variant(s) will lead after enzyme digestion to generation of new peptides, 
because some new cleavage sites were formed (Scheme 6, Scheme 7). ). 
Table 23 represents peptides after in-silico Asp-N digestion of non-deamidated protein P 
(because we demonstrate the study of the customer protein, only fictive protein sequence is 
stated. Amino acid sequence provides information about deamidation sites in corresponding 
peptides; therefore no mass and pI values are included in this table). 
 
 
 
26 microTOF-Q typical accuracy +/- 100 ppm. 
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Table 23: Generated peptides of in-silico Asp-N digested not-deamidated protein P. 
 
Peak name / Sequence 
P1 1-8: QAVKSWIL 
P2 9-15: DSYLWEG 
P3 16-36: DKILAHKMSN25TYQPGN31FGAKR 
P4 37-49: DTYGQN42YPWTHSA 
P5 50-57: DSFTRENQ 
P6 58-71: DTYGQN63YPWETHSA 
P7 72-83: DLSAYEQHTILS 
P8 84-97: DTHSGEHQN92HAVTR 
P9 98-106: DKLAASIKL 
 
In P1, P2, P5, P7 and P9 peptides no deamidation sites are present. But also each 
aspartate isomerization possibility has to be considered. If D9 would be partially isomerized, 
then P1 and P2 will be observable after Asp-N digestion and also some signal for P1+P2 
(with mass increase of 1 Da) will be present. 
 
 
 
Scheme 18: Expected signals after heating stress of Peptide P with possible P3 peptide 
modifications: no deamidation, N25 position deamidated/isomerized, N31 position 
deamidated/isomerized and its combinations. 
 
Moderate deamidation of both N25 and N31 asparagines in P3 could result in all 
illustrated deamidation variants (Scheme 18). Considering partial isomerization, it is possible 
to obtain 8 different peptides (including not-deamidated variant P). Some of them would vary 
only in presence D/Diso. The presence of isoaspartate determines if Asp-N will cleave at this 
site or not (see Scheme 19). Also in the presence of asparagine the enzyme would not 
cleave at this site, but now the isoAsp-peptide fragment is carrying the more negative charge 
and structurally differs from Asn-peptide (DTYQPGDisoFGAKR x DTYQPGNFGAKR). 
Therefore it can be distinguished by means of CZE. 
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Scheme 19: Possible signal variants after Asp-N digest of forced deamidated Peptide P 
(focused on P3 deamidation): no deamidation, N25 position deamidated/isomerized, N31 
position deamidated/isomerized and its combinations. 
 
 
 
Figure 14: CZE: Full zoomed UV-electropherogram (214 nm wavelength) overlay for 
Protein P stressed for 21 d at 40 °C, Asp-N digestion (2.0 mg/mL). From bottom trace to top 
trace: unstressed, Asp-N (black), 21 d 40 °C, Asp-N  (blue). Experimental conditions: BGE:  
3 % AcA pH 2.5, 40/50 cm 50 µm neutral coated capillary, separation temperature: 25 °C, 
separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
In order to monitor the deamidation process in Protein P the sample was incubated in 
deamidation buffer for 3 weeks at 40 °C. The unstressed and stressed samples were than 
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digested with Asp-N and analysed by CZE-UV (Figure 14). Presence of a couple of 
decreasing/increasing or completely new signals in electropherogram indicates deamidation 
of not only one asparagine. 
MS data evaluation of digested Peptide P led to identification of present signals and 
enabled also the recognition of some co-migrating signals (P7 and P8, 11 min). P3 signal is 
present only as a low signal in unstressed sample, but after the forced degradation, this 
signal is clearly visible (7.2 min). P3+P4 signal in both samples determines the partial 
isomerization of D37 in P4, because the Asp-N enzyme was not able to cleave at this site. It 
is possible, that this degradation took place during protein production. As mentioned above, 
the amount of increasing/new peaks signalizes the multiple deamidation and actually four 
deamidation sites were detected. Deamidation of P3 asparagines N25 and N31 followed by 
Asp-N digestion was demonstrated by identification of dP3-1, dP3-2 (blue trace, 7.5 min) 
and dP3-4 (blue trace, 9.5 min). dp3-4 signal co-migrates with P5, but the signal increase is 
obvious. P4 peptide possesses 1 possible deamidation site, which is also partially 
deamidated and isomerized after 3 weeks of incubation. The presence of iso-dP4 (blue 
trace, 8.5 min) and also the two Asp-N cleavage products dp4-1 and dp4-2 (blue trace 8.5- 
9.5 min) is evidence for N42 deamidation. Deamidation of N92 asparagine of P8 was 
confirmed by identification of iso-dP8 (blue trace, 11.5 min) and also presented dP8-2 
fragment that co-migrates with P5. 
 
Forced deamidation of other proteins 
 
Some model proteins were chosen for further investigation of forced deamidation. This 
study material varied in composition; simple proteins (with shorter amino acid sequence – 
Aprotinin, Interferon, Lysozyme or longer amino acid chains – BSA, Hemoglobin) and 
antibodies (IgG1-Avastin, Erbitux), with and without presence of disulfide bridges, with 
diverse amino acid motifs, where the deamidation of asparagines can be expected. 
In general, the portion of deamidation was too small in protein studies. By applying the 
Asp-N enzymatic hydrolysis on unstressed and stressed sample followed by CZE 
separation, there were often no noticeable differences (indicating deamidation) between both 
digested samples. 
The forced degradation study of Hemoglobin represents the above-described situation. 
The CZE-UV examination of intact stressed samples did not lead to the detection of any 
newly formed aspartates/isoaspartates. Also further electrophoretic investigation of Asp-N 
digested samples did not yielded results verifying the presence of deamidated variants (data 
not shown). Based on our previous experience with Hirudin, the further investigations were 
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carried out using Lys-C digestion. The properties of Lys-C cleavage products are stated in 
Table 24. 
 
Table 24: Calculated [131] monoisotopic masses and pI values for in-silico Lys-C 
digested not-deamidated Hemoglobin. 
 
Peak name / Sequence Mass [Da] pI 
Hb1: MVLSPADK 860.04 5.59 
Hb2: TNVK 460.53 8.41 
Hb3: AAWGK 531.61 8.80 
Hb4: VGAHAGEYGAEALERMFLSFPTTK 2582.91 5.50 
Hb5: TYFPHFDLSHGSAQVK 1834.02 6.61 
Hb6: GHGK 397.43 8.76 
Hb7: K – not visible 146.19 8.75 
Hb8: VADALTNAVAHVDDMPNALSALSDLHAHK 2997.33 5.10 
Hb9: LRVDPVNFK 1087.29 8.75 
Hb10: LLSHCLLVTLAAHLPAEFTPAVHASLDK 2968.51 6.26 
Hb11: FLASVSTVLTSK 1252.47 8.75 
Hb12: YR 337.38 8.75 
 
As apparent from Table 24, there are three peptides containing asparagine: Hb2, Hb8 
and Hb9. Therefore the focus will be placed on these peptides. Based on the results of intact 
and Asp-N digested samples, it can be expected that the level of the asparagine 
deamidation will be very low or no aspartates were created during the forced degradation. 
 
Figure 15: RP-HPLC: UV-chromatogram (214 nm wavelength) overlay for Hemoglobin, 
Lys-C digestion. From bottom to top: unstressed, Lys-C (black trace), 4 d 30 °C, Lys-C (blue 
trace). Experimental conditions: X-Bridge BEH300 C18, 3.5 µm, 2.1 x 150 mm column, 
H2O/ACN with 0.1 % TFA, flow rate 0.2 mL/min, column temperature 50 °C. 
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Resulting from the interpretation of the chromatographic data demonstrated in Figure 15, 
the deamidation could not be clearly detected from a signal decrease of some asparagine 
peptide (in unstressed sample) or presence of new signals (in stressed sample). The 
employment of MS detection allowed the identification of two deamidated peptides Hb9D 
(N98 deamidated) and Hb8D,D (N69 and N79 deamidated). The signal representing the 
peptide K62-Hb8 was significant higher in unstressed sample than in stressed sample. The 
apparent signal decrease was not caused by deamidation. The presence of two successive 
lysines K61 and K62 led to a miscleaved peptide bond between K62 and Hb8 and 
production of K62-Hb8 peptide in unstressed peptide. The digestion reaction in unstressed 
sample differed from the situation observed for stressed sample, where only small amount of 
K62-Hb8 peptide was found as a result of more accurate enzyme cleavage. 
Due to low level of deamidation, the deamidated variants could not be recognized by 
visual comparison of electropherograms/chromatograms of unstressed and stressed 
Hemoglobin samples (intact or digested). Therefore some attempts have been made to 
increase the level of the deamidation. Further prolongation of the incubation time of proteins 
or using of higher pH of degradation buffer led often to the protein degradation. Therefore 
other possibilities were considered to accelerate the aspartate deamidation. 
 
3.1.3.6 L-Asparaginase deamidation of peptides and proteins by CZE UV 
 
As discussed in previous chapter, the accelerated creation of deamidated samples was 
requested. Avoiding the long incubation process would decrease the risk of possible test 
sample decomposition. Targeted deamidation would offer faster results and minimize side 
effects (fragmentation/degradation) caused by long incubation. To achieve the objective, L- 
Asparaginase (L-Asp) enzyme was applied to enhance the generation of aspartate peptides. 
The introduced approach should help with the creation of deamidated samples in short 
period. 
Zhang et al. [139] reported the optimal conditions (50 °C) for L-asparaginase produced in 
Escherichia coli. The deamidation rate of two Peptide 1 samples was studied in the 
presence or absence L-Asp. Samples were exposed to a degradation buffer consisting of  
50 mM Tris-HCl pH 8.6 and a temperature of 50 °C. 
As previously introduced in chapter 3.1.3.1, it is expected that the incubation without 
enzyme would lead to the presence of three Peptide 1 variants: P1, P1D and P1D, iso. Using 
L-Asp, the creation of P1D should be favoured over P1D, iso formation, but the isomerization of 
P1D cannot be excluded. 
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Figure  16:  CZE:  UV-electropherogram  (214  nm  wavelength)  overlay  for  Peptide  1 
(2 mg/mL) incubated with L-Asp in 50 mM Tris-HCl pH 8.6 at 50 °C. From bottom trace to 
top trace: 2 h (black trace), 4 h (blue trace), 6 h (green trace) and 24 h (pink trace) of 
incubation. Incubated Peptide 1 without L-Asp is shown in upper right corner. Experimental 
conditions: BGE: 3 % AcA pH 2.5, 40/50 cm 50 µm fused silica capillary, dynamic coating 
with capillary conditioning solution, separation  temperature:  25  °C,  separation  voltage:  
30 kV, injection 0.5 psi 10 s. 
 
An overlay of four electropherograms illustrates the degradation of Peptide 1 in the 
presence of L-Asp enzyme (Figure 16). To compare the impact of L-Asp on peptide 
deamidation, an overlay of four electropherograms was attached showing the peptide 
degradation without L-Asp enzyme (upper right corner). L-Asp was visible as two separated 
peaks in electropherogram (between 3-5 minutes) followed by three Peptide 1 variants in the 
well-known migration order: P1, P1D, P1D, iso. The deamidation rate of P1 in the presence of 
L-Asp was in the first three measurements comparable to the results obtained after 
incubation without enzyme (Table 25). The degradation process was slightly accelerated in 
the presence of L-Asp. The most significant difference was noticed after 24 hours of 
incubation. Whilst the deamidation of the incubated Peptide 1 reached the level of about    
75 %, Peptide 1 was almost completely converted to P1D and P1D, iso in the presence of L- 
Asp. 
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Table 25: Corrected area percentages of P1, P1D, P1D,iso; Peptide 1 incubated without / 
with L-Asp at 50 °C for 2, 4, 6 and 24 h. 
 
50 mM Tris-HCl pH 8.6, 50 °C 
Incubation 
period 
Acorr % P1 
no L-Asp / L-Asp 
Acorr % P1D 
no L-Asp / L-Asp 
Acorr % P1D, iso 
no L-Asp / L-Asp 
P1D, iso / P1D 
no L-Asp / L-Asp 
2 h 88.6 / 86.3 2.6 / 3.3 8.8 / 10.5 3.4 / 3.2 
4 h 79.2 / 70.9 5.7 / 6.7 15.1 / 22.4 2.7 / 3.3 
6 h 66.8 / 60.7 7.1 / 8.9 26.0 / 30.4 3.7 / 3.4 
24 h 22.4 / 0.7 20.0 / 25.8 57.6 / 73.5 2.9 / 2.8 
Results are reported as the means of triplicate determinations. 
 
As apparent from the P1D, iso / P1D results, the creation of P1D was not favoured over   
P1D, iso formation. The approximate isoAsp:Asp ratio of 3:1 was comparable to the results 
obtained after incubation using the elevated temperature only. In the study on Peptide 1 the 
temperature optimum was found between 50 and 60 °C (data not shown). 
Because the deamidation rate in Peptide 1 was accelerated in the presence of L-Asp 
enzyme, the deamidation experiments succeeded also with proteins, which were not able to 
deamidate previously without L-Asp, like Aprotinin, BSA, Interferon and Lysozyme. 
As an example, the deamidation study of Lysozyme is shown. In this experiment the 
studied material was subjected to incubation with and without L-Asp. The results are 
demonstrated in Figure 47 (chapter 7). As compared to the unstressed sample (black trace), 
no signals of deamidated variants could be detected. Even the higher concentration of 
enzyme, prolonged incubation time or enzyme immobilization (over 24 h) did not lead to 
expected result. The explanation for this fact could be the steric hindrance of the adjacent 
amino acids and the protein conformation27. 
 
3.1.4 Conclusion 
 
The CZE separation of asparagine, aspartate and isoaspartate variants was achieved 
using 3 % AcA pH 2.5 as a background electrolyte and applied dynamic coating for fused 
silica capillary. The utilization of Asp-N enzyme for the hydrolysis of newly formed 
aspartate(s) was demonstrated on deamidated samples. The Asp-N enzyme digestion in the 
combination with CZE/HPLC-UV technique is a very attractive tool for the determination of 
 
 
27 Supposing that the L-Asp cannot access the asparagines in the intact proteins, the structure of 
lysozyme was unfolded by denaturation and cleaved by Lys-C. The newly created peptide fragments 
are thought to be accessible for the L-Asp enzyme. Comparison of two electropherograms (Figure 48 
in chapter 7) demonstrates clearly the presence of some new signals in L-Asp digested sample. It is 
possible that some of them represent deamidated variants. Unfortunately the reproducibility of these 
results was not achieved in following experiments, but this idea could be followed in the future. 
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present aspartates in small peptides as demonstrated on Peptide 1 and Glu1-Fibrinopeptide. 
Increasing number of aspartates in polypeptides and proteins lead to the presence of many 
signals after the molecule hydrolysis by Asp-N and electrophoretic/chromatographic 
separation. The risk of co-migration/co-elution is higher; new signals (from deamidated 
asparagines) can stay hidden behind the signals of other peptide fragments. If the portion of 
deamidated asparagine(s) is too small, the signal decrease of the former peptide/protein will 
not be clearly visible and the presence of new signals of deamidated and 
deamidated/isomerized sample variants might not exceed the noise level. An application of 
Asp-N enzyme to such deamidated sample will produce even smaller signals from 
deamidated asparagine variants. Therefore the Asp-N in the combination with UV detection 
is well suited for samples in which the deamidation reached the particular degree. The 
investigation of Asp-N hydrolysed Glu1-Fibrinopeptide and Hirudin (analysed by HPLC and 
CZE) confirmed the published enhanced specificity of the Asp-N enzyme, namely the ability 
to cleave also at the N-terminus of glutamyl residues. The production of unspecific cleaved 
peptide fragments and also the miscleavages (as there are three potential cleavage sites in 
the close proximity) increased the amount of peaks present in Hirudin. This situation made 
the visual comparison of the electrophoretic signals more difficult. The optimization of the 
Asp-N digestion conditions did not lead to any significant improvement of the enzyme 
specificity. Finally, an application of Lys-C enzyme to Hirudin followed by CZE analysis of 
produced peptide fragments allowed the separation of deamidated variants from their non- 
deamidated counterpart. The Asn, Asp and isoAsp variants were clearly visible in 
electropherogram. 
It is apparent that buffer type and its concentration have an effect on deamidation rate of 
peptides as many researchers reported it. In addition to the aforesaid property the buffer 
concentration has an influence on hydrolysis of succinimide during the deamidation process. 
Diverse deamidation buffers also affected the hydrolysis of succinimide and led to various 
isoAsp/Asp ratios despite of the same pH and concentration. If we consider the complex 
structure of proteins (secondary, tertiary, quaternary) and the influence of buffer on the 
opening of this protective mechanism, then it is difficult to predict, how the deamidation 
behaviour will develop. 
The CZE separation of multiple deamidated variants was achieved using the acetate 
buffer (20 mM, pH 4.5) with pH value above the pI values of deamidated species and by 
applying a negative polarity. An increase of the buffer concentration to 50 mM provided 
better current stability during the CZE-ESI-MS run but this improvement still did not allow the 
identification of all present signals. 
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According to the ICH guidelines on impurities in new drug product, the classification of 
organic impurities (process- and drug related-) below the 0.1 % level is considered as not 
necessary [140]. In peptides where only few signals are present, even a small portion of the 
deamidated asparagine can be apparent in the UV-electropherogram/chromatogram. In 
larger molecules multiple deamidation can be expected. Such partially deamidated 
asparagines are subjected to the Asp-N hydrolysis together with all present aspartates of the 
protein. This digestion procedure leads to the creation of a mixture of cleaved signals – 
some have their origin in normal aspartates and some originate from the deamidated 
asparagines. The more aspartates, the more created peptide fragments and very likely the 
lower signals in electropherograms/chromatograms. As a consequence it is very likely that 
these new signals do not achieve limit of detection and will not be recognized using UV 
detection. 
We saw that many proteins were frequently completely degraded before the deamidation 
of asparagine reached some detectable level. Use of L-Asparaginase for the faster creation 
of deamidated samples was examined. The deamidation rate was accelerated in the 
presence of L-Asparaginase enzyme in Peptide 1. This method could not be successfully 
transferred to the proteins. The explanation for it is that the steric hindrance of present amino 
acids does not allow the enzyme’s nucleophile to attack the C-atom of amide leading to the 
release of ammonia. 
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3.2 Evaluation of a CZE method for the analysis of charge variants in antibodies 
alternative and complementary to cIEF 
 
Monoclonal antibodies are large proteins, whose molecular structure is very 
heterogeneous as a result of multiple posttranslational modifications and degradation 
events. Such variants differ in charge and can be commonly designated as acidic or basic 
compared with the main species. Chromatography methods (ion-exchange chromatography 
– IEX) or (capillary) isoelectric focusing (IEF, cIEF) are generally employed for the study of 
charge-related heterogeneity of biopharmaceuticals. Since He et al. [141] have made known 
the CZE method, which allows the separation of mAb isoforms in coated fused silica 
capillary; the method variety applicable for the analysis of charge variants has increased. 
The benefits of using such an analytical method for isoform separation as e.g. low cost 
material (no coated capillaries, no ampholytes or special HPLC columns needed) attract 
scientists from all over the world and many studies have been introduced employing CZE 
instead of IEX or IEF (15, 141, 142, 143). 
The aim of this study is to evaluate and validate the CZE method applicable for the 
analysis of charge variants in antibodies complementary to cIEF. The analytical method 
published by He et al. [141] was optimised and applied to study the isoforms of two 
monoclonal antibodies: Avastin and Erbitux. 
The charge variants and their alterations (such as deamidation) upon e.g. storage cannot 
always be monitored in intact molecules due a co-migration with main signals; therefore the 
samples of interest are frequently enzymatically hydrolysed. Instead of commonly used 
peptide mappings where enzymes such as trypsin, Lys-C, Glu-C etc. are generally applied, 
the selective cleavages of monoclonal antibodies into Fab and Fc portions using papain or 
pepsin can be accomplished. The study of papain and pepsin digested Avastin and Erbitux 
samples, followed by the CZE analysis will be introduced and discussed. 
In this chapter also a novel utilization of the optimised CZE method of He et al. [141] will 
be presented as suitable for the investigation of de-glycosylated antibody portions as an 
alternative to gel capillary electrophoresis. 
 
3.2.1 Introduction 
 
Charge heterogeneity analysis of proteins is a necessary step in characterization of 
biopharmaceuticals. It provides important information about product quality (different types of 
charge variants include antibody fragmentation, deamidation, formation of N-terminal 
pyroglutamate, glycation at lysine residues, sialylation etc.) [144]. These changes could 
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affect e.g. the biological activity of the drug, the affinity of monoclonal antibodies towards 
antigens or their shelf life [145]. 
Despite thorough understanding of the degradation pathways that could be present 
during production by cell cultures, such as purification, formulation and storage of the 
biologics; the biopharmaceutical industry is obliged to characterize the microheterogeneities 
of drugs exhaustively in order to demonstrate batch-to-batch consistency. In the case of 
monoclonal antibodies, these microheterogeneities may have effect on clearance, efficacy, 
immunogenicity and potency [139]. 
Monoclonal antibodies (mAbs) were discovered by Köhler and Milstein in 1975 [146]. This 
breakthrough raised great expectations of many scientists in various research fields 
(biochemistry, cell structure, immunology and cell genetics [147]. After overcoming the 
technical difficulties of the monoclonal antibody production these molecules with high 
specificity for antigens found their place in medical and industrial use. 
The market for mAbs continues to grow steadily. Pharmacological therapeutics are able 
to precisely identify the key targets and found application in cancer therapy and treatment of 
autoimmune and inflammatory diseases [7, 148]. The most currently marketed mAb is the 
IgG class antibody. The molecular weight is approximately 150 kDa, composed of two 
identical light chains (2x 25 kDa) and two identical heavy chains (2x 50 kDa) in the Y shape 
motif (see Scheme 20). The composition can also be described as two antigen-binding 
fragments (Fab, 55 kDa) and one crystallisable fragment (Fc, 35 kDa) [139, 149]. The 
antigen specificity is defined by the complementary determining regions (CDRs), which are 
located in the variable fragment portion (Fv) of the Fab. The hinge region is an amino acid 
area situated in the central part of the heavy chains linking these two chains by disulphide 
bridges. It confers the mobility of two Fabs and enables the bivalent antigen binding and 
activation of Fc. 
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Scheme 20: Schematic representation of monoclonal antibody structure. 
 
Most of the heterogeneity generates alterations in the surface charge of the molecule 
[13]. An overview of the sources of charge-related heterogeneity in monoclonal antibodies 
[150] is presented in Table 26. 
 
Table 26: Sources of charge heterogeneities in mAbs. 
Degradation pathways charge variants source of pI shift 
 
Cyclization of Glu acidic loss of primary amine 
Deamidation acidic gain of carboxylic group 
Glycation acidic loss of basicity of Lys-ε-amino 
group 
Fragments acidic/basic - 
Sialylation acidic gain of carboxylic group 
C-terminal Lys cleavage acidic loss of Lys-ε-amino group 
Amidation basic replacing the -OH group by - 
NH2 
Desialylation basic loss of carboxylic group 
Incomplete removal of C- 
terminal Lys 
basic presence of Lys-ε-amino amino 
group 
 
 
Classification of these alterations can be done according to the properties they possess. 
These variants can be organized into 2 categories: acidic and basic species. For example 
deamidation, C-terminal Lys cleavage or glycation result in an increase in the net negative 
charge. This could be observed as a decrease of pI value and formation of acidic species. 
On the other hand desialylation or amidation cause an additional positive charge or remove 
negative charges leading to an increase of pI value and formation of basic species. Several 
studies have shown that also e.g. cysteinylation, presence of trisulfide bonds (formation of 
acidic species), oxidation of methionine or isomerization of Asp (formation of basic species) 
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can also contribute to the alteration of the charge distribution [151, 152]. The explanation for 
this phenomenon refers to the conformational differences that affect the surface charge 
properties. 
Analytical methods for charge heterogeneity need to detect small changes reproducibly. 
Charge-related heterogeneity characterization requires high throughput analytical methods 
like ion-exchange chromatography - IEX (anion exchange chromatography – AEX, cation 
exchange chromatography – CEX) or isoelectric focusing (IEF, or its capillary form capillary 
isoelectric focusing – cIEF). 
Given both the large size and the structural complexity of an intact mAb may hinder the 
efficient analytical work. An overlapping of charge variant signals with main peak signal in 
intact mAbs lead often to the fact that a lot of important information stays hidden. The main 
point of the interest – deamidation of asparagine (studied in 3.1) is one of the protein 
modifications, which can be determined, inter alia, by charge-based analytical techniques. 
As described in chapter 3.1 the determination of deamidation in biologics requires financial 
investment and time, not solely because many HPLC runs are often mandatory before 
adequate separation is achieved. Although use of analytical techniques as RP-HPLC/CZE 
with MS and MS/MS data analysis is crucial for the characterization of biotherapeutics, at the 
same time, operating a mass spectrometer requires specialised operators and is also 
expensive to run. It might be helpful, if there would be an objective indication that 
demonstrates some molecule alterations, before beginning the mass spectrometry analytical 
works. At present, the optimised CZE method can be used for the examination of the charge 
variant profiles. Because the charge variants and their alterations (such as deamidation) 
upon e.g. storage cannot always be monitored in intact monoclonal antibodies due a co- 
migration with main signals, generally it is useful to study the molecule fragmented into 
peptides (to perform peptide mappings). A variety of specific enzymes can be employed for 
this purpose (e.g. Arg-C, Glu-C, Lys-C, trypsin etc.) [153]. The aforesaid enzyme types 
require frequently certain procedures, that have to be done prior to digestion, such as 
denaturation, sample reducing, alkylation, multiple changing of buffer etc. and especially an 
enzyme purchase (such enzymes with high specificity are expensive; in case of less 
expensive trypsin, the cleavage is often performed in the presence of Lys-C to achieve the 
improved digestion). Some inexpensive enzymes exist that are able to reduce the protein 
(mAb) complexity: papain and pepsin. Both of these enzymes are routinely employed for the 
production of antibody fragments, because such enhanced molecules allow a targeted 
programming of therapeutics [154]. 
This chapter focuses on fast, inexpensive and straightforward analytical methods, which 
can be employed for the study of isoform distribution. Isoelectric focusing (IEF) as a charge- 
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sensitive method provides the information about charge heterogeneities. It is important to 
notice that IEF is an irreplaceable method for pI value determination in routine quality control 
[155]. Capillary isoelectric focusing (cIEF) found its place in the protein analytics because of 
the automation, high resolution and fast run times [156]. If the knowledge of the pI value is 
not obligatory and only the separation profile of charge variants is requested then it is not 
mandatory to use all the quite expensive cIEF equipment (coated FC-cartridges, transfer 
lines) and chemicals (ampholytes). The routine experiences from the past have shown in the 
Solvias lab that independence from such special products (like ampholytes) can save a lot of 
time and money. Occasionally the production of ampholytes can be discontinued, products 
replaced by another (similar) one and consequently, the routine analysis of a sample of 
interest might lead to different isoelectric patterns using the new product. Capillary zone 
electrophoresis (CZE) with ε-aminocaproic acid as the background electrolyte is able to meet 
all named requirements at the beginning of this paragraph. It was proved that this analytical 
tool could be used if the isoelectric profile of whole mAbs is required [141]. In this work 
papain and pepsin are used to reduce the complexity of monoclonal antibodies Avastin and 
Erbitux. 
Avastin is a recombinant humanized monoclonal IgG1 antibody. This glycoprotein is 
composed of two equal light chains (214 AA) and two heavy chains (453 AA) [157]. 
Heterogeneity of heavy chains is caused by the presence of C-terminal lysine residues and 
also N-linked glycosylation at N303. The amino acid sequences of light and heavy chains of 
Avastin received from [158] is presented in Table 42 (chapter 7) and served for calculation of 
pI values (whole mAb or Fab and Fc fragments). 
Erbitux is a chimeric mouse-human monoclonal IgG1 antibody. This glycoprotein consists 
of two light chains (213 AA) and two heavy chains (452 AA) [159]. The amino acid sequence 
of cetuximab has two different glycosylation sites at Asn88 and Asn299 of the heavy chain. 
The heavy chains demonstrate also C-terminal lysine heterogeneity [160]. Properties of light 
and heavy chain are described in Table 43 (chapter 7). 
As introduced above the structure of IgG class antibody can be described by two different 
ways. Composition can be seen as presence of two heavy (HC) and two light chains (LC) or 
two antigen binding fragments (Fab) and one crystallisable fragment (Fc) [139, 149] as 
illustrated in Scheme 21. 
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Scheme 21: Papain cleavage scheme of monoclonal antibody. 
 
The application of Fab fragments found its place in the medical praxis, because these 
molecules are smaller in size than whole IgGs (provide better penetration into tissues) and 
show lower immunogenicity in many diagnostic applications [161]. Fab and Fc fragments are 
generally produced by enzymatic digestion of IgGs using papain [162, 163]. For therapeutic 
uses, Fabs can be purified from the digestion mixture by various analytical techniques (e.g. 
affinity chromatography, gel filtration chromatography, ion exchange or their combination 
[164]. 
Papain as a thiol protease cleaves the monoclonal antibody at the heavy chain hinge 
region. Amino acid sequences of upper, core and lower hinge of humanized IgG1 are well 
known [165]. The upper hinge amino acid sequence (EPKSCDKTHT) will be cleaved behind 
the histidine and in front of disulfide bonds [166]. The hydrolysis leads to the creation of two 
equal Fab fragments (two heavy chains are present) and one Fc fragment and will be 
demonstrated on amino sequence of Avastin in Scheme 24 (page 96). 
Treatment with papain can also yield to partial cleaving of monoclonal antibody [167]. 
Brown et al. [168] observed predominant production of F(ab)2 portion in IgG antibody, if the 
cysteine was absent in digestion procedure, and explained this fact by impossibility to 
reduce the hinge region disulphide. 
Many researchers use an Immunopure Fab preparation Kit from Pierce to produce the 
Fab fragments. We developed a cheap fast method to obtain Fab and Fc fragments using 
papain digestion. Using this method the handling is relatively straightforward (e.g. no 
replacement of formulation buffer is required) and the duration of the entire digestion 
procedure is relatively short. 
86  
Pepsin can be used for a more thorough investigation of charge variants in monoclonal 
antibodies. Analogous to Fab fragments the F(ab)2 also found utilization in medicine. 
Because murine monoclonal antibody therapy can lead to the formation of an unwanted 
immune response in patients when applied in vivo [161], using of immunoglobulin fragments 
(F(ab)2) can be advantageous for immunotherapeutic application. Application of F(ab)2 
fragments to patients minimizes the risks of immunogenic properties of IgGs, because these 
are predominantly located on the Fc part of the molecule [169] and Fc subfragments are 
removed after digestion. Smaller size of F(ab)2 molecules enables better penetration into 
tissue and provide less steric hindrance [170]. 
Acidic endopeptidase pepsin cleaves monoclonal antibodies in the hinge region 
generating the F(ab’)2 an Fc subfragments [170] as illustrated in Scheme 22. 
 
 
Scheme 22: Pepsin cleavage scheme of monoclonal antibody. 
 
It is known, that pepsin is active only at acid pH being irreversibly denatured at neutral or 
alkaline pH [171]. Pepsin cleaves preferentially C-terminal hydrophobic, aromatic residues 
like phenylalanine and leucine. To look closely into the digestion process pepsin cuts the 
monoclonal antibody at the heavy chain lower hinge region. The lower hinge amino acid 
sequence (APELLGGP) will be cleaved behind the disulfide bonds between two leucines as 
illustrated in Scheme 25 on amino sequence of Avastin leading to creation of one F(ab)2 
fragment and one (segmented) Fc fragment. 
 
Further utilization of EACA running buffer 
 
Carboxypeptidase B digestion 
 
C-terminal lysines are commonly present on the heavy chain of monoclonal antibodies. 
Their impact on bioactivity is not well understood until now, but the degree of heterogeneity 
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of C-terminal lysine variants indicates the manufacturing consistency [172]. Heterogeneity of 
C-terminal lysine residues is believed to result from varying degree of proteolysis by 
endogenous carboxypeptidase(s) during cell culture production [173]. 
Carboxypeptidase B is a metallocarboxypeptidase (Zn) that catalyses the hydrolysis of 
the basic amino acids as lysine, arginine and ornithine from the C-terminal position of 
polypeptides [174] as illustrated in Scheme 23. 
 
 
Scheme 23: Carboxypeptidase B cleavage scheme of polypeptide. 
 
3.2.2 Materials and Methods 
 
Materials 
 
Test samples used in this study were purchased from Roche (Avastin) and from Merck 
(Erbitux). Papain and pepsin were obtained from Sigma, PNGase from NEB, and 
Carboxypeptidase B from Worthington. Acetic acid, ε-aminocaproic acid (EACA), ammonium 
bicarbonate, disodium hydrogen phosphate, dithiothreitol (DTT), ethylenediaminetetraacetic 
acid (EDTA), hydroxypropyl methylcellulose (HPMC), iodoacetamide (IAA), L-cysteine, 
phosphoric acid (H3PO4) were purchased from Sigma. Acetonitrile (ACN), ammonium 
hydroxide, hydrochloric acid (HCl), sodium hydroxide (NaOH), trifluoroacetic acid (TFA), 
tris(hydroxymethyl)aminomethane (Tris-HCl) were purchased from Fluka. Conditioning 
solution, SDS-MW gel buffer, SDS sample buffer and internal standard (10 kDa) were 
purchased from AB Sciex, RapiGest from Waters, Pharmalyte 3-10, 5-8.5 from GE, 1 % 
methylcellulose (MC) and pI markers (4.65, 10.10) from ProteinSimple. 
Fused silica capillary was obtained from CM scientific, neutral coated capillary from AB 
Sciex, FC-coated cIEF cartridges from ProteinSimple, 3 and 10 kDa filters from Millipore, air 
displacement pipettes, thermomixer and centrifuge from Eppendorf. 
Methods 
 
Papain digestion. Papain enzyme was added to the protein at a ratio 1:10 (w/w) for 
Avastin and 1:20 for Erbitux and the digestion was performed in presence of 25 mM final 
concentration L-Cys. The protein/enzyme mixture was then diluted to a final concentration of 
2.5 mg/mL with the milli-Q water and incubated at 37 °C for 5 h. 
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Pepsin digestion. Samples were transferred into 0.2 M sodium acetate buffer pH of 4.0 
using 10 kDa filters and centrifugation. Pepsin enzyme was added to the protein at a ratio 
1:20 (w/w) in presence of 0.1 % final concentration of RapiGest (w/v). The protein/enzyme 
mixture was then diluted to a final concentration of 2.5 mg/mL with 0.2 M sodium acetate 
buffer and incubated at 37 °C for 18 h. 
 
Carboxypeptidase B digestion. Erbitux (60 µg) was mixed with 5 µg of carboxypeptidase 
B and incubated at 37 °C for 3.5 h in formulation buffer. 
 
Papain, PNGase digestion. 1.5 µg of PNGase were added to Papain digested Erbitux 
(preparation see above) and the mixture was incubated at 37 °C for 1 h. 
 
Electrophoretic conditions. CZE was carried out on the PA800 Beckman Coulter (AB 
Sciex) instrument with temperature controlled autosampler using fused silica capillary (50 cm 
of length, 50 µm id) with normal polarity. The cathode was at the detector end of the capillary 
for the analyses with lower pH. The capillary was flushed (by HCl, NaOH and milli-Q water) 
from appropriate buffer reservoirs using pressure (50 psi) prior to each run. The capillary 
was filled with running buffer (600 mM EACA, 0.1 % HPMC, pH 6.0, unless otherwise stated) 
using pressure (50 psi). The sample was injected using pressure (0.5 psi) for 10 s, the 
constant voltage of 30 kV was applied and the operation temperature of 25 °C was kept. 
Electropherograms were UV-monitored at 214 nm and the data were processed with 32 
Karat. 
 
cIEF conditions. The cIEF runs were carried out using a Convergent Bioscience iCE280 
Analyzer (Protein Simple) with temperature controlled Prince autosampler on fluorocarbon- 
coated fused silica capillary. Electropherograms were UV-monitored at 280 nm in whole 
column. The anolyte consists of 80 mM phosphoric acid in 0.1 % methylcellulose and the 
anolyte is 100 mM sodium hydroxide in 0.1 % methylcellulose. 
A working ampholyte solution (AS) was prepared by mixing 2000 µl 0.35 % 
methylcellulose, 60 µl broad- and 10 µl narrow-range Pharmalytes 3-10 and 8-10.6 
respectively and pI markers 4.65 and 10.10 at 5 µl each. The sample/ampholyte mixture was 
prepared by mixing 100 µl AS with 10 µl test solution and the mix was carefully transferred 
into glass insert vials avoiding bubbles. 
All test samples were prefocused for 1.5 min using a voltage of 1500 V and focused for a 
variable periods of time (generally for 6-8 min, depending on analyte) using a voltage of 
3000 V. 
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Chromatographic conditions. Reversed phase chromatography was carried out using an 
Agilent 1200 binary pump system with temperature controlled autosampler and vacuum 
degasser. The analytes were introduced onto Vydac C4 column from Grace and the flow 
rate was maintained at 1 mL/min. The column was equilibrated with mobile phase A (0.1 % 
TFA in H2O). Mobile phase A and mobile phase B (0.1 % TFA in ACN) were used to 
establish the 50 min gradient as shown in Table 27. 
The UV chromatograms were obtained by monitoring absorbance at 214 nm and the data 
were processed with Chromeleon software (Dionex). 
 
Table 27: Gradient. 
 
time [min] mobile phase B [%] 
0 5 
5 20 
30 45 
45 90 
50 5 
 
 
3.2.3 Results and Discussion 
 
Optimization of CZE background electrolyte providing the information about 
isoform pattern 
 
Initially, the highly resolved reproducible isoelectric profiles (cIEF) of two monoclonal 
antibodies (Avastin and Erbitux) were obtained. Secondly, the CZE separation method 
based on [141] was adapted to achieve the electrophoretic (CZE) profiles analogous to the 
cIEF. During the examination the following parameters were optimized: (a) pH value of the ε- 
aminocaproic acid (EACA) running buffer; (b) concentration of EACA and ionic strength; (c) 
concentration of hydroxypropyl methylcellulose (HPMC); (d) capillary length, separation 
temperature and field strength; (e) sampling rate and (f) flushing and equilibration conditions. 
It is expected that in addition to the main variant also some acidic and basic variants will 
be visible in the isoelectric profile of Avastin due to N-linked glycosylation and C-terminal 
heterogeneity (lysines). Based on the amino acid sequence of Avastin [158], the pI value 
was calculated using Expasy software [131]. As stated in Table 42, the calculated value of 
8.1 differs from value that was experimentally determined to 8.3 by Kaja et al. [175]). 
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Figure 17: cIEF of Avastin: cend = 0.5 mg/ml, basic AS with Pharmalyte 3-10, 8-10.5, pI M 
4.65, 10.10 and 0.35 % MC. 
 
Charge distribution of unstressed Avastin sample is represented by Figure 17 (using cIEF 
conditions 3.2.2). Main (I0), acidic (Ia) and basic (Ib) species can be evaluated and the 
appropriate relative percentage peak areas used for quality control. The pI values of the 
present isoforms were determined using pI markers (pI markers at pI 4.65 and 10.10 are not 
shown in Figure 17). Consequently, the pI of I0 was calculated with 8.3. Information about 
the pI value generally provides sufficient specificity and serves as identity assay on a control 
system. There are couple of signals visible in the acidic range representing probably 
presence of glycans with sialic acids. Signals for basic variants might indicate e.g. presence 
of lysines, amidation or some fragments. 
As discussed below, the presence of ε-aminocaproic acid and HPMC should provide a 
sufficient dynamic capillary coating. Therefore the initial focus of the work lay first in avoiding 
the application of TETA and optimizing various parameters to achieve the best possible peak 
resolution using CZE. 
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Figure 18: CZE, Avastin (unstressed) in formulation buffer (2 mg/mL). From bottom to top: 
300 mM (black trace), 500 mM (blue trace), 600 mM EACA (green trace), pH 5.5. 
Experimental conditions: BGE: 300-600 mM EACA, 0.1 % HPMC, pH 5.5, 40/50 cm 50 µm 
fused silica capillary, separation temperature: 25 °C, separation voltage: 30 kV, injection 
0.5 psi 10 s. 
 
CZE separation of intact unstressed Avastin with EACA, 0.1 % HPMC running buffer is 
demonstrated in Figure 18. The pH was fixed at 5.5 and the concentration varied from 300- 
600 mM. By the contrast with [141] in the CZE experiments from Figure 18 no additionally 
capillary coating was applied. He et al. [141] reported using of TETA, because in their 
previous experiments [177] an undesirable peak broadening was observed without  
additional coating of the capillary. Positively charged aliphatic oligoamines (such as TETA) 
are able to adsorb at the interface between the capillary wall and the background electrolyte. 
That situation leads to the drastic variation of the positive charge density in the Stern layer, 
which decreases the zeta potential and, hence, reduces the EOF. 
In the electrophoretic measurements in Figure 18, using the background electrolyte 
containing 300 mM EACA led to the presence of a very low signal, most likely as a result of 
analyte adsorption to a capillary wall. Further increase in buffer concentration resulted in an 
improvement of the signal height and also of the resolution of acidic and basic species. The 
adsorption of zwitterionic EACA onto the capillary wall deactivates the electrochemical 
double layer. This is apparent also from the electropherograms shown in Figure 18. With the 
increasing EACA concentration the adsorption of the Avastin onto capillary wall decreased 
and the signal intensity of Avastin grew until the EACA concentration achieved the certain 
level (600 mM). A further increase had no impact on the signal intensity. The most 
appropriate conditions of EACA were therefore set to 600 mM. The presence of HPMC in 
background electrolyte appears to mask efficiently the silanol groups of the fused silica 
capillary as it has been published by various researchers [178, 179]. Even small amounts of 
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polysaccharide derivates (such as HPMC) can significantly improve the resolution of protein 
separations by decreasing the zeta potential. High concentrations of polysaccharide 
derivates (e.g. dextran, HPMC, MC) increase the buffer viscosity to a large extent and cause 
molecular sieving [180]. However, the HPMC concentration of 0.2 % and lower is below the 
entanglement point and therefore the improvement of the peak resolution is thought to be 
due to differential reduction of the protein mobility and attenuation of electroosmotic flow 
[181, 182, 183]. The most appropriate concentration of HPMC, which participated on the 
best charge isoform separation of Avastin, was experimentally set to 0.1 %. 
It is expected that the separation of charge variants will be significantly improved when 
the pH of the 600 mM EACA background electrolyte will rise closely to the pI value of 
Avastin. As reported by He [141], such conditions improves separation, because the relative 
charge differences among charge variants increase. If the pH value of the BGE is too close 
to the pI value of the protein analyte, attention must be paid to the possibility of an increased 
protein adsorption to the capillary wall or of the limited protein solubility [184]. 
 
Figure 19: CZE, Avastin (unstressed, stressed) in formulation buffer (2 mg/mL): From 
bottom to top: unstressed (black trace), 18 d 40 °C (blue trace). Experimental conditions: 
BGE: 600 mM EACA, 0.1 % HPMC, pH 6.0, 40/50 cm 50 µm fused silica capillary, 
separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
The final background electrolyte properties and CE parameters (3.1.2) led to the 
reproducible separation of main, acidic and basic isoforms and allowed analysis of Avastin 
within 30 minutes for unstressed and also stressed test sample (Figure 19). Compared to 
the unstressed profile a signal increase in range of the acidic isoforms could be observed. 
By matching the CZE profile of an unstressed sample with cIEF (Figure 17) the improvement 
of isoform distribution was achieved for basic variants only. 
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As shown in the Table 28 the CZE and cIEF corrected area percentages of main isoforms 
of intact unstressed Avastin were comparable. The CZE acidic and basic charge variant 
distribution differed from cIEF. Presence of acidic variants was higher in CZE than it was 
observed in cIEF. At the same time it was observed that the amount of basic variants was 
lower. 
 
Table 28: Corrected area percentage of main [I0], acidic [Ia] and basic [Ib] isoform of 
unstressed intact Avastin. 
 
 cIEF CZE 
A % [I0] 69.4 68.3 
A % [Ia] 26.6 29.9 
A % [Ib] 4.0 1.8 
Results are reported as the means of triplicate determinations. 
 
It is anticipated that the experiments with Erbitux will offer more heterogeneous charge 
variant profile than it was observed for Avastin due to presence of two different glycosylation 
sites and also C-terminal lysine heterogeneity. 
 
Figure 20: cIEF of Erbitux: cend = 0.5 mg/ml, basic AS with Pharmalyte 3-10, 8-10.5, pI M 
4.65, 10.10 and 0.35 % MC. 
 
The charge isoform distribution of non-stressed Erbitux (using the cIEF conditions 
described in chapter 3.2.2) is shown in Figure 20. The annotations of acidic and basic 
species are congruent to the annotations made in case of Avastin (Figure 17). pI markers at 
pI 4.65 and 10.10 are not shown in Figure 20. High amount of acidic isoforms can be 
explained by the presence of various glycans with attached sialic acids (Quian et al. [185] 
adverts to 21 distinct oligosaccharides in Erbitux) and basic isoforms demonstrate probably 
presence of lysines. The isoelectric point of the main isoform (I0) was experimentally 
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determined to 8.75, which is slightly differing from the calculated value of 8.48 (as listed in 
Table 43). As reported by Shaw et al. [176] this situation is not uncommon and the 
explanation for it can be seen in the different ionization of single amino acid groups in model 
and folded proteins. 
Figure 21: CZE, Erbitux (unstressed, stressed) in formulation buffer (2 mg/mL). From bottom 
to top: unstressed (black trace), 32 d 40 °C. Experimental conditions: BGE: 600 mM EACA, 
0.1 % HPMC, pH 6.0, 40/50 cm 50 µm fused silica capillary, separation temperature: 25 °C, 
separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
The CZE separation with the most suitable conditions (for details see 3.2.2) is 
demonstrated in Figure 21 on unstressed and stressed Erbitux sample. All above-mentioned 
parameters (e.g. running buffer concentration, pH etc.) were also here tested with the 
conclusion, that the same background electrolyte composition as for Avastin offers the most 
convenient isoform resolution. Buffers with pH greater than 6.0, led to peak broadening and 
long analysis times (above one hour, data not shown). Compared to the electropherogram in 
Figure 17, the resolution of charge variants is even better than that achieved with isoelectric 
focusing. Calculating the area percentages, the relative proportion of isoforms of unstressed 
Erbitux is comparable to cIEF (Table 29). Analysis of stressed Erbitux sample did not detect 
any increase of acidic charge variants. With increasing degree of sample degradation, the 
baseline resolution suffered, but the individual isoforms could be clearly separated from each 
other. 
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Table 29: Corrected area percentage of main [I0], acidic [Ia] and basic [Ib] isoform of 
unstressed intact Erbitux. 
 
 cIEF CZE 
A % [I0] 30.0 31.1 
A % [Ia] 46.2 44.9 
A % [Ib] 23.8 24.0 
Results are reported as the means of triplicate determinations. 
 
CZE assay after papain digestion 
 
Expecting that papain digestion of Avastin and Erbitux will allow a better visualization of 
charge variants both monoclonal antibodies were examined by cIEF and CZE after the 
enzymatic digestion. 
Initially, the papain fragmentation of Avastin and Erbitux into Fab and Fc portions was 
optimized. Based on [163, 186, 187] the following parameters were enquired: (a) 
enzyme:substrate ratio (w/w); (b) digestion temperature and incubation time; (c) formulation 
buffer; (d) additives; and (e) enzyme pre-activation. 
As introduced above, using papain, the upper hinge amino acid sequence of some 
humanized IgG1 will be cleaved behind histidine. If the hydrolysis rules will be applied on 
some specific target, under the condition that heavy and light chain sequences are known, 
then it is possible to obtain the exact Fab and Fc amino acid sequences. The cleavage site 
of the investigated Avastin is introduced in Scheme 24. The properties of new emerged 
fragments (as e.g. molecular weight and isoelectric point) can be calculated. As apparent 
from Table 30, the pI values of both fragments differ by ≥one unit; therefore a clearly visible 
separation of both signals can be expected. 
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Scheme 24: The hinge region and part of heavy chains of Avastin with expected papain 
digestion site. 
 
Table 30: Calculated [131] average molecular weights and pI values of Fab and Fc 
fragments of Avastin. 
 
Fragment Mw [kDa] pI 
Fab 48.2 8.21 
Fc 25.1 6.95 
 
Optimization of the papain digestion process on Avastin and Erbitux was monitored by 
cIEF method. The aim was achieved when the complete hydrolysis of IgGs resulted in the 
production of two products (Fab and Fc) and no IgG signal was visible anymore. The charge 
distribution of the fragments was finally analysed by CZE, simultaneously optimizing the 
electrophoretic parameter to achieve the best possible resolution. 
 
Figure 22: cIEF of papain digested Avastin: cend = 0.3 mg/ml, digestion in 1 mM at 37 °C 
for 5 h, basic AS with Pharmalyte 3-10, 8-10.5, pI M 4.65, 10.10 and 0.35 % MC. 
 
Charge distribution of Fab and Fc fragments of papain digested unstressed Avastin 
sample is demonstrated in Figure 22. Sample preparation and isoelectric conditions are 
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described in chapter 3.1.2. Firstly, the signal identification was carried out on the basis of 
knowledge of the isoelectric points (Table 30). The pI values of Fab and Fc fragments were 
set experimentally using two pI markers. Although observed isoelectric points of the 
fragments were higher than expected, the signal assignment was straightforward. The 
difference between Fab and Fc pI values of almost 1 pH unit allowed dramatic separation of 
both main signals. Secondly, the spiking of single fractions was performed (Fab and Fc 
fragments were collected using RP-HPLC separation of papain digested Avastin, subjected 
to vacuum to dry, dissolved again in a minimum volume of water and used for spiking); for 
results see Table 44. As apparent from Figure 22 the Fc fragment is present in the more 
acidic region of the electropherogram and its pI value was experimentally determined to 
7.54. All further acidic forms are clearly baseline separated.  Two signals with pI values of 
6.90 and 7.25 result very likely from present glycans with attached sialic acids. Remaining 
acidic signals could not be identified, but it is presumed that these are also result of papain 
digestion. As described in [162], papain exhibits some specificity for leucine and glycine. The 
enzyme could therefore partially hydrolyse the molecule at other positions than at the C- 
terminal side of the histidine residue in the hinge region. The peak at 9.05 with some 
unresolved acidic variants was assigned as Fab. The acidic isoforms in the Fab region were 
considered to be a result of Fab microheterogeneity or co-migration of some other papain 
cleavage products. Based on research results from Bennet [165], it was expected that the 
signal at 8.6 represents the F(ab)2 fragment (spiking experiments with intact Avastin did not 
approve some remaining signal of the undigested molecule). Bennet published the 
predominant production of F(ab)2 if cysteine (L-Cys) is absent during the papain digestion 
procedure. Using lower concentrations of L-Cys (or its omission) in the digestion process led 
to the increment of the F(ab)2 signal. The signal at 9.60 represents papain. 
The above-introduced CZE separation conditions (in detail described in chapter 3.2.2) 
were seen as the most appropriate for the analysis of digested samples. It is expected that 
using normal polarity and running buffer at pH 6.0, the fragments will be positively charged 
and appear in the reverse order than it was observed by isoelectric focusing. 
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Figure 23: CZE of papain digested Avastin (cend = 2.5 mg/mL), digestion in 1 mM L-Cys at 
37 °C for 5 h. Experimental conditions: BGE: 600 mM  EACA,  0.1  %  HPMC,  pH  6.0, 
40/50 cm 50 µm fused silica capillary, separation temperature: 25 °C, separation voltage:   
30 kV, injection 0.5 psi 10 s. 
 
As demonstrated in Figure 23, the Fab (16.0 min) and Fc (24.5 min) fragments were 
separated within 25 minutes. The electrophoretic signal with the migration time of 17.5 min 
represents very likely the F(ab)2 fragment. It is apparent, that the isoform profiles differ from 
these obtained by isoelectrofocusing. In comparison with Figure 22 a worse separation of 
acidic Fab signals was observed, but as introduced in Table 31 the area percentages of 
single fragments were comparable. 
 
Table 31: cIEF and CZE corrected area percentage of Fab + F(ab)2 and Fc fragments. 
 
 cIEF CZE 
A % [Fab + F(ab)2] 69.6 68.4 
A % [Fc] 30.4 31.6 
Results are reported as the means of triplicate determinations. 
 
As presented in introduction section, this method should allow the better visualization of 
the charge variant alterations. The presence of new signals is expected in stressed sample 
due to possible deamidation or fragmentation. Worthwhile to noting is that the deamidation 
has been widely reported for asparagines in the variable domains of monoclonal antibodies 
[82, 83, 150, 188]. Variable domains are situated in the Fab fragments. 
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Figure 24: CZE of papain digested unstressed and stressed Avastin, digestion in 1 mM L- 
Cys at 37 °C for 5 h (cend = 2.5 mg/mL). From bottom to top: unstressed, papain (black trace) 
and 22 d at 40 °C, papain (blue trace). Experimental conditions: BGE: 600 mM EACA, 0.1 % 
HPMC, pH 6.0, 40/50 cm 50 µm fused silica capillary, separation temperature: 25 °C, 
separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
Using papain digestion to reduce the protein complexity of unstressed and stressed 
Avastin and subsequent CZE separation of resulting fragments is introduced in Figure 24. 
From both electropherograms it is apparent, that some differences could be observed 
between these digested samples. The signals in the acidic region of the Fab fragment (blue 
trace, 12.8 min) indicate the presence of some new charge variants. Presumably, such 
signals represent deamidation of asparagine(s) after forced degradation. This sample can be 
a regarded for further investigations e.g. peptide-mapping with MS detection or Asp-N 
digestion. Also an increment of the F(ab)2 signal of stressed sample (blue trace, 14 min) was 
noticed. This observation could be explained by some molecule conformational changes due 
to forced stress. An access of the enzyme to the target can be aggravated and therefore a 
diminished ability of the enzyme ability to reduce the hinge region disulphide could be 
observed. 
Interesting results were observed after using a second enzyme in the test sample 
preparation: Protein N-Glycosidase (PNGase). PNGase digest was performed after papain 
digestion followed by CZE analysis. This enzyme facilitates the release of N-glycans from 
glycoproteins by the cleavage of the link between asparagine and N-acetylglucosamines 
[189, 190]. Applying PNGase digestion the attached N-glycans will be released and the 
remaining Asn residue will by hydrolysed (deaminated) to Asp. If there are no sialic acids 
attached to glycans then due deamination, the deglycosylated protein will be more acidic as 
its glycosylated counterpart. 
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As mentioned in introduction section (3.2.1), there are two N-glycans present at N303 of 
both heavy chains (which corresponds to Fc fragments). According to Fuller et al. [191], who 
investigated labelled N-glycans of various Avastin lots by chromatography, no Avastin 
glycoforms had sialylated structures. Boeggman et al. [192], who performed the MALDI 
analysis of the biantennary Avastin N-glycans, obtained the same results as Fuller et al. 
Based on this fact it can be expected that the N303 deaminated Fc part of Avastin will 
migrate as a weaker cation with higher migration time than its glycosylated counterpart when 
applying positive polarity and using 600 mM EACA running buffer of pH 6.0. 
 
Figure 25: CZE of papain, PNGase digested Avastin (cend = 2.5 mg/mL), papain digestion 
in 1 mM L-Cys at 37 °C for 5 h. From bottom to top: Papain digest without PNGase (black 
trace), Papain, PNGase digest: 20 min 37 °C (blue trace), Papain, PNGase digest: 1 h 37 °C 
(red trace). Experimental conditions: BGE: 600 mM EACA, 0.1 % HPMC, pH 6.0, 40/50 cm 
50 µm fused silica capillary, separation temperature: 25 °C, separation voltage: 30 kV, 
injection 0.5 psi 10 s. 
 
The electrophoretic separation profile of papain digested Avastin was already introduced 
in Figure 23 and this sample is represented by black trace in Figure 25 (the CGE-SDS 
separation of reduced Avastin is shown in electropherogram (upper right corner) to visualize 
the non-glycosylated (NGHC) and glycosylated heavy chain (HC) forms). In addition to 
presumed F(ab)2 signal (18.0 min) and two dominant  peaks:  Fab  (16.0  min)  and  Fc  
(26.7 min) some further peaks of low signal intensities were detected with migration time of 
30-34 min (black trace). These peaks were supposed to represent the non-glycosylated Fc 
portion (NG-Fc) with zero, one or two attached lysines. Deglycosylation led to a loss of the 
initial Fc signal and to a creation of two new Fc fragment variants (blue trace, 30 and 34 min) 
after 20 minutes of incubation. With longer incubation (one hour), only deglycosylated Fc 
signal is observable (red trace, 33.2 min) in addition to Fab fragment (16.0 min), which 
stayed unchanged. The shift to the higher migration time indicates no terminal sialylation of 
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the Fc fragment. The enzymatic hydrolysis of N-glycans in the presence of sialic acids would 
contribute towards the creation of more basic Fc fragment and towards shift in the opposite 
direction. These observations correlate with the results published by Fuller and Boeggman 
[191, 192]. Because the deglycosylated signal appears now in the more acidic region than it 
was observed for its glycosylated form some additional anionic character can be attributed to 
this molecule. The explanation for this effect is that the asparagine residue from which the 
glycan was removed is deaminated to aspartate. 
Routinely the CGE-SDS is used for the separation of the glycosylated species from their 
non-glycosylated counterparts [193, 194] after reduction of the monoclonal antibody. CGE- 
SDS assay enables the control of the non-glycosylated (NG) variant of heavy chain in the 
presence of gel, which allows separation according to differences in molecular weight. 
Therefore the non-glycosylated species migrate with lower migration times than their 
glycosylated counterparts. CZE separates the analyte based on differences in their 
electrophoretic mobilities. As described above, it was presumed, that the signals at 30-      
34 min (black trace) represent the NG-Fc portion. The calculated area percentage of NG-Fc 
(A % 2.0) correlated with the result obtained for NGHC. However, the NG-Fc peak heights 
were not much above the level of background noise. The CZE results indicate the possibility 
to examine the non-glycosylated and glycosylated forms by CZE using papain digestion and 
EACA background electrolyte. 
After successful papain digestion and CZE separation of Fab and Fc fragments of 
humanized monoclonal antibody (Avastin) the chimeric monoclonal antibody (Erbitux) was 
studied. Papain cleavage at the C-terminal side of histidine residue in upper hinge region 
lead to the creation of the Fab and Fc fragments. The properties of new emerged Fab and 
Fc fragments (molecular weight and isoelectric point) were calculated; for results see Table 
32. A clearly visible separation of both signals can be expected, because the difference 
between pI values of both fragments is large. 
 
Table 32: Calculated [131] average molecular weights and pI values of Fab and Fc 
fragments of Avastin. 
 
Fragment Mw [kDa] pI 
Fab 47.8 8.70 
Fc 50.1 7.12 
 
A high degree of heterogeneity of Fc portion of Erbitux can be expected due to the 
presence of C-terminal lysines and glycosylation at Asn299 [195]. The glycosylation at 
Asn88 [195, 196] with present sialic acids will be among other post-translational changes a 
source of acidic heterogeneity of Fab. 
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Figure 26: cIEF of papain digested Erbitux: cend = 0.3 mg/ml, papain digest 37°C with L- 
Cys for 5 h, AS with Pharmalyte 3-10, 8-10.5, pI M 4.65, 10.10 and 0.35 % MC. 
 
The IEF-electropherogram in Figure 26 represents papain digested Erbitux. In 
comparison to Avastin there are much more isoforms observable in both portions (as also 
shown in Figure 21). The basic isoforms of Fc portion result from two present C-terminal 
lysines (K1, K2) and the acidic not-resolved form represents very likely the glycosylation at 
Asn299. The acidic heterogeneity of Fab was explained by the glycosylation at Asn88. 
Release of such glycans by PNGase (data not shown) led to some minor changes in the 
isoelectrophoretic profile. This can be explained by simultaneously deamination and creation 
of further acidic signals. The signal at 9.60 represents papain. Other signals in the acidic 
region of the Fab portion (pI of 8.5) were presumed to be a product of papain nonspecific 
cleavage. To control the protein hydrolysis and the resulting final products, the digestion 
procedure was monitored by CGE-SDS (Figure 49). The peak identification was done based 
on the knowledge of molecular weights of the possible cleavage products. The digestion 
conditions applied in Figure 26 resulted in the formation of two main portions (Fab) of 50 kDa 
and of only minute amounts of F(ab)2, non-digested IgG and some unidentified fragments of 
approximately 30 kDa. 
As observed for papain digested Avastin experiments, it was expected that the above- 
introduced CZE separation conditions (in detail described in chapter 3.2.2) would lead to 
comparable results using cIEF and CZE for the analysis of papain digested Erbitux. 
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Figure 27: CZE of papain digested Erbitux (cend = 2.5 mg/mL), digestion in 1 mM L-Cys at 
37 °C for 5 h. Experimental conditions: BGE: 600 mM  EACA,  0.1  %  HPMC,  pH  6.0, 
40/50 cm 50 µm fused silica capillary, separation temperature: 25 °C, separation voltage:   
30 kV, injection 0.5 psi 10 s. 
 
The CZE electropherogram of papain digested Erbitux is demonstrated in Figure 27. The 
profiles of Fab and Fc portions are not comparable to cIEF results (Figure 26). The 
explanation for this fact was seen in a co-migration of some present signals. Most likely the 
Fab portions are represented by two signals (29 and 35 min). The split peaks of the acidic 
Fab signal (35 min) seem to be also present in Figure 26 at pI of 8.7. The Fc lysine isoforms 
were not detected. Various buffer pH values and concentrations, separation temperatures, 
voltages or analysis using the neutral coated capillary did not contribute to any improvement 
of the separation profile. Because the peak determination cannot be done in CZE run and 
the CZE and cIEF separation profiles were not comparable further steps were taken to 
identify the Fab and Fc portions. The fragments of papain digested Erbitux were collected 
using RP-HPLC separation, fractions were subjected to vacuum to dry, reconstituted in a 
minimum volume of water and used for individual CZE runs and later for spiking experiments 
(Figure 50). Electrophoretic investigation of the single fractions offered complex 
electrophoretic profiles of both Erbitux fragments. The CZE analysis of the Fab portion 
manifested the presence of two main peaks and further three clearly visible peaks were 
detected after examination of the Fc portion. In addition to the clearly visible peaks, there 
were also some signals observed as peak shoulders (data not shown). The combination of 
the Fab and Fc fragment resulted in the electrophoretic profile obtained for the papain 
digested sample (shown in Figure 27). 
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CZE assay after pepsin digestion 
 
The interpretation of the electrophoretic signals of papain digested Erbitux turned out to 
be difficult due numerous co-migrations. Therefore, the complexity of the protein was 
reduced by pepsin digestion. If the information about the crystallisable region (Fc) is not 
required, pepsin can be taken for the mAb hydrolysis. After digestion, the Fc peptide 
fragments are removed from the test sample prior to analysis. Doing so, the problem of co- 
migration of Fab signals with Fc signals (as seen in Figure 27) will be eliminated. 
It is known, that pepsin is active only at acid pH being irreversibly denatured at neutral or 
alkaline pH [171]. Pepsin cleaves preferentially at the C-terminal side of hydrophobic, 
aromatic residues like phenylalanine and leucine. To look closely into the digestion process 
the pepsin cuts the monoclonal antibody at the heavy chain lower hinge region. The lower 
hinge amino acid sequence (APELLGGP) will be cleaved behind the disulfide bonds 
between two leucine hinge [166]. As illustrated in Scheme 25 of the amino sequence of 
Erbitux the enzymatic hydrolysis leads to a creation of one F(ab)2 fragment and one 
(segmented) Fc fragment. 
 
 
 
Scheme 25: The hinge region and part of heavy chains of Erbitux with expected pepsin 
hydrolysis. 
 
Using Erbitux as the study material the pepsin digestion conditions were optimized. 
Based on published works [169, 170, 171, 197] the influence of the following parameters 
was investigated: (a) pepsin and test sample concentration ratio; (b) digestion temperature 
and duration; (c) formulation buffer; (d) additives; and (e) enzyme pre-activation. The charge 
isoform distribution of pepsin digested unstressed Erbitux sample was studied by cIEF and 
the isoelectrophoretic run using the final method is shown in Figure 28. The sample 
preparation and the isoelectric conditions are described in 3.1.2. 
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As previously described in chapter 3.2.1 and illustrated in Scheme 22, pepsin cleaves 
monoclonal antibodies in the hinge region generating the F(ab’)2 and Fc subfragments. 
These small fragments can be removed from the digestion mixture and F(ab’)2 can be further 
investigated. 
 
 
Figure 28: cIEF of pepsin digested Erbitux: cend = 0.3 mg/ml, digest 37 °C 18 h with 
RapiGest: basic AS with Pharmalyte 3-10, 8-10.5 and 0.35 % MC. 
 
As apparent from the IEF-electropherogram of pepsin digested Erbitux (Figure 28), the Fc 
portion clearly visible in Figure 26 does not appear in the acidic range anymore. The Fc 
subfragments created by the enzyme were effectively removed from the digestion mixture by 
ultracentrifugation. The acidic charge variants of the F(ab)2 part are well resolved compared 
to the peak shoulder slightly visible in the basic range of the highest F(ab)2 peak. The 
presence of the various acidic charge variants can be explained by attached sialic acids. 
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Figure 29: CZE of pepsin digested Erbitux (cend = 2.6 mg/mL), digestion at 37 °C for 18 h. 
Experimental conditions: BGE: 600 mM EACA, 0.1 % HPMC, pH 6.0, 40/50 cm 50 µm fused 
silica capillary, separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 
10 s. 
 
The electrophoretic profile of F(ab)2 charge variants is illustrated in Figure 29. The 
present isoforms exhibit very great similarities with previously discussed cIEF profile (Figure 
28). In comparison to cIEF the CZE method led to a significant improvement of the resolution 
of acidic and also basic variants. The acidic variants were already discussed above. The 
detected basic variants could indicate a presence of some peptide fragments or represent 
some conformational changes that lead to the creation of further charged isoforms [151, 
152]. 
 
Monitoring the extend of Lysine cleavage by carboxypeptidase B activity 
 
The presented CZE method can also be utilized for the investigation of the C-terminal 
lysines. As introduced in chapter 3.2.1 and illustrated by Scheme 23, carboxypeptidase B 
cleaves basic amino acids such as Lys and Arg from C-terminus of a protein [174]. 
Applying the enzyme carboxypeptidase B to Erbitux, the C-terminal lysines can be 
cleaved and the molecule can be investigated by CZE using EACA. Compared to the 
undigested molecule, some differences can be expected in the migration pattern, namely in 
the Ib range. The microheterogeneity pattern created i.a. by the lysine variants will be 
reduced by an amount of the removed lysines. 
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Figure 30: CZE of carboxypeptidase digested unstressed and stressed Erbitux (cend = 
2.5 mg/ml), digest 37 °C 3.5 h. From bottom to top: unstressed, carboxypeptidase (black 
trace), 14 d 40 °C, carboxypeptidase (blue trace). Experimental conditions: BGE: 600 mM 
EACA, 0.1 % HPMC, pH 6.0, 40/50 cm 50 µm fused silica capillary, separation temperature: 
25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
 
The reference for these experiments was introduced above in Figure 21. The 
carboxypeptidase treated unstressed and stressed Erbitux samples were analysed using 
EACA running buffer as shown in Figure 30. Two missing signals (labelled as Ib) clearly 
visible in the electropherogram of undigested Erbitux verify the former presence of two C- 
terminal lysines (as previously seen using isoelectrofocusing – data not shown). 
As apparent from CZE electropherograms in Figure 30, the presence/absence of C- 
terminal lysines can be monitored by utilization of EACA running buffer and 
carboxypeptidase digestion. This method can be applied for unstressed samples and also 
stressed samples. 
 
3.2.4 Conclusion 
 
Objective of this study was to find out whether the application of a simple analytical CZE 
method would be appropriate for the study of charge variants of two monoclonal antibodies, 
intact and also enzymatically hydrolysed. Method, we were trying to develop, should be 
complementary to the cIEF, reproducible, free of oligoamines coating or neutral coated 
capillary and also independent of using ampholytes. 
The EACA running buffer (600 mM, 0.1 % HPMC pH 6.0) provided very similar CZE 
profiles to these obtained by isoelectrofocusing in the study of intact monoclonal antibodies; 
in case of Erbitux even better resolution of acidic and basic isoforms was achieved. Closely 
associated with this finding is the increased probability to monitor even small 
microheterogeneity alterations e.g. lot-to-lot dissimilarities or presence of new charge 
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variants in stressed samples. Although the results obtained for intact mAbs were very 
promising, the separation of papain-digested samples led to a partial success only. Whilst 
the CZE resolution and the area percentages of Avastin Fab and Fc portions were 
comparable with the cIEF method, the exact Erbitux peak assignment to the specific portions 
was made difficult by co-migrating signals. It was demonstrated on Avastin sample, that the 
CZE method in the combination with papain digestion could be utilized in the study of 
degraded (potentially deamidated) samples, because the pre-localization of new acidic 
charge variants was made possible. Applying the CZE for the analysis of F(ab)2 Erbitux 
portion (obtained after pepsin digestion) provided better resolution of present isoforms than it 
could be reached by isoelectrofocusing. Pepsin digestion leads to the partial fragmentation 
of the Fc portion, therefore is this method suitable for the investigation of charge variants of 
F(ab)2 portions only. 
Broad analytical application of EACA running buffer was demonstrated by the 
combination of papain digestion with PNGase. We manifested the power of this technique on 
separation of glycosylated and deglycosylated Avastin Fc fragments. Also the presence or 
absence of C-terminal side lysine residues can be demonstrated as shown in the example of 
the carboxypeptidase digested Erbitux. 
CZE method is preferred compared to cIEF because cIEF does not allow detection at 
wavelengths below 250 nm (absorption of ampholytes) and cannot be directly coupled to 
MS. 
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3.3 Evaluation of a CZE method for the analysis of protein PEGylation in 
erythropoietin 
 
The aim of this work is to establish the number of attached PEG moieties to erythropoietin 
(PEGylation degree), to localize the PEG attachment sites and to estimate the PEG 
occupancy (PEGocc). The study involves the development of capillary electrophoretic 
methods for the detection of intact erythropoietin (native and PEGylated) and also for the 
enzymatically cleaved molecule. Firstly, the CZE and CGE-SDS were applied for the 
investigations of the intact mAb. In further steps the focus was turned on the enzymatically- 
digested (Lys-C) sample; first of all the native (EPO) peptides were identified using various 
tools such RP-HPLC-MS and MALDI-TOF. In the following work the attention was aimed at 
the analysis of the generated peptides using CZE-UV. Spiking of the HPLC collected 
fractions to the digested EPO provided the identification of the present signals. Later, the 
peak assignment was performed and confirmed by CZE-ESI-MS analysis. After completion 
of the examination of the native mAb further investigations were proceed on the PEGylated 
mAb. 
 
3.3.1 Introduction 
 
Since the first successful genetic engineering product was introduced - human insulin in 
1978 [198] the biotechnology manufacturing processing of drugs grew rapidly. Until 2013, 
more than 90 recombinant drug substances have been approved and many new products 
are still under development [199]. Many years of detailed study brought progress in 
production technology and pharmacological understanding of biologics [200]. 
Despite the many advantages that the protein therapeutics offer (e.g. highly specific 
functions which cannot be imitated by small drugs; less potential to interfere with normal 
biologic processes and to induce unwanted immune response; replacement treatment of 
mutated or deleted gene [201]), the risk of immunogenicity, in vitro and vivo instability and 
short half-life can be a limiting factors of using such therapy [202]. To improve the current 
limitations several strategies have been developed creating the second generation of protein 
therapeutics. Attachment of poly(ethylene glycol) (PEG) moiety is one of the drug 
modifications which can overcome above listed issues. Polyethylenglycol, a synthetic 
polyether with the general formula illustrated in Scheme 26 is a water-soluble polymer with 
wide range of molecular weights (typical 500 - 20000 Da [18]). 
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Scheme 26: Formula of polyethylenglycol. 
 
These non-immunogenic non-toxic molecules are amphiphilic (soluble also in most 
organic solvents e.g. ethanol, toluene, acetone) and reactive with the nucleophile of amino 
groups of peptides and proteins through susceptible hydroxyl group creating often covalent 
conjugates. The presence of PEG enhances the therapeutic and biotechnological potential 
of peptides and proteins by masking of protein’s surface and increasing of molecular size 
[203]. Concurrently the biological functions (enzymatic activity, receptor recognition) may be 
maintained. Derivates of biologics are prepared by reaction of an activated PEG moiety 
leading to the attachment of this water-soluble polymer to specific sites of peptides or 
proteins [204]. PEG is usually linked to proteins at the α-amino and ε-amino groups of 
lysines and the linkage can be accomplished by acylation or alkylation [205]. 
The PEG-attachment to the molecule is the problematical part of the drug modification. 
PEGylation process can result in molecular heterogeneity in terms of the number (leading to 
mono-, di-, three- up to polyPEGylation) and positions of attached PEG molecules (one 
position fully PEGylated, several sites partial PEGylated) forming the various protein-PEG 
conjugates [206, 207]. The biological properties may be influenced by these heterogeneities, 
therefore the development of analytical methods for PEGylated drugs has become more 
important [208]. 
Various analytical methods can used for the quantitative measurement of PEG molecules 
and their conjugates with peptides/proteins. Some of them have been in use for many 
decades e.g. colorimetric methods [20] and some have been introduced in recent years e.g. 
asymmetrical-flow field-flow fractionation (AF4) [209]. PEGylated peptides and proteins can 
be separated by various electrophoretic and chromatographic methods. The electrophoresis 
is represented by e.g. microchip electrophoretic separation [210], CGE-SDS and CZE [211]. 
Chromatography (e.g. size exclusion chromatography (SEC), hydrophobic interaction 
chromatography (HIC) and electrostatic interaction chromatography (IEC)) has been 
successfully employed to characterize PEG-protein conjugates [212]. Reversed-phase high- 
performance liquid chromatography (RP-HPLC) is mainly used for study of enzymatic 
digested PEG conjugates [213]. In this work it is discussed, how these methods can be 
employed for the establishment of the number of attached PEG moieties to erythropoietin 
(PEGylation degree) and for the localization of PEG attachment sites with calculation of PEG 
occupancy (PEGocc). 
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Erythropoietin and its PEGylated form 
 
Erythropoietin (EPO) is a glycoprotein hormone that controls formation of red blood cells 
(erythropoiesis) [214]. Glycosylation of proteins depends on several factors such as the 
organism or cell line in which they are produced. N-glycosidic linkage of glycoproteins occurs 
via the asparagine amido group and N-acetyl-D-glucosamine residue, for O-glycosidic 
linkage binding to hydroxyl group of serine or threonine is typical [215]. Erythropoietin has 
also other biological functions as wound healing [216] or prevents neuronal apoptosis after 
cerebral injury [217]. The kidney predominantly produces human erythropoietin, although the 
liver production prevails in the fetal and perinatal period [218]. 
The mature protein consists of 165 amino acids resulting in a molecular mass of 30-      
34 kDa (18 kDa can be assigned the protein portion and the rest depends on amount of 
attached carbohydrates) [214, 218]. The polypeptide chain is linked through two disulfide 
bridges, one between cysteines at position seven and 161 and one between cysteines at 
position 29 and 33 in the amino acid sequence (Scheme 27). About 40 % of molecular mass 
can be attributed to carbohydrate residues: three N-linked (attached to asparagines at 
position 24, 38 and 83) and one O-linked (attached to serine at position 126). The 
carbohydrates (hexoses and N-acetylhexoseamines) induce a high molecular heterogeneity 
leading to a numerous glycoforms. Several isoforms are formed with respect to sialylation, 
glycan size, modifications like O-acetylation of sialic acids, deamidation of protein etc. 
Taichrib et al. [219] presented glycoform profiling of erythropoietin using CE-TOF MS and 
observed that erythropoietin molecule represents a complex mixture of various naturally 
occurring isoforms (>100). 
Sasakis group [220] conducted a study of carbohydrate structure of human urine and 
Chinese hamster ovary cell erythropoietin and published interesting results. The N-linked 
glycans of recombinant erythropoietin are bi-, tri- and tetra-antennary glycans, which 
typically terminate with sialic acid residues: biantennary (1.4 %), triantennary (10 %), 
tetraantennary with one N-acetyllactosaminyl repeat (3.5 %),  tetraantennary  with  one  
(32.1 %), two (16.5 %), or three (4.7 %) N-acetyllactosaminyl repeats. All of these 
saccharides are sialylated via 2→3 linkages. The O-linked glycans were monosialyl 
trisaccharide and disialyl tetrasaccharide. There are many published works about 
recombinant human erythropoietin (rHuEPO) describing the lot-to-lot variability of glycans or 
differences between various rHuEPO products [219, 220, 221]. Glycans attached to 
erythropoietin play a key role in the protein bioactivity. Their structure and profiles influence 
the activity in vivo and in vitro, the half-life in blood and stability of this protein. But also the 
sialylation of glycans participates in biological activity. Higher sialic acid content induces 
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prolonged half-life in vivo, the nature of the linkage prevents the clearance of erythropoietin 
from circulation, if bound to galactose or tetraantennary N-glycans. For that reasons, the 
glycosylation and sialylation have to be controlled for appropriate erythropoietin function. 
Recombinant human erythropoietin was introduced into the market at the end of the 
1980s [222]. Since then a large-scale biotechnological production spread this medicinal drug 
worldwide. Increasing production of biosimilars lead to increased erythropoietin product 
variations since glycosylation depends on producing organism or culture conditions [223]. 
In this chapter, an investigation of two erythropoietin forms will be introduced: 
NeoRecormon – EPO-β (EPO) and its PEGylated form Mircera (pegEPO). As compared to 
NeoRecormon, due PEGylation the Mircera is an erythropoiesis stimulating agent with 
reduced specific activity in vitro, increased activity in vivo and also increased half-life. The 
PEGylation is carried out through integration of an amide bond between 
methoxypolyethylene glycol-succinimidyl butanoic acid (PEG-SBA with molecular weight 
around 30 000 g/mol) and either the N-terminal amino group, or the ε-amino group of lysine, 
predominantly K52 and K45 [224]. This results in a molecular weight of around 60 kDa. The 
erythropoietin used in the manufacturing process is the active substance of the centrally 
authorized product (CAP28) NeoRecormon (Roche) produced by Chinese hamster ovary cell 
line. Group of G. W. Somsen [226] studied the structure of NeoRecormon and found out that 
this molecule possesses 77 different glycoforms even with up to 15 sialic acids attached to 
some oligosaccharides. 
 
 
Scheme 27: Amino acid sequence of erythropoietin and its glycosylation, disulfide bonds 
and PEGylation sites. 
 
 
 
 
28 CAP products can be marketed in all EU/EEA Member States and undergo a co-ordinated quality 
control system [225]. 
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Electrophoretic peptide mapping 
 
The procedure for the localization of PEGylation sites using the Lys-C digestion and CZE 
peptide mapping is explained in the following text and is illustrated on native (P) and 
PEGylated protein (pegP) in Scheme 28. The endoproteinase Lys-C is a protease that 
hydrolyses proteins at the C-terminal side of lysine. Lys-C in comparison to trypsin cleaves 
also lysines followed by prolines [227]. The enzyme digestion is followed by electrophoretic 
(chromatographic) separation with direct UV detection. The peptide mappings of P and pegP 
samples are visually compared. If no PEG moiety is attached to the peptide (for example P1) 
then the area of P1* peptide will be comparable with the area of P1 peptide (if the 
concentration of P and pegP sample is nearly similar). Partial PEGylation is demonstrated 
on P2 peptide of pegP. The non-PEGylated P2 of pegP will migrate with the same migration 
time as P2* in electropherogram. The P2 signal (peak area) will be lower compared to the 
P2* peptide. The PEGylated P2-PEG will migrate later (as a consequence of the larger 
hydrodynamic radius) than its native counterpart with typically broader shape. As all 
synthetic polymers, also PEGs contain polymer chains of unequal lengths – the distribution 
of PEG chain lengths explains the signal broadening. 
Scheme 28: Visualization of Lys-C peptide mapping of native (P) and PEGylated (pegP) 
protein with 1 PEG molecule at K28 analysed by CZE. 
 
Use of acidic background electrolyte for the CZE separation of Lys-C digested native and 
PEGylated protein is demonstrated on four exemplary electropherograms in Scheme 28. For 
native protein a complete enzyme digestion is expected to lead to a formation of four 
peptides whose signals are separated according to a net charge and hydrodynamic radius 
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(upper left panel). One PEG molecule bound to the K28 (P2) affects the separation of 
digested PEGylated protein. The altered (larger) hydrodynamic radius of P2-PEG causes 
lower electrophoretic mobility and leads to greater migration time (lower left panel) than it 
can be observed for P2* (upper left panel). Despite of higher pI value (and therefore higher 
positive charge using acidic running buffer) than P3 and P4, the P2-PEG will be separated 
most likely behind the P3 and P4 in the basic region. This separation behaviour could be 
observed, if the enzymatic digest works as expected. Proteins linked to a PEG molecule can 
be inaccessible for enzymes, because the PEG molecule may turn around the cleavage site 
or lead to the steric hindrance due a bulky chain, which would cause a limited access of 
enzyme to the cleavage site [228]. This fact could be resulting in missed cleavage and 
creation of longer peptide (P2-PEG + P3) as shown in Scheme 28 (lower right panel). It is 
also important to take into account some aspects of PEGylation. This covalent conjugation 
can lead to various number of PEG-protein adducts. If the P2 peptide is not fully PEGylated, 
then the signal for P2 peptide would be still observable (upper right panel). P2 signal will be 
lower than demonstrated in the native form (P2*, upper left panel) and also other signal – 
P2-PEG will be present. Partial PEGylation of K28 results in additional PEGylation of other 
peptide, for example P3 (not shown in Scheme 28). The electrophoretic profile of peptides 
would be similar to the pep-map of the native counterpart with P2* and P3* signals lower 
than it was observed for the native counterparts. Also one new signal will be present (P3- 
PEG) additional to the P2-PEG. 
Since the PEGylation of Mircera is predominantly present on lysines, there is a possibility 
to cleave directly beyond this amino acid using the Lys-C enzyme. Use of an enzyme with 
other cleavage specificity (for example Glu-C) can lead to incomplete information about 
PEGylation. This fact is amino acid sequence dependent. If no glutamic acid is present 
between two PEGylated lysines, only one peptide can be created by Glu-C and the exact 
localization of PEG attachment will be impossible. 
In the case of erythropoietin, the presence of attached glycans and sialylation should be 
considered. The glycosylation is beneficial for the protein stability, but its presence 
complicates the direct peptide identification after Lys-C digestion. Therefore the PNGase 
enzymatic digestion will also be applied to remove the N-glycans. The asparagine residues 
from which the glycans are removed are simultaneously deaminated, because the PNGase 
converts the asparagine site [229], within the N-glycosylation sequon (N-X-S/T/C, where X is 
any amino acid except proline) of glycan attachment to aspartic acid. In case of one 
deaminated asparagine the mass increment of ∆ M = 0.9840 Da will be observable [229]. 
Therefore other steps are necessary (using PNGase to remove the N-glycans, 
combination of RP-HPLC with collecting of fractions and MALDI or additional cleavage of 
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glycosylated peptide by other enzyme and consecutive peptide mapping) to obtain the 
complete information about Lys-C digested products. 
 
Capillary electrophoresis of erythropoietin 
 
Electrophoretic methods are well suited for quality monitoring of proteins; the 
glycoproteins could be analysed even further by these techniques (IEF, SDS-PAGE, 2-D 
PAGE, CE: CZE MEKC, cIEF) [230]. 
As mentioned above, erythropoietin is a biopolymer with attached carbohydrates via N- 
and O-glycosidic linkages. Micro-heterogeneity of post-translational modifications in proteins 
facilitates the separation of a broad range of glycosylated isoforms with high efficiency using 
a capillary zone electrophoresis or isoelectric focusing [231]. The main features of capillary 
electrophoresis are the low costs, high speed of analysis and small sample amount, but it is 
crucial to solve the problem of glycoprotein adsorption onto capillary walls. Insufficient 
separation efficiency, poor reproducibility of the migration times and peak areas can be dealt 
by coating of capillary wall with various substances. Targeted on EPO, the application of 
such chemicals suppresses the glycoprotein adsorption on the capillary surface and control 
the electroosmotic flow (EOF) [215, 229, 232]. Most of the recent work on CE analysis has 
been carried out using fused silica capillary and dynamic coating like diaminoalkanes (for 
example putrescine) [233], UltraTrol LN [234, 235] or carboxymethyl chitosan [236]. There is 
also possibility to use the amine coated capillary (eCAP) [237], but the costs are much 
higher than self-prepared dynamic coating. 
 
3.3.2 Materials and Methods 
 
Materials 
 
Test samples used in this study were purchased from Roche: NeoRecormon (EPO) and 
its PEGylated form Mircera (pegEPO). 
Acetic acid, 2,5-dihydroxybenzoic acid (DHB), dithiothreitol (DTT), ε-aminocaproic acid 
(EACA), ethylenediaminetetraacetic acid (EDTA), hydroxypropyl methylcellulose (HPMC) 
and 1 M Tris-HCl pH 8.0 were purchased from Sigma. Acetonitrile (ACN), hydrochloric acid 
(HCl), sodium hydroxide (NaOH) and trifluoroacetic acid (TFA) were purchased from Fluka. 
Conditioning solution, SDS-MW gel buffer, SDS sample buffer, molecular weight and internal 
standard (10 kDa) were purchased from AB sciex, RapiGest from Waters, MALDI calibrants 
PepMix1 (1000-2500), PepMix2 (1500-6000) from LaserBio Labs. Enzyme Lys-C was 
obtained from WAKO, PNGase F from NEB. 
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Comassie blue R-250, MES SDS running buffer 20x, LDS Sample buffer, SDS-PAGE, 
gel, Mark 12 ladder 2.5-200 kDa, Novex Bis-Tris gel 4-12 % were obtained from 
ThermoFisher. 
Fused silica capillary was obtained from CM scientific, 10 kDa filters from Millipore, air 
displacement pipettes, thermomixer and centrifuge from Eppendorf. 
Methods 
 
Lys-C digestion of EPO. Prior to Lys-C digestion, EPO sample was incubated after 
addition of 50 mM final concentration DTT at 37 °C for 1 h. Current buffer was changed to 
digestion buffer containing 50 mM Tris-HCl/2mM EDTA, pH 8.0 using 10 kDa filter and 
centrifugation. Lys-C enzyme was added to the peptide at a ratio 1:20 (w/w), the 
protein/enzyme mixture was then diluted to a final concentration of 0.8 mg/mL with the 
digestion buffer and incubated at 37 °C for 4 h. 
 
SDS-PAGE. Gel and 1 gel substitution were mounted on electrophoresis apertures fitted 
and MES running buffer was introduced into the chambers. 
Test samples were mixed with LDS sample buffer and incubated at 70 °C for 10 min. 
Protein size standard and samples were loaded into wells and the apparatus was attached 
to the power supply unit. For the first 10 minutes the voltage of 70 V was applied, that 
allowed the samples to stack, followed by separation using the voltage of 200 V. The 
electrophoresis was continued until the Comassie blue of ladder reached the bottom of the 
gel. The gel was rinsed for three five-minute washes with water and the bands were 
visualised by immersing the gel in a staining solution using gently shacking for one hour. 
The destaining and fixing step was performed for one hour using acetic acid/methanol/water 
solution. 
 
Electrophoretic conditions. CZE was carried out on the PA800 Beckman Coulter (AB 
Sciex) instrument with temperature controlled  autosampler  on  fused  silica  capillary  
(40/50 cm 50 µm) with normal polarity (sample components would migrate toward the 
detector either as cations at pH 2.4. The cathode was at the detector end of the capillary for 
the analyses with lower pH. The capillary was flushed (by HCl, NaOH and milli-Q water) from 
appropriate buffer reservoirs using pressure (50 psi) prior to each run. The dynamic coating 
was applied (conditioning solution, 20 psi) and the capillary was filled with running buffer 
using pressure (50 psi). The sample was injected using pressure (0.5 psi), the constant 
voltage of 30 kV was applied and the operation temperature of 25 °C was kept. 
Electropherograms were UV-monitored at 214 nm and the data were processed with 32 
Karat. 
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Mass spectrometry analyses were carried out in positive mode on Agilent G1600 AX and 
Bruker microTOF-Q instruments using sheath Liquid: IPA/H2O 60:40 + 1 % FAc.29 
CGE-SDS was carried out on fused silica capillary (20/30 cm 50 µm) with reverse 
polarity. The capillary was flushed (by HCl, NaOH and milli-Q water) from appropriate buffer 
reservoirs using pressure (70 psi) prior to each run. The capillary was filled with running 
buffer using pressure (70 psi). The sample was injected using voltage (-5 kV), the constant 
voltage of -15 kV was applied and the operation temperature of 25 °C was kept. 
 
Chromatographic conditions. Reversed phase chromatography was carried out using an 
Waters Acquity UPLC with temperature controlled autosampler and vacuum degasser 
coupled to Thermo ScientificTM Q ExactiveTM hybrid quadrupole-Orbitrap. 
The analytes were injected onto X-Bridge BEH300 C18 (Waters) column and the flow rate 
was maintained at 0.2 mL/min. The column was equilibrated with mobile phase A (0.1 % 
TFA in H2O). Mobile phase A and mobile phase B (0.1 % TFA in ACN) were used to 
establish the 120 min gradient as shown in Table 33. The UV chromatograms were obtained 
by monitoring absorbance at 214 nm and the data were processed with Chromeleon 
software (Dionex). Peptides were then analysed on the Orbitrap equipped with Thermo 
Scientific™ HESI-II probe at an electrospray potential of 3.5 kV, S-lens RF Voltage of 60 V 
and capillary temperature of 275 °C, sheath gas pressure 25 psi, auxiliary gas flow 10 arb 
units. The Orbitrap was set to perform data acquisition in the positive ion mode (m/z full scan 
range 200-2000). The most intense ion was selected for Zoom Scan and then for MS/MS by 
using a data dependent scheme and dynamic exclusion. MS data acquisition was carried out 
on Thermo Scientific™ Xcalibur™ software. Data analysis was performed using Thermo 
Scientific™ PepFinder™. 
 
Table 33: Gradient. 
 
time [min] mobile phase B [%] 
0 0 
5 0 
85 50 
86 90 
96 90 
97 0 
120 0 
 
MALDI-TOF. Model MALDI time-of-flight (TOF) mass spectrometer Autoflex 111 from 
Bruker Daltonics equipped with 200 Hz, Nd:YAG laser was used. Acquisitions were 
 
29 CZE MS results provided K. Jooss, University Aalen. 
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performed in positive ion reflectron mode. For all MALDI TOF analyses a saturated DHB 
matrix was prepared in a mixture of ACN: 1 % aqueous TFA (1:1, v/v). For the sample 
preparation the volume technique was utilized: 2 µl of matrix and 2 µl of sample solution 
were mixed thoroughly in an Eppendorf tube prior to deposition onto the stainless steel plate 
(MTP 384 target plate ground steel). Afterwards, 0.5 µl of the homogeneous solution was 
deposited on the spot of the sample plate (the solution was dropped onto at least two spots) 
and let dry under ambient conditions. Acquisition of mass spectra is done in Flex Control 
(using RP_PepMix method with these parameters: high voltage ion source 1: 20 kV, ion 
source 2: 18.55 kV, lens 9.0 kV, Delay 0-130 ns, pulsed ion extraction: 200 ns, laser 
attenuation 50-70 %, in the mass range of m/z 200 to 2000 and 1500 to 5000 and with 
approximately 1000 laser shots per spectrum). Spectrum processing and annotation was 
carried out in Flex Analysis. 
 
3.3.3 Results and Discussion 
 
3.3.3.1 Analysis of intact EPO and pegEPO 
 
Capillary zone electrophoresis 
 
Acetic acid represents a running buffer, providing a fast separation with the possibility of 
MS detection of even minor isoforms [234]. The isoform resolution is apparently sufficient for 
correct MS identification of the glycans and the possible sample modification as acetylation, 
oxidation and sulfation [234]. It has been demonstrated, that this technique is useful for 
carbohydrate characterization and for demonstration of differences between various 
erythropoietin products or lot-to-lot variability [219]. 
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Figure 31: CZE: Full scale UV-electropherogram (214 nm wavelength) overlay for 
Erythropoietin; EPO and pegEPO (0.8 mg/mL). From bottom trace to top trace: not 
PEGylated form (black), PEGylated form (blue). Experimental conditions: BGE: 3  %  AcA 
pH 2.4, 40/50 cm 50 µm fused silica capillary, dynamic coating with capillary conditioning 
solution, separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
Capillary zone electrophoretic (214 nm) profiles of both erythropoietin forms in formulation 
buffer are demonstrated in Figure 31. Although the employed conditions provided a sufficient 
resolution of different glycoforms (containing various numbers of sialic acids) of EPO and 
allowed a direct MS characterization, the not-well resolved charge isoform pattern was not 
suitable for the evaluation of individual signals. Separation of pegEPO revealed the 
presence of isoforms, even if they were not completely resolved. The improvement of the 
peak resolution was not achieved by the utilization of various pH values and concentrations 
of the acetate running buffer, therefore several BGEs were applied for the analysis of EPO 
and pegEPO. 
As previously described above in chapter 3.2, the CZE can be applied for the separation 
of charge variants using ε-aminocaproic acid as BGE. Utilization of the EACA method for the 
investigation of EPO and pegEPO samples can provide several benefits over the introduced 
methods. Baseline separation of eight isoforms (I1-I8 from the most acidic to the most basic) 
suitable for the direct analysis of erythropoietin can be achieved using the Pharmacopoeia 
CZE method [233]. The significant advantage of the EACA method is the avoidance of using 
special chemicals (the Pharmacopeia method demands sophisticated composition of BGE, 
consisting of putrescine, tricine and urea). Other method known for EPO isoform separation 
is the Bietlot-Girard technique [238] using a relatively high ionic strength of 200 mM 
phosphate applicable also in the presence of human serum albumin as an excipient. Lee 
and Na [211] reported the use of 100 mM phosphate buffer, pH 2.5 (thus similar conditions 
as described by Bietlot) for the investigation of PEGylated protein. 
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There the most appropriate running buffer has been 300 mM EACA, 0.1 % HPMC, pH 
4.7. The pH value of BGE was close to the pI value of erythropoietin that was reported as 
3.7-4.7 [239]). 
 
 
Figure  32:  CZE:  Full  scale  UV-electropherogram  (214  nm  wavelength)  of  EPO   
(0.8 mg/mL). Experimental conditions: BGE: 300 mM  EACA,  0.1  %  HPMC,  pH  4.7,  
40/50 cm 50 µm fused silica capillary, dynamic coating, separation temperature: 25 °C, 
separation voltage: -30 kV, injection 0.5 psi 10 s. 
 
EPO was reproducibly separated into 7 isoforms within 35 minutes as apparent from 
electrophoretic profile in Figure 32. Although the peak resolution of EPO isoforms was 
comparable to the method described by Bietlot-Girard [238] and was very promising for 
further investigations of the PEGylated counterpart, its application for the examination of 
pegEPO was not effective (data not shown). However, also the aforesaid methods could not 
be employed for direct analysis of pegEPO (the analysis took a long time and the signals 
were low or missing). Further the conditions (100 mM phosphate buffer) described by Lee 
and Na [211] were tested. After some experiments with EPO and pegEPO, it has been 
stated, that the phosphate buffer is not well suited for this product because the molecule 
very likely precipitates and therefore no signal could be observed (data not shown). 
As shown in Figure 31, the acetic acid running buffer was not suitable for the sufficient 
resolution of EPO and pegEPO isoforms. Further investigations with the ε-aminocaproic acid 
have shown the potential of this method for the separation of EPO. The conditions that 
allowed a good visualization of present EPO isoforms did not provided the same for 
pegEPO. Although CZE is a very powerful method for the separation of PEGylated products 
[211] and could be effective in separation of PEGylated species from their non-PEGylated 
counterparts, it is not suitable for every protein. It is important to bear in mind that an 
improvement of baseline separation of PEGylated peptides and proteins [206, 240, 241] is 
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not the only problem to solve. Some proteins can precipitate using an inappropriate running 
buffer, or by applying the voltage; or tend to stick to the capillary wall. 
 
Capillary gel electrophoresis 
 
Na et al. [242] have studied a PEGylated interferon alpha by CGE-SDS and have shown, 
that this technique has a great potential in size-based separations of PEGylated proteins. As 
demonstrated below, D. H. Na’s method can also be applied for separations of PEGylated 
glycoproteins from their non-PEGylated forms. 
Using SDS as an anionic detergent leads to the linearization of proteins, as previously 
described in chapter 2.2.1. For glycoproteins the lower than predicted charge-to-mass ratio 
was observed, which leads to overvaluation of molecular masses. Because the intrinsic 
charge of single glycoforms is masked, only the mass differences might contribute to the 
separation. This has the consequence that a successful separation can be obtained only for 
glycoproteins having large differences between shape, number and site of attached glycans. 
[243]. The following experiment demonstrates, that the separation of EPO can be still 
achieved and the explanation for it is seen in the presence of sialic acid anions. 
 
 
Figure 33: CGE-SDS: Full scale UV-electropherogram (214 nm wavelength) overlay for 
Erythropoietin; EPO and pegEPO (0.4 mg/mL). From bottom trace to top trace: not 
PEGylated form (black trace), PEGylated form (blue trace). Experimental conditions: BGE: 
gel buffer (Beckman), 20/30 cm 50 µm fused silica capillary, separation temperature: 25 °C, 
separation voltage: -15 kV, injection 5 kV 20 s. 
 
An example of CGE-SDS analysis of EPO and pegEPO is demonstrated in Figure 33. 
The separation of EPO isoforms (black trace) is clearly visible, but better peak resolution as 
shown above (Figure 32) was not achieved. Also the low signal of EPO was typical for this 
method, but use of higher concentration of sample (>0.4 µg/µL) or higher amount of sample 
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injected into the capillary could solve this problem. It is possible to separate the non-, mono-, 
di-, tri- etc. PEGylated conjugates from each other based on the different molecular weights 
using a gel-sieving matrix. This situation represents the pegEPO sample (blue line), where 
the native (21 min.) and PEGylated forms (27 min.) of size 31 and 61 kDa were completely 
separated. Separation of isoforms, however, could not be achieved anymore. It was obvious, 
that only one PEG molecule was attached to the molecule (another signal was not observed 
having a longer migration time which would be typical for a molecule of higher molecular 
weight). Only a small signal was detected for non-PEGylated erythropoietin at 21 min. The 
question, that remained unanswered, was, if this signal represents the molecule that was not 
PEGylated from the beginning, or if some dePEGylation occurred during the storage over 
time, or if this was an artefact caused by heating during the test sample preparation. 
 
3.3.3.2 Peptide mapping after Lys-C digestion 
As previously described in detail in chapter 3.3.1 (Electrophoretic peptide mapping) the 
digestion of the molecule into smaller peptides followed by electrophoretic separation allows 
the detection of PEG moieties. 
 
The Lys-C cleavage of EPO (pegEPO) yields peptides of different lengths as 
demonstrated in Scheme 29. The physicochemical properties (mass and pI value) of newly 
created peptide fragments after Lys-C digest are listed in Table 34. The masses and pI 
values were calculated for their amino acid sequences only, without additional attachments 
of oligosaccharides and sialic acids. 
 
 
Scheme 29: PEGylated glycosylated erythropoietin with expected Lys-C cleavage sites. 
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Table 34: Calculated [131] monoisotopic masses and pI values for in-silico Lys-C 
digested EPO/pegEPO (without attached oligosaccharides and sialic acids). Blue highlighted 
pI values represent the peptide properties after removing of glycans. 
 
Peak name / Sequence Mass [Da] pI 
P1: A1-K20 NH2-APPRLICDSRVLERYLLEAK 2341.29 8.24 
P2: E21-K45 EAENITTGCAEHCSLNENITVPDTK 2688.20 4.25 
P3: V46-K52 VNFYAWK 927.07 8.56 
P4: R53-K97 RMEVGQQAVEVWQGLA 
LLSEAVLRGQALLVNSSQPWEPLQLHVDK 5021.65 4.96 
P5: A98-K116 AVSGLRSLTTLLRALGAQK 1954.17 12.01 
P6: E117-K140 EAISPPDAASAAPLRTITADTFRK 2498.31 6.22 
P7: L141-K152 LFRVYSNFLRGK 1498.84 11.00 
P8: L153-K154 LK 259.19 8.75 
P9: L155-D165 LYTGEACRTGD 1184.51 4.37 
X – PEGylated site; N, S – glycosylation (+ sialic acids), C – disulphide bridges 
 
Firstly, the digestion procedure was monitored by SDS-PAGE as demonstrated in Figure 
51. The molecular weight size marker was used for the calibration of the gel. Blank in the 
fourth lane represents a digestion mixture without test sample. Lys-C was identified based 
on the knowledge of the molecular size (33 kDa, [244]). As a result of attached glycans the 
band representing EPO migrates with an apparent molecular mass of about 40 kDa (lane 
five and six). Because only the traces of intact EPO were observed after the incubation of 
four hours (lane eight), this digestion period was chosen for further experiments. 
 
HPLC-HESI-MS, MALDI-TOF 
 
In order to precisely affirm the conjunction of PEG moiety to the individual peptides the 
reversed phase high-performance liquid chromatography directly coupled to the mass 
spectrometer (and also UV detector) was utilized. The chromatographic conditions for EPO 
Lys-C peptide mapping reported previously in [245, 246] were optimized with respect to the 
highest peak resolution, (needed for fraction collection). 
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Figure 34: Zoomed UV-chromatogram (20-90 min, 214 nm wavelength) of Lys-C (black 
trace), and Lys-C, PNGase (blue trace) digested EPO (cend= 0.7 µg/µL). Experimental 
conditions: X-Bridge BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, 
flow rate 0.2 mL/min, column temperature 50 °C. 
 
After the RP-HPLC separation and the MS analysis the non-glycosylated signals were 
directly assigned to the peptide fragments (P1, P3, P5, P7, P8, P9 – with retention time of    
9 min, the P8 was not visible in the zoomed chromatogram) as illustrated in Figure 34. The 
observed molecular masses are listed in Table 35. The instability of the baseline was 
induced by an interruption of the blank injection before the EPO, Lys-C sample run and did 
not have any impact on the peak areas of single signals (based on results from earlier 
experiments with LTQ-DECA – data not shown). The glycopeptides of EPO, Lys-C sample 
(black trace) eluted as typically broader peaks (resulting from heterogeneous glycans). To 
identify the N-glycosylated peptides directly by HPLC-MS the PNGase digestion was 
performed after the Lys-C protein hydrolysis (blue trace). It was expected, that 
deglycosylated peptides elute later than their glycosylated counterparts [247], because the 
deglycosylation increases the hydrophobicity of the peptides carrying glycans. This shift was 
observed for P2 (34 min) and P4 peptides (75 min). P2 peptide with two attached glycans at 
N24 and N38 eluted at 40 min after PNGase treatment (blue trace). Because the mass 
increment of about 2 Da was observed the deamination of both asparagines to aspartic 
acids could be authenticated. The similar situation was also seen after deglycosylation of P4 
at 80 min with only one deamidated asparagine. All peptides were collected as single 
fractions for further spiking experiments and their masses were double-checked by MALDI- 
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TOF for eventual presence of some impurities. The PNGase digestion was also applied for 
the glycan hydrolysis from two collected fractions followed by MALDI-TOF analysis30. 
The fraction of the presumed P6 peptide (43 min) with attached O-glycans was 
investigated by MALDI-TOF MS. As demonstrated in chapter 7, Figure 53 the typical O- 
glycan fragmentation pattern -18/+203/+162 could be obtained; despite of low signals. 
Resemann [251] demonstrated the MALDI MS spectra using the Anchorchip plate with 
hydrophilic anchors, but the cleavage between galactose, N-acetylgalactosamine and the 
peptide with an additional loss of water was also detected in our experiment. The non- 
glycosylated form of Peptide 6 is also present as a low signal at 47 min. The presence of 
further low signals is induced by nonspecific cleaved peptides in negligible or very small 
amounts. 
 
Table 35: Matching theoretical m/z values [131] with observed masses and corresponding 
sequences in Lys-C (PNGase) digested EPO/pegEPO (HPLC-HESI-MS).31 
 
Peak 
name tR [min] Calculated m/z Measured m/z Sequence 
P5 f1 17.45 587.341+ / 294.182+ 587.361+ / 294.182+ ALGAQK 
P5 f2 18.53 743.441+ / 372.222+ 743.451+ / 372.232+ RALGAQK 
P5 f3 22.50 602.351+ / 301.682+ 602.361+ / 301.692+ AVSGLR 
P2 f1*§ 24.47 538.252+ 538.312+ EDITTGCAEH 
P9 25.00 1185.51+ 1185.521+ LYTGEACRTGD 
P7 f2 27.67 821.461+ 821.461+ SNFLRGK 
P2 
trunc*§ 33.00 1281.57
2+ 1281.602+ AEDITTGCAEHCSLN EDITVPDTK 
P2f2 33.50 537.722+ 537.772+ ENITTGCAEH 
P1 f3 31.97 736.421+ 736.421+ YLLEAK 
P1 f4 32.32 892.521+ / 446.762+ 892.52 / 446.772+ RYLLEAK 
P1 f5 32.71 564.302+ 564.302+ APPRLICDSR 
P1 f6 39.0 617.362+ 617.362+ VLERYLLEAK 
P2* 39.45 897.733+ 897.523+ EAENITTGCAEHCSL NENITVPDTK 
P1 f7 39.95 812.962+ 812.952+ APPRLICDSRVLER 
P5 f4 34.15 903.521+ / 452.262+ 903.531+ / 452.272+ AVSGLRSLT 
 
 
30 Singly and doubly charged ions of deglycosylated P4 are demonstrated in Figure 52. This RP- 
HPLC fraction was treated by PNGase to remove the glycans and analysed in presence of 2,5- 
dihydroxybenzoic acid (DHB). This commonly used water soluble MALDI matrix [248] is suitable for 
protein digests, small proteins and glycopeptides below 10 kDa building large heterogeneous white 
crystal needles [249] in presence of acetonitrile (ACN) and trifluoroacetic acid (TFA). TFA added to 
the matrix solution in a concentration of 0.1 % assists the protonation of peptide/protein and serves 
for better ionization of studied molecule [250]. 
31 OrbiTrap typical accuracy +/- 2 ppm. 
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Peak 
name tR [min] Calculated m/z Measured m/z Sequence 
P5 f5 34.85 802.471+ 802.481+ AVSGLRSL 
P5 f6 37.30 535.832+ 535.842+ TLLRALGAQK 
P3 40.35 927.072+ 927.472+ VNFYAWK 
P6 46.93 1250.162+ / 833.73+ 1250.662+ / 834.113+ EAISPPDAASAAPLRT ITADTFRK 
P7 45.81 1499.841+ / 750.422+ 1500.851+ / 750.432+ LFRVYSNFLRGK 
P7 f5 38.18 697.401+ / 349.202+ 697.401+ / 349.212+ LFRVY 
P7 f6 41.17 693.882+ 693.892+ FRVYSNFLRGK 
P7 f7 47.96 657.862+ 657.872+ LFRVYSNFLR 
P5f7 50.00 686.412+ / 457.943+ 686.422+ / 457.953+ SLTTLLRALGAQK 
P1 53.36 1171.652+ / 781.773+ 1172.162+ / 781.773+ APPRLICDSRVLERYL LEAK 
P5 59.67 978.091+ 978.091+ AVSGLRSLTTLLRAL GAQK 
P5 f8 62.96 785.982+ / 524.323+ 785.992+ / 524.323+ AVSGLRSLTTLLRAL 
 
P4* 
 
75.58 
 
1256.914+ / 1005.535+ 
 
1257.044+ / 1005.715+ 
RMEVGQQAVEVWQ 
GLA 
LLSEAVLRGQALLVN 
SSQPWEPLQLHVDK 
1+ z = 1, 2+ z = 2 etc.; * PNGase, §pegEPO. 
 
Further experiments were performed with PEGylated substance, after the peptide 
identification of the non-PEGylated sample has been carried out. The presence of PEG 
moieties is highly expected in P1, P2 and P3 peptides as specified by the manufacturer and 
illustrated in Scheme 29. 
 
 
Figure 35: Full scale UV-chromatogram (214 nm wavelength) of Lys-C digested EPO 
(black trace) and pegEPO (blue trace) (cend= 0.7 µg/µL). Experimental conditions: X-Bridge 
BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 
mL/min, column temperature 50 °C. 
127  
As illustrated in Figure 35 (blue trace), besides the presence of main signals, nonspecific 
cleaved peptide fragments were detected. The first impression may lead to the assumption 
that P1, P5 and P7 can be PEGylated, because the P1, P5 and P7 pegEPO, Lys-C signals 
are significantly reduced in comparison with EPO, Lys-C sample. The Peptide 5 (blue trace, 
60 min) was even completely degraded and no remaining signal was present. Closer 
examination of the amino acid sequences around the nonspecific cleavage sites revealed 
that the Lys-C digestion yielded many peptides cleaved at the arginine residues (1/3 of all 
identified signals) using the above introduced digestion conditions. Gershon and Raijimakers 
[252, 253] have studied the Lys-C and Lys-N hydrolyses of different substrates, but only the 
Lys-N enzyme exhibited some arginine specificity. Jekel et al. [254] demonstrated in their 
study the Lys-C cleavage of two different arginine bonds on ribonuclease. Protein 
PEGylation may explain the presence of larger quantity of the nonspecific cleaved fragments 
in the pegEPO sample. The attached PEG molecule acts as a barrier and the enzyme is not 
capable of reaching its typical cleavage site, therefore some other amino acid will be 
attacked for so long until the nonspecific hydrolysis will not be completed. 
The presence of numerous non-specific fragments besides the expected P1-P9 signals 
makes the calculation of the PEG molecule occupancy (PEGocc, Table 36) more difficult. 
Therefore the results predicate more of the PEGylation trend than of the exact PEGocc. 
Despite of this fact, we tried to calculate the PEGocc for every peptide. For the determination 
of the PEG molecule occupancy (PEGocc), a stable signal (without attached PEG moiety) 
has to be chosen as a reference. The lowest probability of PEG attachment was presumed 
for the P9 because no lysine is present in the amino acid sequence of this peptide. 
Practically no nonspecific cleaved P9 fragments were observed in this RP-HPLC analysis. 
Each peptide was individually compared to the P9 (P1/P9, P2/P9 and so forth) resulting in 
the area percentages of P1-P7 (P8 was excluded for its low signal) as listed in Table 36. 
Areas of nonspecific cleaved fragments were summed with corresponding main signals. The 
pair area percentages (EPO P1 A% - pegEPO P1 A%, EPO P2 A% - pegEPO P2 A% etc.) 
of both samples were used for the evaluation of PEGocc of pegEPO (Table 36). Peptide 6 
was excluded from the evaluation, because the pegEPO A % of P6 was higher than the 
value of the non-PEGylated form. Some nonspecific cleaved fragments co-eluted with P6 
and caused increase of the peak area. For the calculation of P5 A% the signals of 
nonspecific cleaved P5 fragments were summed with the specific digested P5 signal. The 
same principle was applied for the calculation of P7 A%. Results in Table 36 point at high 
PEGocc of peptides P1 and P5. From the results can also be derived that only a minute 
amount of PEG is attached to the other peptides leading to a total PEGocc of 86 %. The 
missing 14 % may be comprised of P6, because the PEGylation of P6 could not be 
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evaluated. As described by the manufacturer [224], the PEGylation of P1 (N-terminal amino 
group) and also of P2 (K45) and P3 (K52) can be expected. The high value of PEGocc of P5 
is slightly surprising, but as mentioned in chapter 3.3.1, it is difficult to control the attachment 
process of the PEG moiety to the molecule [206, 207]. 
 
Table 36: Area percentage of single peptides of Lys-C digested EPO and pegEPO 
(Figure 35) and PEGocc over single peptides (P9 as reference signal) analysed by RP- 
HPLC. 
 
HPLC EPO pegEPO PEGocc/P932 
Peptide A % [Px/P9] A % [Px/P9]  
P1 66.1 36.6 0.45 
P2 72.0 68.7 0.05 
P3 74.1 71.9 0.03 
P4 86.7 83.4 0.04 
P5 58.3 41.0 0.30 
P6 70.7 74.8 - 
P7 50.2 50.4 0.00 
total   0.86 
 
Furthermore the PEGocc can be calculated from the deglycosylated samples. The 
removal of N-linked oligosaccharides from glycoproteins leads to the creation of narrow 
peaks (P2 and P4) and allows the detection of possible non-specific cleaved peptides. 
These signals would co-elute with broader glycopeptides and could not be later used for 
calculation of PEGocc. Therefore the EPO and pegEPO were deglycosylated using  
PNGase F after Lys-C digestion. The resulting peptides were investigated by RP- 
chromatography. The peak areas of EPO and pegEPO peptides were used for the 
calculation of PEGocc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 PEGocc calculation: 100 − ! % !"#$%& ∙ 100 !% !"# 
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Figure 36: Full scale UV-chromatogram (214 nm wavelength) of Lys-C, PNGase digested 
EPO and pegEPO (cend= 0.7 µg/µL). Experimental conditions: X-Bridge BEH300 C18, 
3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 mL/min, column 
temperature 50 °C. 
 
Many similarities were observed after comparing the data of deglycosylated Lys-C 
digested EPO (black trace) and pegEPO samples (blue trace) in Figure 36. The greater 
quantity of nonspecific cleaved fragments was obvious also in the deglycosylated Lys-C 
digested pegEPO sample. The PNGase treatment of Lys-C digested pegEPO led to a 
formation of N-terminal truncated peptide P2 (P2 trunc, 38 min) and further P2 variants  
(24.5 min, 39.5 min). The N-terminal P2 truncation could be explained by the attached PEG 
moiety to this peptide. It can be calculated if the area of the P2 peptide has been effectively 
reduced. The area of the truncated peptide was converted to the area, which this signal 
would have as a non-truncated. Because the detection wavelength of 214 nm was used, the 
area of non-truncated peptide can be calculated from the known truncated peptide using the 
number of peptide bonds as shown in the following equation: 
 
𝐴𝐴!"!!!"#$%   =  !!"#$%    ∙ 𝑃𝑃𝐵𝐵!"!!!"#$% (3.1) !"#$%  
where A is the area of peptide and PB is the amount of peptide bonds in peptide. 
The recalculated area of the P2 trunc (non-truncated) was summed with the area of the 
P2 (and present fragments) giving the total P2 area needed for the comparison with P9. The 
evaluation of the single peptides compared to the P9 is listed in Table 37. The pegEPO A % 
of P6 was higher than the value of non-PEGylated form and was excluded from the 
evaluation (observed also for EPO P6, Table 36). For the calculation of A % of P5 (P7) the 
corresponding nonspecific cleaved fragments were summed with the specific digested P5 
(P7). The results in Table 37 demonstrate a high amount of attached PEG molecule to P1 
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and P5 peptides, also observed for the Lys-C digested molecule (Table 36), but some 
differences between the results were noticed. Peptide P1 (Lys-C) seems to be PEGylated 
from 45 % whilst P1 (Lys-C, PNGase) only from 41 %. In case of P5 the difference became 
even more distinct (30 % of attached PEG to Lys-C P5 and 38 % of attached PEG to Lys-C, 
PNGase P5). An increase of PEGocc of 8 % was also observed for deglycosylated P4. 
Please note, the co-elution of some signals has been observed (mainly nonspecific cleavage 
fragments) influencing the measure of A% P1-P9 by up to several A %. The total PEGocc of 
104 % (Table 37) differs from the observation in Table 36 (86 %), where only Lys-C digested 
samples were evaluated. 
 
Table 37: Area percentage of single peptides of Lys-C, PNGase digested EPO and 
pegEPO (Figure 36) and PEGocc over single peptides (P9 as reference signal) analysed by 
RP-HPLC. 
 
HPLC EPO pegEPO PEGocc/P933 
Peptide A % [Px/P9] A % [Px/P9]  
P1 65.8 38.7 0.41 
P2 66.3 64.1 0.03 
P3 73.8 71.0 0.04 
P4 83.6 73.6 0.12 
P5 56.2 35.0 0.38 
P6 70.7 74.6 - 
P7 43.5 43.3 0.00 
total   1.04 
 
CZE-UV, CZE-ESI-MS 
 
The presence of PEG moieties was further investigated by capillary zone electrophoresis. 
The individual peptides, created by Lys-C digestion were separated using various buffer 
systems until the best peak resolution was achieved. As illustrated in Scheme 28, the great 
advantage of CZE over RP-HPLC is the possibility of the visualization of attached PEGs. In 
addition to the presence of the native peptides also their PEGylated variants can be 
expected in the electropherogram. The distinguishing characteristics that make the 
PEGylated variants clearly recognizable from non-PEGylated ones are broader peaks and 
higher migration times. Later also the PNGase digested samples will be introduced. 
As indicated in Table 34 some peptides have similar pI values. Additionally, three 
glycopeptides (P2, P4 and P6) are sialylated and have therefore lower pI values than stated 
in table. Using acetate at pH 2.5 as running buffer the sialylated glycopeptides will be 
 
 
33 PEGocc calculation: 100 − ! % !"#$%& ∙ 100 !% !"# 
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separated with higher migration times than P1, P3, P5, P7 or P9 peptides. As specified by 
the manufacturer, the presence of PEG moieties is highly expected in P1, P2 and P3 
peptides (as illustrated in Scheme 29). Performing the Lys-C cleavage of EPO and pegEPO 
samples, then in the case of the presence of PEG moieties attached to P1 and P2, these 
peaks are also expected in pegEPO, Lys-C sample. Peptides P1, P2 will appear with lower 
intensity than P1 and P2 of EPO, Lys-C sample and in addition to these signals also pegP1 
and pegP2 should be observed with in the electropherogram (with typically broader shape 
and higher migration time than non-PEGylated peptides). It is important to take into account 
that the presence of PEG moieties could restraint the access of the enzyme to the cleavage 
site. This can result in the creation of the non-specific cleaved peptide pegP1-pegP2 as 
previously shown in Scheme 28 and discussed below the scheme. The presence of sialic 
acids attached to the P2 peptide may also have an effect on the quantity of P2 signals (non- 
PEGylated and PEGylated). 
 
 
Figure 37: Full scale UV-electropherogram (214 nm wavelength) of Lys-C digested EPO 
and pegEPO (cend = 0.7 µg/µL). Experimental conditions: BGE: 3 % AcA pH 2.4, 40/50 cm 
50 µm fused silica capillary, dynamic coating with capillary conditioning solution, separation 
temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
The capillary zone electropherograms of the Lys-C digested EPO and pegEPO are 
shown in Figure 37. The separation profiles of both analytes are similar except for the 
presence of PEGylated signals of pegEPO. The pI values based pre-assignment of the 
signals to the single peptides was not possible. The first identification of peptides was 
performed by spiking of single high concentrated RP-HPLC fractions leading to the signal 
increase of respective peaks. The peptides P1, P3, P5, P7 and P9 were identified as single 
signals. P4 is present at 10.5 and 14.0 min representing a glycopeptide differing by the 
number of sialic acids. The variability of each signal (oligosaccharide pattern) is given by the 
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antennary complexity. Similar situation as for P4 was observed for P6 peptide (where two P6 
peaks were separated at 5.8 and 7.8 min). The identity of P4 and P6 peptides was also 
verified by the spiking experiment. 
Spiking of the Peptide 2 fraction did not induce an increase of any peak signal height. 
Using negative polarity or acidic phosphate buffer were not beneficial, the signal was not 
present. The peak assignment was later verified using the more elegant tool: CZE-ESI-MS34 
and the results are summarised in Table 38. Also the MS data evaluation did not confirm any 
presence of P2 peptide in the electropherogram. The CZE peptide mapping of the Lys-C 
digested pegEPO (blue trace) showed many similarities to the HPLC analysis (Figure 35, 
blue trace). The presence of a few nonspecific cleaved fragments (primary P5 and P7) was 
detected, although any of them could not be separated clearly from other signals. However, 
the CZE run compared to the RP-HPLC offers an excellent visualization of PEGylated 
signals and therefore might be considered as preferred tool for the comparison of reference 
with its PEGylated conjugate. There are at least four signals present symbolizing the 
PEGylated peptides labelled as pegPa - pegPd between 25-55 min. Comparing the non- 
PEGylated signal intensities of EPO and pegEPO Lys-C digested samples, the signal 
reduction is obvious for P1 and P5 in pegEPO, Lys-C sample. These two peptides can be 
represented e.g. by pegPa and pegPb signals at 17 and 19 min. As introduced above, it is 
highly expectable that PEG moiety is attached to the P2 peptide. The sialylation of P2 could 
lead to the observation of two P2 signals (as it can be seen for P4 and P6 peptides) after 
electrophoretic separation. Therefore it can be presumed that the remaining PEGylated 
peaks pegPc and pegPd represent the variously sialylated forms of PEG-P2 peptide. 
 
Table 38: Matching theoretical m/z values [131] with observed masses and corresponding 
sequences in Lys-C (PNGase) digested EPO/pegEPO (CZE-ESI-MS).35 
 
Peak 
name tm [min] Calculated m/z Measured m/z Sequence 
P7 3.0 750.422+ 750.382+ / 500.593+ LFRVYSNFLRGK 
P1 3.2 781.773+ / 586.574+ 781.733+ / 586.554+ APPRLICDSRVLER YLLEAK 
P5 3.5 489.552+ 489.672+ AVSGLRSLTTLLRA LGAQK 
P7 f7 3-5 657.862+ / 438.573+ 657.832+ / 438.893+ LFRVYSNFLR 
P1 f6 3-5 617.362+ 617.322+ VLERYLLEAK 
P5 f1 3-5 587.341+ 587.321+ ALGAQK 
P5 f3 3-5 602.351+ 602.321+ AVSGLR 
P5 f7 3-5 686.412+ 686.382+ SLTTLLRALGAQK 
 
 
34 CZE MS results provided K. Jooss, University Aalen. 
35 Micro-TOF typical accuracy +/- 100 ppm. 
133  
Peak 
name tm [min] Calculated m/z Measured m/z Sequence 
P7 f6 3-5 693.882+ 693.882+ FRVYSNFLRGK 
P7 f5 3-5 349.202+ 349.192+ LFRVY 
P1 f3 3-5 736.421+ 736.371+ YLLEAK 
P2 f1*§ 6.0 538.252+ 538.312+ EDITTGCAEH 
P3 4.2 464.042+ 464.212+ VNFYAWK 
P9 5.7 593.252+ 593.232+ LYTGEACRTGD 
P6 5.8, 7.8 833.772+ / 626.083+ 834.062+ / 625.803+ EAISPPDAASAAPL RTITADTFRK 
 
 
P4* 
 
 
6.0 
 
1257.414+ / 
1006.135+ 
 
1257.434+ / 
1005.955+ 
RMEVGQQAVEVW 
QGLA 
LLSEAVLRGQALLV 
NSSQPWEPLQLHV 
DK 
P2* 7.5 897.733+ 897.403+ EAEDITTGCAEHCS LNEDITVPDTK 
1+ z = 1, 2+ z = 2 etc.; * PNGase; § pegEPO. 
 
As previously seen in the HPLC section, for the calculation of the PEGocc the area 
percentages of single peptides were matched. Corrected areas of EPO (pegEPO) peptides 
were compared with corrected area of P9 resulting in e.g. Acorr % of P1 EPO and Acorr % of 
P1 pegEPO as listed in Table 39. Then the PEGocc in pegEPO could be calculated. Peptide 
2 was not detected in electropherogram (Figure 37) and therefore its evaluation was not 
possible. As previously seen in Table 36 the Acorr % of pegEPO Peptide 6 was higher than   
A % of EPO P6. If there is no attached PEG moiety present on P6 lysine then the peak 
areas have to be comparable. A decrease in peak area of pegEPO would point at PEG 
linked to this peptide whereas an increase of pegEPO signal is not expected and could be 
explained by different sialylation of P6 of both samples. These two erythropoietin samples 
were produced as two different batches and slight lot-to-lot variability could be observed 
between these products. The second explanation for this observation might be a presence of 
a co-migrating signal with pegEPO P6 peptide increasing the corrected area of this signal. 
The results in Table 39 indicate the PEGylation of predominantly P1 and P5 peptides. It was 
not possible to sum all the P1 and P5 peptide fragments with their main signals, because 
some of them co-migrated with other nonspecific cleaved fragments. This fact led to 
differences in PEGocc of P1 and P5 between HPLC and CZE results. Minute amount of 
attached PEG molecule was detected for P3 and P4 peptide, P7 seems to be non- 
PEGylated. 
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Table 39: Area percentage of single peptides of Lys-C digested EPO and pegEPO and 
PEGocc (Figure 37) over single peptides (P9 as reference signal) analysed by CZE. 
 
CZE EPO pegEPO PEGocc/P936 
Peptide 
P1 
Acorr % [Px/P9] Acorr % [Px/P9]  
0.31 49.2 33.9 
P2 - - - 
P3 63.6 60.6 0.05 
P4 92.2 90.3 0.02 
P5 29.3 15.8 0.46 
P6 72.3 74.0 - 
P7 34.1 34.2 0.00 
total   0.86 
Results are reported as the means of triplicate determinations. 
 
Applying the PNGase enzyme to the Lys-C digested EPO a migration time shift of the N- 
deglycosylated peptides is expected. This effect can be observed due to loss of a negative 
charge caused by the removal of sialic acids attached to glycans. Using acetic acid at pH 2.5 
as BGE and positive polarity, these deglycosylated peptides are separated with lower 
migration times than their glycosylated/sialylated counterparts (please note, P2 peptide was 
not found in Lys-C digested sample). 
 
 
Figure 38: Zoomed UV-electropherogram (214 nm wavelength) of Lys-C and Lys-C, 
PNGase digested EPO (cend= 0.7 µg/µL). Experimental conditions: BGE: 3 % AcA pH 2.4, 
40/50 cm 50 µm fused silica capillary, dynamic coating with capillary conditioning solution, 
separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
 
 
 
36 PEGocc calculation: 100 − ! % !"#$%& ∙ 100 !% !"# 
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The peptide mapping of the deglycosylated EPO Lys-C digested sample is demonstrated 
by the blue trace in Figure 38. This sample treatment led to visible changes in the migration 
pattern of peptide P4. This pair of signals is visible between 13 and 22 min (black trace) 
migrates after deglycosylation as a single signal (6 min, blue trace). Besides the P4 peptide 
migration time shift, there is also another new signal noticeable between P9 and P6 after 
PNGase digestion. After CZE-MS analysis this peak was identified as P2. As previously 
shown in Table 34 the peptides P2 and P9 are part of the group of acidic peptides having pI 
values of 4.25 and 4.37 respectively. Using the above described separation conditions; both 
of them migrate as weak cations (behind the peptides with high pI values which are carrying 
strong positive charges). 
The deglycosylated pegEPO Lys-C sample was subject to further electrophoretic 
investigation. Although nowadays it is possible to characterize the PEGylated proteins 
directly using the newest generation of Orbitrap instruments [255] such state-of-the-art 
instrument for online CZE-MS identification of PEGylated signals was not available. As 
previously demonstrated above (Figure 38), the deglyco peptide variants of EPO are 
separated with lower migration times than their glycosylated counterparts. The same 
principle can be expected for the glycopeptides with attached PEG moieties (pegPa - pegPd). 
Such migration time shift would represent very likely one of the two-glycosylated peptides: 
P2 or P4 (PNGase does not hydrolyse the O-linked glycans of P6). 
 
 
Figure 39: Full scale UV-electropherogram (214 nm wavelength) of Lys-C and Lys-C, 
PNGase digested EPO (cend= 0.7 µg/µL). Experimental conditions: BGE: 3 % AcA pH 2.4, 
40/50 cm 50 µm fused silica capillary, dynamic coating with capillary conditioning solution, 
separation temperature: 25 °C, separation voltage: 30 kV, injection 0.5 psi 20 s. 
 
The comparison of electropherograms obtained after the analysis of Lys-C digested 
pegEPO samples is shown in Figure 39. Besides the Lys-C cleavage (black trace), PNGase 
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was used to remove the N-linked glycans from pegEPO sample (blue trace) and interesting 
results were observed. The migration pattern of the present signals changed significantly 
after deglycosylation. In addition to the migration time shift of the deglycosylated P4 peptide 
also P2 was present (as previously observed for EPO, Figure 38). Further some visible 
changes occurred between 25 and 55 minutes. As apparent from the electropherogram 
overlay, four broad peaks illustrating the presence of attached PEG moieties (pegPa-pegPd) 
were reduced to three signals after PNGase treatment. From the mobility shift of pegPd it 
can be presumed that this signal represents some N-glycosylated, sialylated peptide (P2 or 
P4). 
Furthermore the PEGocc can be calculated from the deglycosylated EPO and pegEPO 
samples as it has been already introduced for chromatography. 
 
Figure 40: Zoomed UV-electropherogram (214 nm wavelength) of Lys-C, PNGase 
digested EPO (black trace) and pegEPO (blue trace) (cend= 0.7 µg/µL). Experimental 
conditions: BGE: 3 % AcA pH 2.4, 40/50 cm 50 µm fused silica capillary, dynamic coating 
with capillary conditioning solution,  separation  temperature:  25  °C,  separation  voltage: 
30 kV, injection 0.5 psi 20 s. 
 
The electrophoretic examination of EPO and pegEPO Lys-C digested deglycosylated 
samples has been already introduced in Figure 38 and Figure 39. The Figure 40 represents 
zoomed overlay of these two electropherograms. As previously seen in Lys-C digested 
samples (Table 39), also here some P5 and P7 peptide fragments were detected. The 
CZE/MS peptide mapping evidenced a few co-migrations of these peptide fragments, which 
impended the precise calculation of PEGocc37. As previously seen in HPLC experiment with 
 
 
37 To avoid the presence of unspecific cleaved fragments the digestion conditions were modified 
by the group of Maria Schwarz (2015) and further CZE experiments were performed. It can be stated 
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PNGase treated EPO and pegEPO Lys-C digested samples (Figure 36.), the greater 
quantity of nonspecific cleaved fragments was present in pegEPO sample after 
electrophoretic separation. 
The calculated PEGocc values for deglycosylated samples are demonstrated in Table 40. 
The results point at high PEGocc of P1 and P5 peptides and minute amount of attached 
PEG moieties to the P3 and P4 peptides. From very low P6 and P7 PEGocc value, it can be 
presumed that these peptides are completely non-PEGylated. 
 
Table 40: Area percentage of single peptides of Lys-C, PNGase digested EPO and 
pegEPO and PEGocc (Figure 40) over single peptides (P9 as reference signal) analysed by 
CZE. 
 
CZE EPO pegEPO PEGocc/P938 
Peptide 
P1 
Acorr % [P9] Acorr % [P9]  
0.38 49.6 30.9 
P2 61.8 55.9 0.10 
P3 63.5 60.1 0.05 
P4 79.6 73.0 0.08 
P5 25.6 14.1 0.45 
P6 74.5 75.2 0.01 
P7 31.6 31.8 0.01 
total   1.07 
Results are reported as the means of duplicate determinations. 
 
3.3.4 Conclusion 
 
An effective CZE method was introduced for the investigation of charge variants of native 
erythropoietin (EPO). Using EACA as BGE yields well resolved peaks and allows separation 
of 7 EPO isoforms. The advantage of the demonstrated CZE method consists of the 
possibility of isoform analysis without the need to coat the capillary or to use the pre-coated 
capillary as stated in other methods that are commonly used for routine quality control of 
 
 
 
 
that the results from these measurements also pointed at high PEGocc of P1 and P5. But each 
digestion procedure leads to small differences between PEGocc of individual peptides. The 
inconsistency of the cleavage process is very likely caused by the linkage of PEG moieties to the 
EPO molecule. The PEGs impeded the access of the enzyme to its cutting positions leading to the 
inconsistent amounts of the generated peptides. 
 
 
38 PEGocc calculation: 100 − ! % !"#$%& ∙ 100 !% !"# 
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erythropoietin. However the introduced method was suitable for the visualization of charge 
variants of native EPO, the method was not applicable for pegEPO. 
Capillary gel electrophoresis was introduced for the study of EPO and pegEPO. 
Separation of the native molecule led to unexpected well-resolved glycosylated variants. 
Using this analytical method, a good peak resolution is anticipated only for glycoproteins 
having large differences between shape, number and site of attached glycans. Therefore the 
explanation for this observation is seen in the presence of sialic acid anions. Further, the 
capillary gel electrophoresis was used for the study of the PEGylation degree of pegEPO. 
Applying this method, minute amount of non-PEGylated and mono-PEGylated conjugates 
could be detected in pegEPO. 
Capillary zone electrophoresis and reversed-phase chromatography were introduced for 
the investigation of the occurrence of PEG. Peptide mapping of the EPO reference sample 
and its PEG-conjugate were used for the investigation of the precise PEG site localization 
and the PEG occupancy (PEGocc). Both analytical techniques determined two main 
PEGylation sites (at peptide 1 and peptide 5) by comparing the A % of EPO and pegEPO 
peptides. The differences between the PEGocc values estimated by HPLC and CZE were 
explained by presence of high amount of unspecific cleaved fragments that co-eluted/co- 
migrated with other signals. The usability of this method requires an optimization of the 
digestion procedure (especially of the PEGylated molecule) to obtain the lowest possible 
amount of unspecific cleaved fragments. This would contribute to the simplification of the 
evaluation process. We have demonstrated that the CZE method is suitable for the 
visualization of PEGylated variants. 
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4 Conclusion 
 
This thesis comprises three studies evaluating CZE-UV and HPLC-MS based methods 
for the characterization of post-translational modifications in therapeutic proteins. 
The first study focused on the deamidation of proteins. Within this study we demonstrated 
the impact of various degradation conditions on the extent of deamidation in peptides and 
proteins. A buffer composed of 50 mM ammonium bicarbonate, pH 8.0, was chosen as the 
most appropriate buffer for studying deamidation. Excellent resolution of the main 
deamidated species could be achieved by using capillary zone electrophoresis of peptides. 
Targeted cleavage on the N-terminal side of aspartate by the enzyme Asp-N was introduced 
for cutting of newly formed aspartates followed by CZE/RP-HPLC separation. Comparison of 
the non-stressed with the stressed electrophoretic/chromatographic profiles allowed the 
visual detection of deamidation in peptides. The application of the Asp-N digestion to 
polypeptides and proteins was found being more difficult compared to peptides, because the 
presence of deamidated variants was not clearly recognisable in UV 
electropherograms/chromatograms. An acceleration of the asparagine deamidation rate was 
observed by applying L-asparaginase enzyme to the peptide. This procedure could not be 
successfully transferred to the proteins under the used conditions. 
In the second study, a CZE-UV method was used for the study of charge variants present 
in IgG type immunoglobulins. The visualization of protein isoforms was facilitated in bare 
fused silica capillary using ε-aminocaproic acid (EACA) as BGE additive and detecting at a 
wavelength of 214 nm. Utilizing the CZE method, the isoform distribution of Avastin and 
Erbitux samples was comparable to the results obtained by capillary isoelectrofocusing. The 
CZE method was also employed for the examination of charge variants in unstressed and 
stressed papain digested Avastin. Although the efficient resolution of Avastin charge variants 
was performed using CZE, the signals of papain digested Erbitux co-migrated and the 
electrophoretic profile was not comparable to cIEF. A wider application range of EACA 
separation method is demonstrated on enzymatic (pepsin, lysine) hydrolysis of Erbitux and 
papain-PNGase digestion of Avastin. 
Finally, in the third study, CZE-UV was introduced as a versatile analytical tool for the 
analysis of PEGylated proteins. Its power is demonstrated on the study of PEGylated 
glycosylated erythropoietin. CGE-SDS was applied for the investigation of the PEGylation 
degree, using EACA running buffer in bare fused silica capillary for isoform visualization) and 
also for the visualization of PEGylated variants (CZE using acetate). Using this method, the 
localization of PEGylation sites could be attained and the calculation of PEG occupancy was 
enabled. Because of the presence of many unspecific cleaved fragments,(especially in the 
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PEGylated molecule, the precise calculation of PEGocc was not possible and an 
optimization of the digestion procedure is required. 
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5 Abbreviations 
 
Table 41: Table of standard amino acids and abbreviations. 
 
Amino acid 1-Letter 3-Letter 
Alanine A Ala 
Arginine R Arg 
Asparagine N Asn 
Aspartic acid D Asp 
Cysteine C Cys 
Glutamic acid E Glu 
Glutamine Q Gln 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Leucine L Leu 
Lysine K Lys 
Methionine M Met 
Phenylalanine F Phe 
Proline P Pro 
Serine S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine Y Tyr 
Valine V Val 
 
 
d – day 
 
Da – Dalton 
h – hour 
CHAPS – 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate 
min – minute 
mM – millimolar 
 
pI – isoelectric point 
 
pKa – acid dissociation constant 
s – second 
tm – migration time 
tR – retention time 
V - volt 
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7 Appendix 
 
 
 
Figure 41: RP-HPLC MS: Analog chromatogram (214 nm wavelength, top trace), ion 
chromatogram (middle trace) and corresponding mass signals (bottom trace) overlay for 
Peptide 1. Unstressed (left), 24 h 40 °C (right). Experimental conditions: X-Bridge BEH300 
C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 mL/min, column 
temperature 50 °C. 
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Figure 42: RP-HPLC MS: Analog chromatogram (214 nm wavelength, top trace), ion 
chromatogram (middle trace) and corresponding masses (bottom trace) overlay for Peptide 
1. Unstressed  (left), 24  h  40  °C  (right). Experimental conditions: X-Bridge  BEH300  C18, 
3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 mL/min, column 
temperature 50 °C. 
 
 
 
 
Figure 43: RP-HPLC MS: Ion chromatogram (top trace) with MS/MS spectra of stressed 
(7 d 40 °C) Glu1-Fibrinopeptide. Experimental conditions: X-Bridge BEH300 C18, 3.5 µm, 
2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, flow rate 0.2 mL/min, column temperature 
50 °C. 
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Figure 44: RP-HPLC: Zoomed (18.0-53.7 min) UV-chromatogram (214 nm wavelength) 
overlay for Hirudin. From bottom to top: unstressed, Asp-N (black), 12 d 40 °C, Asp-N (blue). 
Experimental conditions: X-Bridge BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN 
with 0.1 % TFA, flow rate 0.2 mL/min, column temperature 50 °C. 
 
 
 
 
Figure  45:  CZE:  UV-electropherogram  (214  nm  wavelength)  overlay  for  Hirudin   
(1.5 mg/mL). From bottom trace to top trace: 12 d 40 °C, Lys-C (black), 12 d 40 °C spiked to 
12 d 40 °C, Lys-C (blue). Experimental conditions: BGE: 3 % AcA, 40/50 cm 50 µm fused 
silica capillary, dynamic coating with capillary conditioning solution, separation temperature: 
25 °C, separation voltage: 30 kV, injection 0.5 psi 10 s. 
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Figure 46: CZE, Peptide 1 in 50 mM Tris-HCl pH 8.6 (2 mg/mL), incubated at 50 °C for 2, 
4, 6 and 24 h (no L-Asp); SB: 3 % AcA pH 2.5. 
 
 
 
 
 
 
 
Figure 47: CZE, Lysozyme in 50 mM Tris-HCl pH 8.6 (2 mg/mL), unstressed (black 
trace), incubated without L-Asp at 50 °C for 24 h (blue trace), incubated in presence of L- 
Asp at 50 °C for 24 h (green trace); SB: 75 mM EACA/1 M Urea pH 3.5. 
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Figure 48: CZE, Lysozyme in 50 mM Tris-HCl pH 8.6 (2 mg/mL), Lys-C digested (black 
trace), incubated at 50 °C for 24 h (blue trace), incubated with L-Asp at 50 °C for 24 h (green 
trace); SB: 75 mM EACA/1 M Urea pH 3.5. 
 
 
Table 42: Amino acid sequence of light (LC) and heavy chain (HC) of Avastin with 
calculated [131] average molecular weights and pI values. 
 
Sequence Mw [kDa] pI 
LC: 
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKA 
PKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC 
QQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV 
VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS 
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 
 
 
23.5 
 
 
6.34 
HC: 
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAP 
GKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMN 
SLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSAST 
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL 
TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS 
NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL 
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE 
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK 
AKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEW 
ESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF 
SCSVMHEALHNHYTQKSLSLSPGK 
 
 
 
 
 
 
49.8 
 
 
 
 
 
 
8.35 
Whole IgG 146.5 8.09 
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Table 43: Amino acid sequence of light (LC) and heavy chain (HC) of Erbitux with 
calculated [131] average molecular weights and pI values. 
 
Sequence Mw [kDa] pI 
LC: 
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSP 
RLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQ 
NNNWTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCL 
LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS 
TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA 
 
 
23.5 
 
 
6.34 
HC: 
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPG 
KGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSL 
QSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVF 
PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT 
FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK 
RVEPKSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS 
RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY 
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES 
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC 
SVMHEALHNHYTQKSLSLSPGK 
 
 
 
 
 
 
49.7 
 
 
 
 
 
 
8.69 
Whole IgG 145.6 8.48 
 
 
Table 44: Area % of papain digested Avastin Fab, Fc fragments after spiking experiment. 
 
Sample Area % of Fc Area % of Fab 
Avastin 28.5 71.5 
Avastin + 5 µl Fc 29.5 70.5 
Avastin + 10 µl Fc 30.4 69.6 
Avastin + 5 µl Fab 27.4 72.6 
Avastin + 10 µl Fab 25.5 74.5 
 
 
Papain digested Erbitux 
 
Table 45: Area % of papain digested Erbitux Fab, Fc fragments after spiking experiment. 
 
Sample Area % of Fc Area % of Fab 
Erbitux 30.3 69.7 
Erbitux + 5 µl Fc 33.7 66.3 
Erbitux + 10 µl Fc 41.4 58.6 
Erbitux + 5 µl Fab 29.0 71.0 
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Figure 49: CGE-SDS of papain digested Erbitux: cend = 0.9 mg/ml, papain digest 37 °C 
with/without L-Cys for 5 h. 
 
 
 
 
Figure 50: HPLC of papain digested Erbitux (cend = 2.5 mg/mL), digestion in 1 mM L-Cys 
at 37 °C for 5 h and CZE separation of collected Fab and Fc fractions,. Experimental 
conditions: X-Bridge BEH300 C18, 3.5 µm, 2.1 x 150 mm column, H2O/ACN with 0.1 % TFA, 
flow rate 0.2 mL/min, column temperature 50 °C. BGE: 600 mM EACA, 0.1 % HPMC, pH 6.0 
(I AcA, NaOH = 4.5) 
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Figure 51: SDS-PAGE of Lys-C digested EPO. 
 
 
 
 
Figure 52: MALDI mass signals of Lys-C digested EPO, fraction of P4 after 
deglycosylation by PNGase: Experimental conditions: peptide II and protein I calibration 
standards, DHB matrix, positive mode, ground steel target. 
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Figure 53: MALDI mass signals of Lys-C digested EPO, fraction of P6: Experimental 
conditions: peptide II and protein I calibration standards, DHB matrix, positive mode, ground 
steel target. 
